A Phase 4 interventional study of APRETUDE and Cabotegravir tablet in HIV Infections, sponsored by ViiV Healthcare. Completed at 22 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 14th largest by enrollment, is one of 3 that started in 2022, is one of 3 in phase 4, and was the 26th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 295 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 44th largest by enrollment of the 210 interventional ones that give a count, is one of 6 that started in 2022, is one of 18 in phase 4, and was the 230th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two participant types in the study are the Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available CAB PrEP via prescription from the PrEP provider. The second are Staff Study Participants (SSPs) who are site staff involved in the administrative and clinical aspects of offering and administering PrEP to PSPs at the clinical site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The SI arm evaluated cabotegravir long-acting injectable (CAB LA) for pre-exposure prophylaxis (PrEP) delivery using standard toolkits made available with the commercial release of CAB LA for providers and patients to use as needed, along with implementation monitoring.
Drug: APRETUDE · Drug: Cabotegravir tablet
The EI arm evaluated CAB LA delivery using the standard toolkits plus enhanced supports to use as needed, along with implementation monitoring. EI sites received supports like patient-provider discussion tools, informational tools, and provider education.
Drug: APRETUDE · Drug: Cabotegravir tablet
The ECI arm evaluated CAB LA delivery using the standard toolkits plus enhanced supports to use as needed, along with implementation monitoring. ECI sites received supports like a sexual health assessment, provider education, videos, informational tools, persistence support, and peer ambassadors.
Drug: APRETUDE · Drug: Cabotegravir tablet
Available as intramuscular injection.
Available as marketed orally administered tablets.
Mean Intervention Appropriateness Measure (IAM) Score Assessed for SSPs at Month 12
The IAM was used to assess among SSPs the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for Black women at our clinic/practice 2. APRETUDE seems suitable for Black women at our clinic/practice 3.APRETUDE seems applicable for Black women at our clinic/practice 4.APRETUDE seems like a good match for Black women at our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving Optional oral Lead in \[OLI\])
Time frame: At Month 12
Mean IAM Score Assessed for SSPs Over Time
Timeframe for evaluation of this outcome measure is Baseline (BL), M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI)
Time frame: At Baseline (Month 1), Month 4 and Month 12
Change From Baseline in IAM Score Assessed for SSPs
This outcome assesses the change in IAM score for SSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.
Time frame: At Month 4 and Month 12 compared to Baseline (Month 1)
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by Implementation Science Questionnaire (ISQs) at Baseline
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ at baseline are displayed in this outcome measure. In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.
Time frame: At Baseline (Month 1)
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by ISQs at Month 4
SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.
Time frame: At Month 4
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by ISQs at Month 12
SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.
Time frame: At Month 12
Number of SSPs With Responses to APRETUDE Staffing Sufficiency Assessed by ISQs at Months 4 and 12
SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs evaluated staff sufficiency to manage the current or anticipated number of APRETUDE patients on an ongoing basis.
Time frame: At Month 4 and Month 12
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by Semi-structured Interview (SSI) at Month 4
Semi-structured interview (SSI) guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 4
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by SSI at Month 12
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 12
Mean IAM Score Assessed for PSPs
The IAM was used to assess the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for me, 2. APRETUDE seems suitable for my lifestyle, 3. APRETUDE seems applicable in my life, 4. APRETUDE seems like a good match) with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5, with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Change From Baseline in IAM Score Assessed for PSPs
This outcome assesses the change in IAM for PSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI) compared to BL.
Time frame: At Month 4 and Month 12 compared to Baseline (Month 1)
Number of SSPs With Responses to Perceived Appropriateness of APRETUDE for Different Patient Characteristics Assessed by ISQ
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSP perceptions on the appropriateness of APRETUDE for patients, including specific patient groups or characteristics influencing appropriateness.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs Reporting That APRETUDE is More Appropriate for Specific Demographic Groups Assessed by ISQ
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. The number of SSPs reporting in the ISQ that APRETUDE is more appropriate for specific patient demographic groups is displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs Reporting Specific Demographic Groups for Which APRETUDE May be More Appropriate Assessed by ISQ
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions of the appropriateness of APRETUDE for specific patient demographics groups as reported in the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs Reporting Appropriateness of APRETUDE Via Level of Concern Surrounding Patient Beliefs and Experiences Assessed by ISQ
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this outcome measure, appropriateness of APRETUDE for patients was reported by SSPs by rating in the ISQ their level of concern (ranging from "Not at all concerned" to "Extremely concerned") surrounding patients' belief in the efficacy of APRETUDE and experience with pain.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of PSPs With Responses to Perception of Appropriateness of APRETUDE Assessed by SSI at Baseline
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the appropriateness of APRETUDE gathered during SSIs at baseline are displayed. This outcome measure presents common concepts identified from qualitative analysis of PSPs' perceived appropriateness of APRETUDE. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Perception of Appropriateness of APRETUDE Assessed by SSI at Month 12
Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
Time frame: At Month 12
Number of Cis- and Trans Black Women Who Complete a Sexual Health Assessment in ECI Arm
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by gender. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs Who Complete a Sexual Health Assessment in ECI Arm
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by clinic type to represent differences across clinical settings. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Study Arm
Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.
Time frame: Up to Month 12
Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Clinic Setting
Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.
Time frame: Up to Month 12
Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Study Arm
Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.
Time frame: Up to Month 12
Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Clinic Setting
Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.
Time frame: Up to Month 12
Mean Feasibility of Intervention Measure (FIM) Score for PrEP Training Assessed for SSPs
The FIM was used to assess the feasibility of the PrEP training provided only to EI and ECI arms using a four-item measure (1. The PrEP training would be easily implemented as part of my continuing education 2. It would be possible to incorporate the PrEP training into my continuing education efforts 3. The PrEP training was doable as a continuing education activity 4. The PrEP training was easy to use) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI); and was not assessed at baseline as sites had not had time to utilize the tool.
Time frame: At Month 4 and Month 12
Change in FIM Score for PrEP Training Assessed for SSPs
This outcome assesses the change in FIM score for PrEP Training for SSPs over time. The change in FIM score was calculated as the longitudinal mean change from Month 4 to Month 12. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI) compared to M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 12 compared to Month 4
Number of SSPs With Responses to Feasibility and Ease of Clinical Tool Implementation Assessed by SSP Questionnaire Responses at Baseline
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of study tools gathered through the ISQ at BL, M4, and M12 are displayed. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents SSPs'perception of ease of implementation of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool.
Time frame: At Baseline (Month 1)
Number of SSPs With Responses to Planned Frequency of Use for PrEP Options Communication and Sexual Health Assessment Tools Assessed by SSP Questionnaire Responses at Baseline
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the planned frequency of use of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool among SSPs' clinics.
Time frame: At Baseline (Month 1)
Number of SSPs With Responses to Feasibility, Ease of Use, and Implementation of PrEP Training and Clinical Tools Assessed at Month 4
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).
Time frame: At Month 4
Number of SSPs With Responses to Feasibility, Ease of Use, and Implementation of PrEP Training and Clinical Tools Assessed at Month 12
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).
Time frame: At Month 12
Number of SSPs With Responses to Frequency of PrEP Options Communication Tool and Sexual Health Assessment Tool Use Assessed at Month 4
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).
Time frame: At Month 4
Number of SSPs With Responses to Frequency of PrEP Options Communication Tool and Sexual Health Assessment Tool Use Assessed at Month 12
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).
Time frame: At Month 12
Number of SSPs With Responses to Current Use of the PrEP Options Communication Tool
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 4 and Month 12
Number of SSPs Indicating Reasons Why the PrEP Options Communications Tool Was Not Used, Assessed at Month 4
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.
Time frame: At Month 4
Number of SSPs Indicating Reasons Why the PrEP Options Communications Tool Was Not Used, Assessed at Month 12
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.
Time frame: At Month 12
Number of SSPs With Responses to Current Use of the Sexual Health Assessment Tool
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 4 and Month 12
Number of SSPs Indicating Reasons Why the Sexual Health Assessment Tool Was Not Used, Assessed at Month 4
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons the Sexual Health Assessment Tool was not used by a clinic/practice.
Time frame: At Month 4
Number of SSPs Indicating Reasons Why the Sexual Health Assessment Tool Was Not Used, Assessed at Month 12
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons why the Sexual Health Assessment Tool was not used by a clinic/practice.
Time frame: At Month 12
Number of SSPs With Responses to Feasibility and Utility of Implementation Strategies Assessed by SSI at Month 4
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.
Time frame: At Month 4
Number of SSPs With Responses to Feasibility and Utility of Implementation Strategies Assessed by SSI at Month 12
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.
Time frame: At Month 12
Number of SSPs That Respond to PrEP Education Training and Utility of Strategies by Study Arm
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on if study tools were fit for use were gathered. Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).
Time frame: Up to Month 12
Number of SSPs That Respond to Helpfulness for Utilized Implementation Strategies by Study Arm
Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.
Time frame: Up to Month 12
Number of SSPs That Respond to Perceived Utility, Effectiveness, and Facilitation of PrEP Training and Clinical Tools by Study Arm
PrEP training and tools were only available to selected arms (EI and/or ECI). Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients" (ECI only).
Time frame: Up to Month 12
Number of SSPs That Respond to PrEP Education Training and Utility of Strategies by Clinic Characteristics
Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).
Time frame: Up to Month 12
Number of SSPs That Respond to Helpfulness for Utilized Implementation Strategies by Clinic Characteristics
Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.
Time frame: Up to Month 12
Number of SSPs That Respond to Perceived Utility, Effectiveness, and Facilitation of PrEP Training and Clinical Tools by Clinic Characteristics
Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients (ECI only)".
Time frame: Up to Month 12
Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Study Arm
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.
Time frame: Up to Month 12
Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Study Arm
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.
Time frame: Up to Month 12
Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Clinic Characteristics
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.
Time frame: Up to Month 12
Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Clinic Characteristics
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.
Time frame: Up to Month 12
Number of PSPs With Responses to Sexual Health Assessment Completion and Result Discussion by Clinic Characteristics
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".
Time frame: Up to Month 12
Number of PSPs With Responses to Personnel for Sexual Health Assessment Discussions by Clinic Characteristics
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question: "Who discussed the results of the assessment with you? (ECI only)".
Time frame: Up to Month 12
Number of PSPs With Responses to Helpfulness of Discussing Sexual Health Assessment Results by Clinic Characteristics
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".
Time frame: Up to Month 12
Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Clinic Characteristics
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.
Time frame: Up to Month 12
Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Patient Subgroups
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies by patient gender subgroups.
Time frame: Up to Month 12
Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Patient Subgroups
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials by patient gender subgroups.
Time frame: Up to Month 12
Number of PSPs With Responses to Sexual Health Assessment Completion and Result Discussion by Patient Subgroups
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".
Time frame: Up to Month 12
Number of PSPs With Responses to Personnel for Sexual Health Assessment Discussions by Patient Subgroups
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question regarding the sexual health assessment: "Who discussed the results of the assessment with you? (ECI only)".
Time frame: Up to Month 12
Number of PSPs With Responses to Helpfulness of Discussing Sexual Health Assessment Results by Patient Subgroups
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".
Time frame: Up to Month 12
Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Patient Subgroups
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.
Time frame: Up to Month 12
Number of PSPs With Responses to Perceptions of Utility of Implementation Tools and Strategies Assessed by SSI by Study Arm
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies.
Time frame: Up to Month 12
Number of PSPs With Responses to Perceptions of Utility of Implementation Tools and Strategies by Patient Subgroups
PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies by patient gender subgroups.
Time frame: Up to Month 12
Number of Injections Occurring Within the Target Window From Target Date
This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as +/- 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs With Responses to Ease of Target Appointment Date Understanding Across Traditional and Non-traditional Settings
PSP perceptions of barriers and facilitators to fidelity to APRETUDE injection windows were gathered via the ISQ. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs responses to the following question: "How easy was it to understand the Target Appointment Date?"
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Missed APRETUDE Injection Visits Assessed Traditional and Non-traditional Settings
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Have you missed any of your APRETUDE injection visits in the last 6 months?".
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Planned/Unplanned Nature of Missed Injection Visits Across Traditional and Non-traditional Settings
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Was missing your APRETUDE injection visits planned or unplanned?".
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Initiation of Oral PrEP Following Missed Visits Across Traditional and Non-traditional Settings
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Did you start oral PrEP after missing any of your injection visit?".
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Ease or Difficulty of Initiating Oral PrEP After a Missed Visit Across Traditional and Non-traditional Settings
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How easy or difficult was it to start oral PrEP after a missed injection visit?".
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Acceptability of Initiating Oral PrEP After a Missed Visit Assessed Across Traditional and Non-traditional Settings
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How acceptable was it to start oral PrEP after a missed injection visit?".
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Target Appointment Date Understanding and Access Across Traditional and Non-traditional Settings
Data below were collected via SSIs or interviews, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs understanding and access to the target appointment date. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to APRETUDE Adherence and Barriers/Facilitators to Injection Fidelity Across Traditional and Non-traditional Settings
Data below were collected via SSIs or interviews, and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSP responses to the APRETUDE adherence and the specified barriers and facilitators to injection fidelity.
Time frame: At Month 12
Number of SSPs With Responses to APRETUDE Patient Management Challenges and Injection Fidelity Across Traditional and Non-traditional Settings
Data below were collected by ISQ and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses for the specified items regarding patient management challenges and injection fidelity for APRETUDE.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Injection Visits, Adherence, and Missed Doses Across Traditional and Non-traditional Settings Assessed by SSI
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Data displayed represent injection fidelity topics discussed by SSPs while describing the APRETUDE implementation process. SSIs were not conducted with SSPs at baseline. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 4
Number of SSPs With Responses to Perceived Barriers/Facilitators to Injection Window Fidelity Across Traditional and Non-traditional Settings Assessed by SSI
Data below were collected via SSIs, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents topics surrounding managing adherence and missed doses as discussed by SSPs during SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
Time frame: At Month 12
Number of Clinics With Responses to Implementation Monitoring Calls (IMC) Assessed Barriers/Facilitators to Injection Window Fidelity Across Traditional and Non-traditional Settings
IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to barriers and facilitators to fidelity to APRETUDE injection windows as discussed during IMC calls. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of PSPs Completing Target Number of Injections by Patient Subgroups
Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of SSPs With Responses to APRETUDE Implementation and Patient Management Assessed by Questionnaires
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified APRETUDE implementation and patient management. Only a selection of items are applicable for BL timepoint.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Clinic Climate and Change Readiness Assessed by Questionnaires
Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs response to the specified items regarding to the clinic climate and change readiness as implementation barriers and facilitators.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Perceived Benefits of Bi-monthly Injections Assessed by Questionnaires
Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs perception of the bi-monthly injection benefits.
Time frame: At Month 12
Number of PSPs With Responses to Prior Knowledge of HIV/PrEP Assessed by Questionnaires
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified questions regarding prior knowledge of HIV/PrEP. For each timepoint assessed for this outcome measure only specific questions were applied.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of PSPs With Responses to HIV Knowledge and Misconceptions Assessed by Questionnaires
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified items regarding HIV knowledge and misconceptions.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of PSPs With Responses on Social Support, Stigma, and Personal Attitudes Towards PrEP Use Assessed by Questionnaires
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement regarding the social and personal perceptions (support, stigma, attitude) towards PrEP use.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of PSPs With Responses on Community Attitude Towards PrEP Assessed by Questionnaires
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs response to the following question: "In general, what kind of attitude do you think your community has toward PrEP?".
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Worry Regarding APRETUDE Disclosure Assessed by Questionnaires
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs response to the following question: "How often are you worried that people may find out that you are taking APRETUDE?".
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Sources of Pre-enrollment APRETUDE Information Assessed by Questionnaires
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the sources of information for APRETUDE pre-enrollment. This outcome measure presents the PSPs response to the following question: "If you have questions about APRETUDE, where do you find information?" The answer "the study app/website" was inconsistently displayed to study arms at different time points due to a programming error.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Perceived Benefits of In-person APRETUDE Injection Visits
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the PSPs perception of the benefits of in-person APRETUDE injection visits.
Time frame: At Month 12
Number of PSPs With Responses to Overall Feelings to APRETUDE Assessed by Questionnaires
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Overall, how are you feeling about getting APRETUDE?".
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 4
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.
Time frame: At Month 4
Number of SSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 12
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.
Time frame: At Month 12
Number of Clinics With Responses to Facilitators and Barriers to Implementation Assessed by IMCs
IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to overall SSP perceptions of facilitators and barriers to APRETUDE implementation discussed during IMC calls. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to qualitative data collection.
Time frame: Up to Month 12
Number of PSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Baseline
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 12
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.
Time frame: At Month 12
Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs
The AIM was used to assess among PSPs the acceptability of APRETUDE using a four-item measure (1. I believe APRETUDE will meet my approval for preventing HIV, 2. APRETUDE for the prevention of HIV is appealing to me, 3. I think I will like APRETUDE for the prevention of HIV, 4. I welcome APRETUDE for the prevention of HIV) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI)
Time frame: At Baseline (Month 1), Month 4 and Month 12
Mean FIM Score Assessed for PSPs
The FIM was used to assess among PSPs the feasibility of APRETUDE using a four-item measure (1. Receiving APRETUDE injections every 2 months seems workable in my life, 2. Receiving APRETUDE injections every 2 months seems possible for me, 3. Receiving APRETUDE injections every 2 months seems doable in my life, 4. Receiving APRETUDE injections every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Mean AIM Score Assessed for SSPs
The AIM was used to assess the acceptability of APRETUDE using a four-item measure (1. APRETUDE in our clinic/practice meets my approval, 2. APRETUDE in our clinic/practice is appealing to me, 3. I like APRETUDE in our clinic/practice, 4. I welcome APRETUDE in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Mean FIM Score Assessed for SSPs
The FIM was used to assess the feasibility of APRETUDE using a four-item measure (1. APRETUDE seems implementable in our clinic/practice, 2. APRETUDE seems possible in our clinic/practice, 3. APRETUDE seems doable in our clinic/practice, 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Feasibility of APRETUDE Implementation
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding feasibility of APRETUDE implementation.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Clinic Capacity for APRETUDE Patient Management
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding clinic capacity for APRETUDE patient management (i.e. "Number of APRETUDE patients that the clinic can manage per week").
Time frame: At Baseline (Month 1), Month 4 and Month 12
Mean Number of Staff Needed to Incorporate APRETUDE Into Clinics Per Week
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This endpoint presents the results on mean number of staff needed to incorporate APRETUDE into clinics per week.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Staff Time/Full-time Equivalent Hours (FTE) Requirements Per Week
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to staff time/FTE requirements per week to incorporate APRETUDE.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Clinic/Practice Methods for Patient Tracking
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods for patient tracking.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Clinic/Practice Methods to Remind Patients of an Upcoming Appointment
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods to remind patients of an upcoming appointment
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Clinic/Practice Approaches for Offering Injection Appointments
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice approaches for offering injection appointments.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Perceived Ease/Difficulty of Implementing APRETUDE in Clinics
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived ease/difficulty of implementing APRETUDE in clinics.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Acceptability of APRETUDE Implementation
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to acceptability of APRETUDE implementation.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Perceived Positive Perception of Implementing APRETUDE
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived positive perception of implementing APRETUDE.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to Patient Time in Waiting Room and Exam Room for APRETUDE Injection Visits
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to patient time in waiting room and exam room for APRETUDE injection visits.
Time frame: At Month 12
Number of SSPs With Responses to Post-injection Observation Period for Patients After APRETUDE
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to post-injection observation period for patients after APRETUDE.
Time frame: At Month 12
Number of PSPs With Responses to Convenience Level of Clinic Hours
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to convenience level of clinic hours.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of PSPs With Responses to Sources of First Injection Appointment Reminders at Baseline
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to sources of first injection appointment reminders at baseline.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Sources of Injection Appointment Reminders at Month 12
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to sources of injection appointment reminders at Month 12.
Time frame: At Month 12
Number of PSPs With Responses to Preferred Appointment Reminder Types at Baseline
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to preferred appointment reminder types at baseline (Month 1).
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Most Helpful Types of Appointment Reminders at M4 and M12
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to most helpful types of appointment reminders at M4 and M12.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Need for Additional Care for Injection Visits
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to need for additional care for injection visits.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of PSPs With Responses to Anticipated Time Off Work for APRETUDE Injections at Baseline
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to anticipated time off work for APRETUDE injections at baseline.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Time Taken Off Work for Injections at M4 and M12
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to time off work for APRETUDE injections at M4 and M12.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Amount of Time Off Work Taken for Injections at M4 and M12
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to amount of time off work taken for injections at M4 and M12.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Status of Time Off Work for Injections at M4 and M12
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to status of time off work for injections at M4 and M12.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Frequency of Worry About Forgetting APRETUDE Injections
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to frequency of worry about forgetting APRETUDE injections.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Perceived Ease/Difficulty of Scheduling Injection Appointments
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of scheduling injection appointments.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Perceived Ease/Difficulty of Rescheduling Injection Appointments
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of rescheduling injection appointments.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Acceptability of Attending the Clinic Every 2 Months
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to how easy or difficult it has been to get to the clinic every 2 months at M4 and M12.
Time frame: At Month 4 and at Month 12
Number of PSPs With Responses to Length of Journey to the Clinic/Practice at M12
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to "Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?" at M12.
Time frame: At Month 12
Number of PSPs With Responses to Concerns About APRETUDE
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to concerns about APRETUDE.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of PSPs With Responses to Specific Concerns About APRETUDE at Baseline
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at baseline (M1).
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Specific Concerns About APRETUDE at Month 4
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M4.
Time frame: At Month 4
Number of PSPs With Responses to Specific Concerns About APRETUDE at Month 12
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M12.
Time frame: At Month 12
Number of PSPs With Responses to Acceptability of Bi-monthly Clinic Visits for Injections
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of bi-monthly clinic visits for injections.
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of PSPs With Responses to Acceptability of HIV and STI Testing Frequency
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of HIV and STI testing frequency.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Local Reactions Following an APRETUDE Injection
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to local reactions following an APRETUDE injection.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Acceptability of Local Reactions
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of local reactions following an APRETUDE injection.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses on Return to Daily Activities Post-injection
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses on return to daily activities post-injection (e.g., going back to work, social events, exercise, driving).
Time frame: At Month 4 and Month 12
Number of PSPs Indicating How Bothered by Pain They Were During APRETUDE Injections
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents data indicating how bothered by pain PSPs were during injection.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Acceptability of Injection-related Pain
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of injection-related pain.
Time frame: At Month 4 and Month 12
Number of PSPs With Responses to Pain Reduction Strategies Post-injection
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to pain reduction strategies post-injection.
Time frame: At Month 4 and Month 12
Mean Rating of Pain/Discomfort Following First APRETUDE Injection
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following first APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).
Time frame: At Month 4 and Month 12
Mean Rating of Pain/Discomfort Following Most Recent APRETUDE Injection
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following the most recent APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).
Time frame: At Month 4 and Month 12
Number of SSPs With Influences on and Facilitators/Barriers of Acceptability of APRETUDE Assessed by SSI
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions of the acceptability of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of acceptability of APRETUDE.
Time frame: At Month 4 and Month 12
Number of SSPs With Influences on and Facilitators/Barriers of Feasibility of APRETUDE
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSP perceptions of the feasibility of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of feasibility of APRETUDE.
Time frame: At Month 12
Number of PSPs With Influences of Acceptability of APRETUDE at Baseline
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of acceptability of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
Time frame: At Baseline (Month 1)
Number of PSPs With Influences of Acceptability of APRETUDE at Month 12
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of acceptability of APRETUDE at M12.
Time frame: At Month 12
Number of PSPs With Influences of Feasibility of APRETUDE at Baseline
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of feasibility of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
Time frame: At Baseline (Month 1)
Number of PSPs With Influences of Feasibility of APRETUDE at Month 12
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of feasibility of APRETUDE at M12.
Time frame: At Month 12
Number of PSPs Who Had Oral lead-in Before APRETUDE Injection - Data Collected by ISQ at Baseline
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of use of oral cabotegravir pills as oral lead-in to APRETUDE injections was gathered using the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs who had OLI before APRETUDE injection.
Time frame: At Baseline (Month 1)
Number of SSPs Reporting Use of Oral lead-in Before APRETUDE Injection on Baseline ISQ
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs who chose OLI before APRETUDE injection at baseline (M1).
Time frame: At Baseline (Month 1)
Number of SSPs Who Chose Oral lead-in Before APRETUDE Injection - Data Collected by ISQ at Month 4 and 12
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs who chose OLI before APRETUDE injection at M4 and M12.
Time frame: At Month 4 and Month 12
Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by SSI
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions on reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). SSIs were not conducted with SSPs at BL. This outcome measure presents the SSPs with responses on reasons for decision to use OLI assessed by SSI at M4 and M12.
Time frame: At Month 4 and Month 12
Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Baseline
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at baseline (M1).
Time frame: At Baseline (Month 1)
Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Month 4
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M4.
Time frame: At Month 4
Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Month 12
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M12.
Time frame: At Month 12
Number of PSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by SSI
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons for using oral cabotegravir pills as OLI to APRETUDE injections were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs' experiences with and reasons for using OLI or direct-to-injection (DTI) approach, assessed by SSIs.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses on Decision Making for Use of OLI Assessed by Surveys
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs on reasons for decision to use OLI, assessed by surveys.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses on Reasons for Decision for Use of OLI Assessed by Surveys
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses on reasons for decision for use of OLI, assessed by surveys.
Time frame: At Baseline (Month 1)
Number of PSPs With PrEP History
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. Timeframe for evaluation of this outcome measure is BL.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Consistency in Oral PrEP Use in Past 6 Months
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to consistency in Oral PrEP use in past 6 months.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Oral PrEP Duration
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to Oral PrEP duration.
Time frame: At Baseline (Month 1)
Number of PSPs Who Completed a SHA and Initiate APRETUDE
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP use of the sexual health assessment (available only to the ECI arm) was gathered via the ISQ. Timeframe for evaluation of this outcome measure is at Baseline (BL) and M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs who completed a SHA and initiate APRETUDE. All PSPs enrolled in the study initiated APRETUDE.
Time frame: At Baseline (Month 1) and Month 12
Number of PSPs With Responses to Experiences With Oral PrEP Assessed by Surveys
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to experiences with Oral PrEP, assessed by surveys.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Oral PrEP Side Effects Assessed by Surveys
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to Oral PrEP side effects, assessed by surveys.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Frequency of Worry About Oral PrEP Disclosure Assessed by Surveys
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to frequency of worry about Oral PrEP disclosure, assessed by surveys.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses to Reasons for Choosing APRETUDE Assessed by Surveys
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to reasons for choosing APRETUDE, assessed by surveys.
Time frame: At Baseline (Month 1)
Number of PSPs With Responses for Choosing or Switching to APRETUDE Assessed by SSI at Baseline
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection. This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at baseline (M1).
Time frame: At Baseline (Month 1)
Number of PSPs With Responses for Choosing or Switching to APRETUDE Assessed by SSI at Month 12
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at M12.
Time frame: At Month 12
A total of 24 clinics were randomized to Standard implementation(SI), EI(Enhanced Implementation) and ECI(Enhanced Collaborative Implementation) arms. In these clinics, a total of 163 patient study participants (PSPs) were enrolled and all of them received study treatment and 132 Staff Study Participants (SSPs) were enrolled that included healthcare providers, nurses, staff performing injections, clinic administrators, social workers, case managers, pre-exposure prophylaxis(PrEP) educators, etc.
| Milestone | Standard Implementation (SI) | Enhanced Implementation (EI) | Enhanced Collaborative Implementation (ECI) |
|---|---|---|---|
| Started | 96 | 115 | 84 |
| Psp | 56 | 63 | 44 |
| Ssp | 40 | 52 | 40 |
| Completed | 77 | 85 | 63 |
| Not completed | 19 | 30 | 21 |
| Withdrew: Adverse event | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 8 | 9 | 9 |
| Withdrew: Physician decision | 1 | 2 | 3 |
| Withdrew: Withdrawal by subject | 9 | 14 | 8 |
| Withdrew: Site terminated by sponsor | 0 | 4 | 0 |
The IAM was used to assess among SSPs the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for Black women at our clinic/practice 2. APRETUDE seems suitable for Black women at our clinic/practice 3.APRETUDE seems applicable for Black women at our clinic/practice 4.APRETUDE seems like a good match for Black women at our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving Optional oral Lead in \[OLI\])
| Scores on a scale | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Mean Intervention Appropriateness Measure (IAM) Score Assessed for SSPs at Month 12 | 4.4 ± 0.90 | 4.7 ± 0.49 | 4.3 ± 0.69 |
Timeframe for evaluation of this outcome measure is Baseline (BL), M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI)
| Scores on a scale | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Baseline | 4.4 ± 0.84 | 4.6 ± 0.55 | 4.6 ± 0.66 |
| Month 4 | 4.3 ± 0.86 | 4.5 ± 0.61 | 4.3 ± 0.70 |
| Month 12 | 4.4 ± 0.90 | 4.7 ± 0.49 | 4.3 ± 0.69 |
This outcome assesses the change in IAM score for SSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.
| Scores on a scale | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Month 4 compared to Baseline | -0.3 ± 0.89 | -0.1 ± 0.58 | -0.3 ± 0.60 |
| Month 12 compared to Baseline | -0.3 ± 1.20 | 0.0 ± 0.65 | -0.5 ± 0.76 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ at baseline are displayed in this outcome measure. In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Identifying eligible individuals for APRETUDE — Extremely concerned | 3 | 6 | 0 |
| Identifying eligible individuals for APRETUDE — Moderately concerned | 1 | 5 | 1 |
| Identifying eligible individuals for APRETUDE — Somewhat concerned | 7 | 7 | 6 |
| Identifying eligible individuals for APRETUDE — Slightly concerned | 8 | 15 | 8 |
| Identifying eligible individuals for APRETUDE — Not at all concerned | 21 | 19 | 25 |
| Staff resourcing to ensure appropriate clinic flow — Extremely concerned | 2 | 3 | 0 |
| Staff resourcing to ensure appropriate clinic flow — Moderately concerned | 2 | 3 | 5 |
| Staff resourcing to ensure appropriate clinic flow — Somewhat concerned | 7 | 4 | 5 |
| Staff resourcing to ensure appropriate clinic flow — Slightly concerned | 10 | 10 | 10 |
| Staff resourcing to ensure appropriate clinic flow — Not at all concerned | 19 | 32 | 20 |
| Number of exam rooms for injections — Extremely concerned | 2 | 3 | 3 |
| Number of exam rooms for injections — Moderately concerned | 4 | 2 | 3 |
| Number of exam rooms for injections — Somewhat concerned | 1 | 3 | 4 |
| Number of exam rooms for injections — Slightly concerned | 6 | 5 | 5 |
| Number of exam rooms for injections — Not at all concerned | 27 | 39 | 25 |
| Clinic staff to administer injections — Extremely concerned | 4 | 3 | 2 |
| Clinic staff to administer injections — Moderately concerned | 3 | 1 | 2 |
| Clinic staff to administer injections — Somewhat concerned | 2 | 3 | 4 |
| Clinic staff to administer injections — Slightly concerned | 8 | 9 | 7 |
| Clinic staff to administer injections — Not at all concerned | 23 | 36 | 25 |
SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Identifying eligible individuals for APRETUDE — Extremely concerned | 2 | 1 | 0 |
| Identifying eligible individuals for APRETUDE — Moderately concerned | 3 | 0 | 0 |
| Identifying eligible individuals for APRETUDE — Somewhat concerned | 3 | 3 | 7 |
| Identifying eligible individuals for APRETUDE — Slightly concerned | 4 | 7 | 7 |
| Identifying eligible individuals for APRETUDE — Not at all concerned | 17 | 21 | 24 |
| Staff resourcing to ensure appropriate clinic flow — Extremely concerned | 2 | 0 | 1 |
| Staff resourcing to ensure appropriate clinic flow — Moderately concerned | 0 | 2 | 2 |
| Staff resourcing to ensure appropriate clinic flow — Somewhat concerned | 7 | 4 | 10 |
| Staff resourcing to ensure appropriate clinic flow — Slightly concerned | 7 | 6 | 8 |
| Staff resourcing to ensure appropriate clinic flow — Not at all concerned | 13 | 20 | 17 |
| Number of exam rooms for injections — Extremely concerned | 0 | 0 | 2 |
| Number of exam rooms for injections — Moderately concerned | 0 | 0 | 0 |
| Number of exam rooms for injections — Somewhat concerned | 3 | 1 | 4 |
| Number of exam rooms for injections — Slightly concerned | 4 | 7 | 10 |
| Number of exam rooms for injections — Not at all concerned | 22 | 24 | 22 |
| Clinic staff to administer injections — Extremely concerned | 1 | 1 | 1 |
| Clinic staff to administer injections — Moderately concerned | 2 | 1 | 0 |
| Clinic staff to administer injections — Somewhat concerned | 4 | 3 | 8 |
| Clinic staff to administer injections — Slightly concerned | 7 | 3 | 9 |
| Clinic staff to administer injections — Not at all concerned | 15 | 24 | 20 |
SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Identifying eligible individuals for APRETUDE — Extremely concerned | 3 | 0 | 0 |
| Identifying eligible individuals for APRETUDE — Moderately concerned | 4 | 2 | 3 |
| Identifying eligible individuals for APRETUDE — Somewhat concerned | 4 | 1 | 4 |
| Identifying eligible individuals for APRETUDE — Slightly concerned | 3 | 5 | 7 |
| Identifying eligible individuals for APRETUDE — Not at all concerned | 12 | 18 | 18 |
| Staff resourcing to ensure appropriate clinic flow — Extremely concerned | 2 | 0 | 2 |
| Staff resourcing to ensure appropriate clinic flow — Moderately concerned | 3 | 0 | 4 |
| Staff resourcing to ensure appropriate clinic flow — Somewhat concerned | 3 | 3 | 6 |
| Staff resourcing to ensure appropriate clinic flow — Slightly concerned | 5 | 6 | 4 |
| Staff resourcing to ensure appropriate clinic flow — Not at all concerned | 13 | 17 | 16 |
| Number of exam rooms for injections — Extremely concerned | 1 | 0 | 3 |
| Number of exam rooms for injections — Moderately concerned | 3 | 0 | 2 |
| Number of exam rooms for injections — Somewhat concerned | 4 | 2 | 5 |
| Number of exam rooms for injections — Slightly concerned | 3 | 5 | 6 |
| Number of exam rooms for injections — Not at all concerned | 15 | 19 | 16 |
| Clinic staff to administer injections — Extremely concerned | 3 | 0 | 4 |
| Clinic staff to administer injections — Moderately concerned | 3 | 0 | 2 |
| Clinic staff to administer injections — Somewhat concerned | 2 | 2 | 7 |
| Clinic staff to administer injections — Slightly concerned | 4 | 5 | 4 |
| Clinic staff to administer injections — Not at all concerned | 14 | 19 | 15 |
SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs evaluated staff sufficiency to manage the current or anticipated number of APRETUDE patients on an ongoing basis.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — No | 1 | 3 | 5 |
| Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Yes, the clinic has sufficient staff to manage only the current number of APRETUDE patients | 11 | 7 | 14 |
| Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Yes, the clinic has sufficient staff for current and anticipated APRETUDE patients | 15 | 20 | 9 |
| Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Unsure | 2 | 2 | 10 |
| Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Missing | 0 | 0 | 0 |
| Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — No | 2 | 0 | 4 |
| Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Yes, the clinic has sufficient staff to manage only the current number of APRETUDE patients | 10 | 10 | 12 |
| Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Yes, the clinic has sufficient staff for current and anticipated APRETUDE patients | 11 | 11 | 9 |
| Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Unsure | 3 | 4 | 7 |
| Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Missing | 0 | 1 | 0 |
Semi-structured interview (SSI) guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Importance for women | 5 | 7 | 6 |
| Changes in perceptions of appropriateness | 8 | 4 | 5 |
| Barrier: Insurance issues (Access) | 7 | 7 | 11 |
| Barrier: Injection aversion (Initiation) | 8 | 9 | 10 |
| Barrier: Injection schedule (Initiation) | 6 | 5 | 8 |
| Barrier: Patient beliefs (Initiation) | 7 | 5 | 4 |
| Barrier: Comfort with oral PrEP (Initiation) | 1 | 3 | 3 |
| Barrier: Challenges with Visits (Maintenance) | 8 | 8 | 12 |
| Barrier: Injection Side Effects (Maintenance) | 10 | 11 | 11 |
| Barrier: Lack of resources (Maintenance) | 4 | 4 | 6 |
| Facilitator: Absence of daily pill regimen (Initiation) | 19 | 12 | 13 |
| Facilitator: Perceived protection from HIV (Initiation) | 7 | 5 | 1 |
| Facilitator: Privacy (Initiation) | 9 | 2 | 1 |
| Facilitator: Minimal Side Effects (Maintenance) | 4 | 3 | 2 |
| Patient Selection for APRETUDE | 22 | 22 | 23 |
| Patient Selection Strategies | 20 | 17 | 19 |
| Patient Selection Criteria | 4 | 7 | 8 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Enthusiasm about APRETUDE | 10 | 8 | 12 |
| Belief in appropriateness | 14 | 8 | 5 |
| Patient Selection-Assessment of sexual-behavioral history | 8 | 9 | 6 |
| Patient Selection-Discussions using shared decision-making | 6 | 3 | 5 |
| Patient Selection-Results of STI-HIV testing | 7 | 3 | 1 |
| Patient identification-Consider specific criteria | 7 | 4 | 6 |
| Patient identification-Discuss with sexually active patients | 6 | 3 | 7 |
| Patient identification-Utilize routine sexual history assessments | 5 | 5 | 2 |
| Patient identification-Discuss with all patients | 6 | 2 | 3 |
| Patient identification-Employ an open nonjudgmental approach | 3 | 3 | 1 |
| Patient identification-Train providers | 3 | 4 | 0 |
| Facilitator: Need for injectable option | 10 | 10 | 10 |
| Facilitator: For anyone having sex | 11 | 5 | 6 |
| Facilitator: Needed for high-risk people | 4 | 6 | 2 |
| Facilitator: Needed for women-Black women | 4 | 3 | 3 |
| Facilitator: General need for APRETUDE | 2 | 2 | 5 |
| Patient lifestyle barriers | 4 | 0 | 2 |
The IAM was used to assess the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for me, 2. APRETUDE seems suitable for my lifestyle, 3. APRETUDE seems applicable in my life, 4. APRETUDE seems like a good match) with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5, with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).
| Scores on a scale | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Baseline | 4.3 ± 0.83 | 4.2 ± 0.74 | 4.6 ± 0.52 |
| Month 4 | 4.6 ± 0.60 | 4.3 ± 0.59 | 4.7 ± 0.52 |
| Month 12 | 4.7 ± 0.49 | 4.3 ± 0.65 | 4.7 ± 0.54 |
This outcome assesses the change in IAM for PSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI) compared to BL.
| Scores on a scale | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Month 4 compared to BL | 0.2 ± 0.89 | 0.0 ± 0.60 | 0.1 ± 0.55 |
| Month 12 compared to BL | 0.2 ± 0.60 | 0.1 ± 0.61 | 0.1 ± 0.64 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSP perceptions on the appropriateness of APRETUDE for patients, including specific patient groups or characteristics influencing appropriateness.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - People who have been sexually active with 1 or more partners in the last 6 months | 34 | 50 | 37 |
| BL - People who have sex without a condom | 39 | 50 | 37 |
| BL - People who engage in anal sex | 36 | 48 | 36 |
| BL - People who have a sexual partner living with HIV | 37 | 51 | 39 |
| BL - People who are in monogamous relationships | 21 | 17 | 14 |
| BL - People who have sex with a person/people who inject drugs | 35 | 47 | 37 |
| BL - People who have sex with someone who has recently been in jail/prison | 32 | 42 | 34 |
| BL - People who currently have or recently (within the past 6 months) have had an STI other than HIV | 36 | 45 | 36 |
| BL - People who are currently adherent on daily oral PrEP | 30 | 21 | 26 |
| BL - Adherent daily oral PrEP users preferring a long-acting option | 34 | 38 | 36 |
| BL - People who are non-adherent on daily oral PrEP | 27 | 32 | 31 |
| BL - People who use oral PrEP on demand (i.e., event-based PrEP, PrEP 2-1-1) | 25 | 23 | 26 |
| BL - People who could benefit from PrEP but do not want to use daily oral PrEP | 34 | 43 | 36 |
| BL - People who have previously used and discontinued oral PrEP | 28 | 38 | 32 |
| BL - People who feel stigmatized about taking oral PrEP | 31 | 45 | 35 |
| BL - People who request APRETUDE spontaneously | 22 | 33 | 26 |
| BL - People who experience stigma around using HIV prevention | 28 | 38 | 32 |
| BL - People who are concerned about taking pills every day | 33 | 43 | 35 |
| BL - People who experience stress of anxiety over adherence of a daily pill regimen | 32 | 45 | 34 |
| BL - People who live in areas with high HIV prevalence | 35 | 43 | 35 |
| BL - People who inject drugs | 33 | 40 | 36 |
| BL - People who have more chaotic lifestyles | 23 | 31 | 31 |
| BL - People who have more structured lifestyles | 22 | 27 | 21 |
| BL - People who have difficulty planning or organizing | 20 | 29 | 29 |
| BL - People who have stable income and stable housing | 23 | 24 | 22 |
| BL - People who experience homelessness or are unstably housed | 25 | 35 | 29 |
| BL - People who have psychiatric comorbidities | 22 | 28 | 24 |
| BL - People who are incarcerated, temporarily incarcerated, or recently released from incarceration | 27 | 31 | 25 |
| BL - Other | 2 | 0 | 1 |
| M4 - People who have been sexually active with 1 or more partners in the last 6 months | 28 | 31 | 37 |
| M4 - People who have sex without a condom | 27 | 31 | 35 |
| M4 - People who engage in anal sex | 29 | 28 | 33 |
| M4 - People who have a sexual partner living with HIV | 29 | 31 | 36 |
| M4 - People who are in monogamous relationships | 19 | 14 | 18 |
| M4 - People who have sex with a person/people who inject drugs | 27 | 32 | 35 |
| M4 - People who have sex with someone who has recently been in jail/prison | 26 | 28 | 30 |
| M4 - People who currently have or recently (within the past 6 months) have had an STI other than HIV | 28 | 31 | 34 |
| M4 - People who are currently adherent on daily oral PrEP | 21 | 22 | 21 |
| M4 - Adherent daily oral PrEP users preferring a long-acting option | 26 | 30 | 33 |
| M4 - People who are non-adherent on daily oral PrEP | 24 | 26 | 30 |
| M4 - People who use oral PrEP on demand (i.e., event-based PrEP, PrEP 2-1-1) | 20 | 23 | 24 |
| M4 - People who could benefit from PrEP but do not want to use daily oral PrEP | 27 | 29 | 33 |
| M4 - People who have previously used and discontinued oral PrEP | 25 | 28 | 30 |
| M4 - People who feel stigmatized about taking oral PrEP | 26 | 28 | 33 |
| M4 - People who request APRETUDE spontaneously | 21 | 23 | 28 |
| M4 - People who experience stigma around using HIV prevention | 26 | 28 | 31 |
| M4 - People who are concerned about taking pills every day | 27 | 31 | 35 |
| M4 - People who experience stress of anxiety over adherence of a daily pill regimen | 25 | 31 | 34 |
| M4 - People who live in areas with high HIV prevalence | 26 | 29 | 32 |
| M4 - People who inject drugs | 21 | 29 | 30 |
| M4 - People who have more chaotic lifestyles | 19 | 21 | 26 |
| M4 - People who have more structured lifestyles | 22 | 20 | 26 |
| M4 - People who have difficulty planning or organizing | 21 | 20 | 26 |
| M4 - People who have stable income and stable housing | 21 | 16 | 26 |
| M4 - People who experience homelessness or are unstably housed | 23 | 21 | 29 |
| M4 - People who have psychiatric comorbidities | 21 | 20 | 25 |
| M4 - People who are incarcerated, temporarily incarcerated, or recently released from incarceration | 21 | 21 | 23 |
| M4 - Other | 0 | 0 | 1 |
| M12 - People who have been sexually active with 1 or more partners in the last 6 months | 25 | 24 | 30 |
| M12 - People who have sex without a condom | 26 | 23 | 31 |
| M12 - People who engage in anal sex | 25 | 20 | 28 |
| M12 - People who have a sexual partner living with HIV | 25 | 26 | 32 |
| M12 - People who are in monogamous relationships | 17 | 11 | 20 |
| M12 - People who have sex with a person/people who inject drugs | 25 | 25 | 28 |
| M12 - People who have sex with someone who has recently been in jail/prison | 24 | 22 | 26 |
| M12 - People who currently have or had an STI other than HIV within the past 6 months | 25 | 24 | 29 |
| M12 - People who are currently adherent on daily oral PrEP | 19 | 14 | 24 |
| M12 - Adherent daily oral PrEP users preferring a long-acting option | 22 | 22 | 29 |
| M12 - People who are non-adherent on daily oral PrEP | 21 | 21 | 25 |
| M12 - People who use oral PrEP on demand (i.e., event-based PrEP, PrEP 2-1-1) | 21 | 16 | 23 |
| M12 - People who could benefit from PrEP but do not want to use daily oral PrEP | 24 | 20 | 29 |
| M12 - People who have previously used and discontinued oral PrEP | 24 | 19 | 26 |
| M12 - People who feel stigmatized about taking oral PrEP | 23 | 20 | 27 |
| M12 - request APRETUDE spontaneously | 22 | 18 | 25 |
| M12 - People who experience stigma around using HIV prevention | 24 | 21 | 27 |
| M12 - People who are concerned about taking pills every day | 24 | 21 | 27 |
| M12 - People who experience stress of anxiety over adherence of a daily pill regimen | 24 | 24 | 27 |
| M12 - People who live in areas with high HIV prevalence | 24 | 21 | 29 |
| M12 - People who inject drugs | 20 | 21 | 27 |
| M12 - People who have more chaotic lifestyles | 18 | 14 | 23 |
| M12 - People who have more structured lifestyles | 22 | 15 | 24 |
| M12 - People who have difficulty planning or organizing | 20 | 16 | 21 |
| M12 - People who have stable income and stable housing | 22 | 16 | 23 |
| M12 - People who experience homelessness or are unstably housed | 21 | 17 | 23 |
| M12 - People who have psychiatric comorbidities | 21 | 12 | 20 |
| M12 - People who are incarcerated, temporarily incarcerated, or recently released from incarceration | 19 | 15 | 21 |
| M12 - Other | 1 | 0 | 0 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. The number of SSPs reporting in the ISQ that APRETUDE is more appropriate for specific patient demographic groups is displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| At Baseline — Yes | 24 | 35 | 22 |
| At Baseline — No | 16 | 17 | 18 |
| At Month 4 — Yes | 16 | 22 | 20 |
| At Month 4 — No | 13 | 10 | 18 |
| At Month 12 — Yes | 11 | 14 | 15 |
| At Month 12 — No | 15 | 12 | 17 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions of the appropriateness of APRETUDE for specific patient demographics groups as reported in the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Patients <35 years old | 22 | 31 | 21 |
| BL - Patients 35-50 years old | 18 | 25 | 18 |
| BL - Patients >50 years old | 14 | 23 | 12 |
| BL - Black patients | 23 | 30 | 21 |
| BL - White patients | 18 | 23 | 19 |
| BL - Hispanic/Latinx patients | 22 | 27 | 21 |
| BL - Patients of other races/ethnicities | 18 | 28 | 17 |
| BL - Cis-women (assigned female at birth, identify as female) | 21 | 27 | 19 |
| BL - Trans-women (assigned male at birth, identify as female) | 23 | 33 | 21 |
| BL - Trans-men (assigned female at birth, identify as male) | 19 | 26 | 17 |
| BL - Cis-men (assigned male at birth, identify as male) | 20 | 23 | 19 |
| BL - Non-binary individuals | 19 | 21 | 15 |
| BL - Heterosexual women | 20 | 24 | 18 |
| BL - Bisexual/pansexual women | 22 | 27 | 20 |
| BL - Lesbian women | 12 | 18 | 12 |
| BL - Heterosexual men | 19 | 22 | 18 |
| BL - Men who have sex with men | 21 | 34 | 20 |
| BL - None of the above | 1 | 0 | 0 |
| BL - Other | 0 | 0 | 0 |
| M4 - Patients <35 years old | 14 | 19 | 18 |
| M4 - Patients 35-50 years old | 13 | 17 | 15 |
| M4 - Patients >50 years old | 12 | 14 | 9 |
| M4 - Black patients | 14 | 19 | 16 |
| M4 - White patients | 12 | 13 | 13 |
| M4 - Hispanic/Latinx patients | 12 | 18 | 16 |
| M4 - Patients of other races/ethnicities | 11 | 13 | 13 |
| M4 - Cis-women (assigned female at birth, identify as female) | 13 | 17 | 16 |
| M4 - Trans-women (assigned male at birth, identify as female) | 14 | 21 | 18 |
| M4 - Trans-men (assigned female at birth, identify as male) | 13 | 14 | 16 |
| M4 - Cis-men (assigned male at birth, identify as male) | 13 | 16 | 15 |
| M4 - Non-binary individuals | 12 | 12 | 14 |
| M4 - Heterosexual women | 14 | 19 | 14 |
| M4 - Bisexual/pansexual women | 15 | 17 | 15 |
| M4 - Lesbian women | 10 | 9 | 10 |
| M4 - Heterosexual men | 12 | 15 | 11 |
| M4 - Men who have sex with men | 15 | 21 | 18 |
| M4 - None of the above | 0 | 0 | 0 |
| M4 - Other | 1 | 1 | 0 |
| M12 - Patients <35 years old | 10 | 12 | 14 |
| M12 - Patients 35-50 years old | 8 | 11 | 12 |
| M12 - Patients >50 years old | 6 | 11 | 11 |
| M12 - Black patients | 9 | 12 | 14 |
| M12 - White patients | 8 | 11 | 12 |
| M12 - Hispanic/Latinx patients | 8 | 12 | 13 |
| M12 - Patients of other races/ethnicities | 7 | 9 | 11 |
| M12 - Cis-women (assigned female at birth, identify as female) | 9 | 10 | 13 |
| M12 - Trans-women (assigned male at birth, identify as female) | 9 | 11 | 13 |
| M12 - Trans-men (assigned female at birth, identify as male) | 8 | 10 | 13 |
| M12 - Cis-men (assigned male at birth, identify as male) | 8 | 10 | 12 |
| M12 - Non-binary individuals | 8 | 10 | 12 |
| M12 - Heterosexual women | 9 | 10 | 11 |
| M12 - Bisexual/pansexual women | 9 | 11 | 12 |
| M12 - Lesbian women | 6 | 7 | 7 |
| M12 - Heterosexual men | 8 | 8 | 11 |
| M12 - Men who have sex with men | 10 | 13 | 13 |
| M12 - None of the above | 0 | 0 | 0 |
| M12 - Other | 1 | 1 | 0 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this outcome measure, appropriateness of APRETUDE for patients was reported by SSPs by rating in the ISQ their level of concern (ranging from "Not at all concerned" to "Extremely concerned") surrounding patients' belief in the efficacy of APRETUDE and experience with pain.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Patients' injection-related pain/soreness — Extremely concerned | 2 | 6 | 0 |
| BL - Patients' injection-related pain/soreness — Moderately concerned | 5 | 12 | 5 |
| BL - Patients' injection-related pain/soreness — Somewhat concerned | 7 | 7 | 7 |
| BL - Patients' injection-related pain/soreness — Slightly concerned | 15 | 21 | 17 |
| BL - Patients' injection-related pain/soreness — Not at all concerned | 11 | 6 | 11 |
| M4 - Patients' injection-related pain/soreness — Extremely concerned | 4 | 1 | 0 |
| M4 - Patients' injection-related pain/soreness — Moderately concerned | 2 | 4 | 0 |
| M4 - Patients' injection-related pain/soreness — Somewhat concerned | 6 | 5 | 10 |
| M4 - Patients' injection-related pain/soreness — Slightly concerned | 14 | 10 | 17 |
| M4 - Patients' injection-related pain/soreness — Not at all concerned | 3 | 12 | 11 |
| M12 - Patients' injection-related pain/soreness — Extremely concerned | 4 | 0 | 0 |
| M12 - Patients' injection-related pain/soreness — Moderately concerned | 3 | 4 | 2 |
| M12 - Patients' injection-related pain/soreness — Somewhat concerned | 9 | 6 | 8 |
| M12 - Patients' injection-related pain/soreness — Slightly concerned | 7 | 6 | 12 |
| M12 - Patients' injection-related pain/soreness — Not at all concerned | 3 | 10 | 10 |
| BL - Patient lack of belief in the efficacy of APRETUDE — Extremely concerned | 3 | 6 | 0 |
| BL - Patient lack of belief in the efficacy of APRETUDE — Moderately concerned | 4 | 4 | 3 |
| BL - Patient lack of belief in the efficacy of APRETUDE — Somewhat concerned | 7 | 9 | 8 |
| BL - Patient lack of belief in the efficacy of APRETUDE — Slightly concerned | 12 | 13 | 10 |
| BL - Patient lack of belief in the efficacy of APRETUDE — Not at all concerned | 14 | 20 | 19 |
| M4 - Patient lack of belief in the efficacy of APRETUDE — Extremely concerned | 1 | 0 | 0 |
| M4 - Patient lack of belief in the efficacy of APRETUDE — Moderately concerned | 4 | 1 | 0 |
| M4 - Patient lack of belief in the efficacy of APRETUDE — Somewhat concerned | 3 | 4 | 3 |
| M4 - Patient lack of belief in the efficacy of APRETUDE — Slightly concerned | 10 | 12 | 12 |
| M4 - Patient lack of belief in the efficacy of APRETUDE — Not at all concerned | 11 | 15 | 23 |
| M12 - Patient lack of belief in the efficacy of APRETUDE — Extremely concerned | 2 | 0 | 1 |
| M12 - Patient lack of belief in the efficacy of APRETUDE — Moderately concerned | 4 | 1 | 1 |
| M12 - Patient lack of belief in the efficacy of APRETUDE — Somewhat concerned | 4 | 5 | 9 |
| M12 - Patient lack of belief in the efficacy of APRETUDE — Slightly concerned | 6 | 4 | 7 |
| M12 - Patient lack of belief in the efficacy of APRETUDE — Not at all concerned | 10 | 16 | 14 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the appropriateness of APRETUDE gathered during SSIs at baseline are displayed. This outcome measure presents common concepts identified from qualitative analysis of PSPs' perceived appropriateness of APRETUDE. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Belief that injectable has better adherence than pill | 1 | 2 | 3 |
| PSPs felt prepared to get APRETUDE | 18 | 12 | 17 |
| PSPs felt unprepared to get APRETUDE | 3 | 1 | 3 |
| Concerns about effectiveness | 5 | 0 | 2 |
| No concerns about effectiveness | 18 | 12 | 17 |
| Confused about what is required for APRETUDE to work | 4 | 3 | 3 |
| No confusion about what is required for APRETUDE to work | 10 | 5 | 10 |
| Expectations for APRETUDE to be effective | 6 | 2 | 6 |
| Perceived need for a long-acting injection such as APRETUDE | 16 | 8 | 17 |
| No perceived need for a long-acting injection such as APRETUDE | 0 | 0 | 1 |
| APRETUDE is considered a good match for PSPs and women like them | 15 | 12 | 10 |
Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Intends to continue using APRETUDE | 14 | 9 | 12 |
| APRETUDE is a long-term fit | 8 | 5 | 11 |
| APRETUDE can protect or is convenient | 7 | 6 | 3 |
| Facilitators to continued use of APRETUDE | 12 | 5 | 5 |
| Barriers to continued use of APRETUDE | 5 | 3 | 3 |
| Endorsed appropriateness of APRETUDE | 3 | 3 | 4 |
| APRETUDE is convenient | 16 | 7 | 11 |
| APRETUDE addressed adherence challenges | 1 | 2 | 4 |
| APRETUDE perceived as providing an additional layer of protection | 6 | 4 | 5 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by gender. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | ECI - Cisgender | ECI - Transgender |
|---|---|---|
| Yes | 10 | 4 |
| No | 0 | 1 |
| I don't know | 6 | 2 |
| Missing | 1 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by clinic type to represent differences across clinical settings. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | ECI - Women's Health Clinic | ECI - Primary Care Clinic | ECI - HIV Specialist Clinic |
|---|---|---|---|
| Yes | 7 | 1 | 6 |
| No | 0 | 1 | 0 |
| I don't know | 3 | 2 | 3 |
| Missing | 0 | 0 | 1 |
Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Study Arm | 13 | 10 | 6 |
Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Clinic Setting | 4 | 10 | 15 |
Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Study Arm | 32 | 10 | 22 |
Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Clinic Setting | 13 | 22 | 29 |
The FIM was used to assess the feasibility of the PrEP training provided only to EI and ECI arms using a four-item measure (1. The PrEP training would be easily implemented as part of my continuing education 2. It would be possible to incorporate the PrEP training into my continuing education efforts 3. The PrEP training was doable as a continuing education activity 4. The PrEP training was easy to use) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI); and was not assessed at baseline as sites had not had time to utilize the tool.
| Scores on a scale | EI - SSP | ECI - SSP |
|---|---|---|
| Month 4 | 4.3 ± 0.62 | 3.9 ± 0.73 |
| Month 12 | 4.6 ± 0.50 | 4.3 ± 0.67 |
This outcome assesses the change in FIM score for PrEP Training for SSPs over time. The change in FIM score was calculated as the longitudinal mean change from Month 4 to Month 12. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI) compared to M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).
| Scores on a scale | EI - SSP | ECI - SSP |
|---|---|---|
| Change in FIM Score for PrEP Training Assessed for SSPs | -0.1 ± 0.40 | 0.4 ± 0.81 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of study tools gathered through the ISQ at BL, M4, and M12 are displayed. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents SSPs'perception of ease of implementation of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool.
| Participants | EI - SSP | ECI - SSP |
|---|---|---|
| The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Completely disagree | 0 | 0 |
| The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Disagree | 0 | 0 |
| The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Neither agree nor disagree | 15 | 0 |
| The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Agree | 19 | 0 |
| The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Completely agree | 14 | 0 |
| The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Completely disagree | 0 | 0 |
| The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Disagree | 0 | 1 |
| The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Neither agree nor disagree | 0 | 17 |
| The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Agree | 0 | 17 |
| The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Completely agree | 0 | 5 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the planned frequency of use of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool among SSPs' clinics.
| Participants | EI - SSP | ECI - SSP |
|---|---|---|
| Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — Annually with each patient | 3 | — |
| Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — Before every visit with each patient | 5 | — |
| Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — As needed based on patient demographics | 5 | — |
| Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — As needed based on patient behaviors | 14 | — |
| Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — I don't know | 21 | — |
| Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — Other | 0 | — |
| Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — Annually with each patient | — | 1 |
| Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — Before every visit with each patient | — | 8 |
| Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — As needed based on patient demographics | — | 2 |
| Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — As needed based on patient behaviors | — | 4 |
| Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — I don't know | — | 24 |
| Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — Other | — | 1 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).
| Participants | EI - SSP | ECI - SSP |
|---|---|---|
| The PrEP training was easy to use — Completely disagree | 0 | 0 |
| The PrEP training was easy to use — Disagree | 0 | 0 |
| The PrEP training was easy to use — Neither agree nor disagree | 1 | 2 |
| The PrEP training was easy to use — Agree | 8 | 13 |
| The PrEP training was easy to use — Completely agree | 5 | 3 |
| The amount of time involved in using this PrEP training has been fitting for me — Completely disagree | 0 | 0 |
| The amount of time involved in using this PrEP training has been fitting for me — Disagree | 0 | 0 |
| The amount of time involved in using this PrEP training has been fitting for me — Neither agree nor disagree | 1 | 4 |
| The amount of time involved in using this PrEP training has been fitting for me — Agree | 8 | 12 |
| The amount of time involved in using this PrEP training has been fitting for me — Completely agree | 5 | 2 |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Completely disagree | 0 | — |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Disagree | 0 | — |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Neither agree nor disagree | 4 | — |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Agree | 11 | — |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Completely agree | 6 | — |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Completely disagree | — | 0 |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Disagree | — | 0 |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Neither agree nor disagree | — | 4 |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Agree | — | 7 |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Completely agree | — | 2 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).
| Participants | EI - SSP | ECI - SSP |
|---|---|---|
| The PrEP training was easy to use — Completely disagree | 0 | 0 |
| The PrEP training was easy to use — Disagree | 0 | 0 |
| The PrEP training was easy to use — Neither agree nor disagree | 0 | 1 |
| The PrEP training was easy to use — Agree | 6 | 9 |
| The PrEP training was easy to use — Completely agree | 8 | 7 |
| The amount of time involved in using this PrEP training has been fitting for me — Completely disagree | 0 | 0 |
| The amount of time involved in using this PrEP training has been fitting for me — Disagree | 0 | 1 |
| The amount of time involved in using this PrEP training has been fitting for me — Neither agree nor disagree | 2 | 3 |
| The amount of time involved in using this PrEP training has been fitting for me — Agree | 7 | 9 |
| The amount of time involved in using this PrEP training has been fitting for me — Completely agree | 5 | 4 |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Completely disagree | 0 | — |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Disagree | 0 | — |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Neither agree nor disagree | 1 | — |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Agree | 8 | — |
| The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Completely agree | 6 | — |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Completely disagree | — | 0 |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Disagree | — | 0 |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Neither agree nor disagree | — | 4 |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Agree | — | 5 |
| The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Completely agree | — | 3 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).
| Participants | EI - SSP | ECI - SSP |
|---|---|---|
| Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Rarely | 1 | — |
| Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Sometimes | 8 | — |
| Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Often | 6 | — |
| Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — All the time | 6 | — |
| Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Rarely | — | 2 |
| Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Sometimes | — | 4 |
| Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Often | — | 2 |
| Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — All the time | — | 5 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).
| Participants | EI - SSP | ECI - SSP |
|---|---|---|
| Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Rarely | 0 | — |
| Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Sometimes | 5 | — |
| Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Often | 5 | — |
| Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — All the time | 5 | — |
| Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Rarely | — | 0 |
| Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Sometimes | — | 6 |
| Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Often | — | 2 |
| Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — All the time | — | 4 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Participants | EI - SSP |
|---|---|
| M4 - Currently using PrEP Options Communication Tool — Yes | 21 |
| M4 - Currently using PrEP Options Communication Tool — No | 6 |
| M4 - Currently using PrEP Options Communication Tool — I don't know | 5 |
| M12 - Currently using PrEP Options Communication Tool — Yes | 15 |
| M12 - Currently using PrEP Options Communication Tool — No | 3 |
| M12 - Currently using PrEP Options Communication Tool — I don't know | 8 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.
| Participants | EI - SSP |
|---|---|
| Already have a similar tool | 1 |
| Do not have time in a clinical visit to use the tool | 1 |
| Do not understand the information in the tool | 0 |
| Tool does not provide the right information | 0 |
| Tool is not needed | 3 |
| Other | 1 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.
| Participants | EI - SSP |
|---|---|
| Already have a similar tool | 2 |
| Do not have time in a clinical visit to use the tool | 0 |
| Do not understand the information in the tool | 0 |
| Tool does not provide the right information | 0 |
| Tool is not needed | 2 |
| Other | 0 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Participants | ECI - SSP |
|---|---|
| M4 - Currently using Sexual Health Assessment Tool — Yes | 13 |
| M4 - Currently using Sexual Health Assessment Tool — No | 9 |
| M4 - Currently using Sexual Health Assessment Tool — I don't know | 16 |
| M12 - Currently using Sexual Health Assessment Tool — Yes | 12 |
| M12 - Currently using Sexual Health Assessment Tool — No | 6 |
| M12 - Currently using Sexual Health Assessment Tool — I don't know | 14 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons the Sexual Health Assessment Tool was not used by a clinic/practice.
| Participants | ECI - SSP |
|---|---|
| Already have a similar assessment | 8 |
| Does not integrate with the EMR | 5 |
| The assessment is difficult to administer | 0 |
| Concerns about patient privacy | 0 |
| The assessment does not ask the right questions | 0 |
| The assessment takes too much time | 0 |
| The assessment is not needed | 0 |
| Other | 1 |
Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons why the Sexual Health Assessment Tool was not used by a clinic/practice.
| Participants | ECI - SSP |
|---|---|
| Already have a similar assessment | 5 |
| Does not integrate with the EMR | 2 |
| The assessment is difficult to administer | 0 |
| Concerns about patient privacy | 0 |
| The assessment does not ask the right questions | 0 |
| The assessment takes too much time | 0 |
| The assessment is not needed | 0 |
| Other | 1 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Guide to Getting Started - Useful | 9 | 11 | 9 |
| Frequently Asked Questions - Useful | 8 | 10 | 7 |
| Dosing and Administration Guide - Useful | 11 | 7 | 10 |
| Injection Education Video - Useful | 10 | 11 | 13 |
| Instructions for Use Flashcard - Useful | 9 | 9 | 8 |
| Medication Administration Planner - Useful | 4 | 5 | 8 |
| Important Safety Information - Useful | 9 | 9 | 9 |
| Readiness Considerations Checklist - Useful | 5 | 7 | 6 |
| ViiVConnect Materials - Useful | 8 | 2 | 3 |
| GSK Response Center - Useful | 2 | 2 | 4 |
| Provider Website - Useful (SI Only) | 10 | — | — |
| EBONI Spot - Useful (EI/ECI Only) | — | 12 | 15 |
| PrEP are for Black Women Training - Useful (EI/ECI Only) | — | 2 | 6 |
| How to Discuss Sexual Health Guidance Document - Useful (EI/ECI Only) | — | 4 | 3 |
| Implementation Guidance Video - Useful (EI/ECI Only) | — | 5 | 5 |
| PrEP Communications Options Tool - Useful (EI Only) | — | 7 | — |
| Medication Acquisition Tracker - Useful (EI Only) | — | 1 | — |
| Introduction to ViiVConnect Video - Useful (EI Only) | — | 5 | — |
| APRETUDE Payer Information - Useful (EI Only) | — | 4 | — |
| Sexual Health Assessment - Useful (ECI Only) | — | — | 9 |
| Other Tools and Resources | 11 | 8 | 9 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Guide to Getting Started - Useful | 10 | 7 | 10 |
| FAQ Brochure - Useful | 10 | 6 | 9 |
| Dosing and Administration Guide - Useful | 12 | 9 | 11 |
| Injection Education Video - Useful | 3 | 10 | 11 |
| Instructions for Use Flashcard - Useful | 11 | 8 | 10 |
| Medication and Administration Planner - Useful | 7 | 1 | 4 |
| Important Safety Information - Useful | 13 | 8 | 7 |
| Readiness Considerations Checklist - Useful | 4 | 4 | 4 |
| ViiVConnect Materials - Useful | 11 | 6 | 8 |
| GSK Response Center - Useful | 2 | 4 | 4 |
| Provider Website - Useful | 7 | — | — |
| EBONI Spot - Useful | — | 8 | 10 |
| PrEPare for Black Women Training - Useful | — | 8 | 3 |
| Sexual Health Guidance Document - Useful | — | 5 | 3 |
| Implementation Guidance Video - Useful | — | 9 | 7 |
| PrEP Communication Options Tool - Useful | — | 9 | — |
| Medication Acquisition Tracker - Useful | — | 2 | — |
| Introduction to ViiVConnect Video - Useful | — | 6 | — |
| APRETUDE Payer Information - Useful | — | 4 | — |
| Sexual Health Assessment - Useful | — | — | 4 |
| Tools and strategies adequate: No gaps | 15 | 13 | 12 |
| Tools and strategies not needed: Past experience | 3 | 1 | 4 |
| Patient-facing resource needs | 4 | 3 | 2 |
| Need for guidance on insurance and product acquisition | 5 | 0 | 1 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on if study tools were fit for use were gathered. Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Used Frequently Asked Questions Brochure — Yes | 16 | 17 | 17 |
| Used Frequently Asked Questions Brochure — No | 6 | 6 | 8 |
| Used Frequently Asked Questions Brochure — I don't remember | 4 | 3 | 7 |
| Used Readiness Considerations Checklist — Yes | 18 | 17 | 13 |
| Used Readiness Considerations Checklist — No | 4 | 4 | 9 |
| Used Readiness Considerations Checklist — I don't remember | 4 | 5 | 10 |
| Used Getting Started Guide — Yes | 17 | 17 | 14 |
| Used Getting Started Guide — No | 6 | 5 | 8 |
| Used Getting Started Guide — I don't remember | 3 | 4 | 10 |
| Used Injection Education Video — Yes | 18 | 16 | 20 |
| Used Injection Education Video — No | 5 | 7 | 7 |
| Used Injection Education Video — I don't remember | 3 | 3 | 5 |
| Used Provider Website (SI only) — Yes | 19 | — | — |
| Used Provider Website (SI only) — No | 4 | — | — |
| Used Provider Website (SI only) — I don't remember | 3 | — | — |
| Used Instructions for Use flashcard — Yes | 20 | 16 | 17 |
| Used Instructions for Use flashcard — No | 4 | 6 | 8 |
| Used Instructions for Use flashcard — I don't remember | 2 | 4 | 7 |
| Used Important Safety Information document — Yes | 19 | 15 | 19 |
| Used Important Safety Information document — No | 4 | 7 | 6 |
| Used Important Safety Information document — I don't remember | 3 | 4 | 7 |
| Used patient materials (e.g., welcome brochure) — Yes | 18 | 14 | 17 |
| Used patient materials (e.g., welcome brochure) — No | 5 | 7 | 6 |
| Used patient materials (e.g., welcome brochure) — I don't remember | 3 | 5 | 9 |
| Used Dosing and Administration Guide — Yes | 18 | 14 | 18 |
| Used Dosing and Administration Guide — No | 5 | 8 | 7 |
| Used Dosing and Administration Guide — I don't remember | 3 | 4 | 7 |
| Used Implementation Guidance Video (ECI/EI only) — Yes | — | 13 | 12 |
| Used Implementation Guidance Video (ECI/EI only) — No | — | 7 | 10 |
| Used Implementation Guidance Video (ECI/EI only) — I don't remember | — | 6 | 10 |
| Used Medication Administration Planner — Yes | 12 | 12 | 8 |
| Used Medication Administration Planner — No | 7 | 9 | 15 |
| Used Medication Administration Planner — I don't remember | 7 | 5 | 9 |
| Used document on how to discuss sexual health (ECI/EI only) — Yes | — | 14 | 9 |
| Used document on how to discuss sexual health (ECI/EI only) — No | — | 9 | 13 |
| Used document on how to discuss sexual health (ECI/EI only) — I don't remember | — | 3 | 10 |
| Used EBONI Spot (ECI/EI only) — Yes | — | 18 | 19 |
| Used EBONI Spot (ECI/EI only) — No | — | 4 | 5 |
| Used EBONI Spot (ECI/EI only) — I don't remember | — | 4 | 8 |
| Used GSK Response Center — Yes | 8 | 7 | 6 |
| Used GSK Response Center — No | 13 | 17 | 25 |
| Used GSK Response Center — I don't remember | 5 | 2 | 1 |
| Used ViiV Connect Video — Yes | 3 | 8 | 4 |
| Used ViiV Connect Video — No | 3 | 1 | 5 |
| Used ViiV Connect Video — I don't remember | 3 | 1 | 0 |
| Used Medication Acquisition Tracker (EI only) — Yes | — | 5 | — |
| Used Medication Acquisition Tracker (EI only) — No | — | 3 | — |
| Used Medication Acquisition Tracker (EI only) — I don't remember | — | 2 | — |
| Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — Yes | — | 14 | 17 |
| Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — No | — | 9 | 9 |
| Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — I don't remember | — | 3 | 6 |
Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Helpfulness of Frequently Asked Questions Brochure — Very helpful | 7 | 10 | 8 |
| Helpfulness of Frequently Asked Questions Brochure — Somewhat helpful | 5 | 5 | 5 |
| Helpfulness of Frequently Asked Questions Brochure — A little helpful | 3 | 1 | 4 |
| Helpfulness of Frequently Asked Questions Brochure — Not at all helpful | 1 | 1 | 0 |
| Helpfulness of Readiness Considerations Checklist — Very helpful | 8 | 11 | 9 |
| Helpfulness of Readiness Considerations Checklist — Somewhat helpful | 6 | 4 | 3 |
| Helpfulness of Readiness Considerations Checklist — A little helpful | 3 | 2 | 1 |
| Helpfulness of Readiness Considerations Checklist — Not at all helpful | 1 | 0 | 0 |
| Helpfulness of Getting Started Guide — Very helpful | 6 | 11 | 8 |
| Helpfulness of Getting Started Guide — Somewhat helpful | 5 | 5 | 3 |
| Helpfulness of Getting Started Guide — A little helpful | 5 | 1 | 3 |
| Helpfulness of Getting Started Guide — Not at all helpful | 1 | 0 | 0 |
| Helpfulness of Injection Education Video — Very helpful | 10 | 14 | 15 |
| Helpfulness of Injection Education Video — Somewhat helpful | 5 | 1 | 5 |
| Helpfulness of Injection Education Video — A little helpful | 2 | 1 | 0 |
| Helpfulness of Injection Education Video — Not at all helpful | 1 | 0 | 0 |
| Helpfulness of Provider Website (SI only) — Very helpful | 7 | — | — |
| Helpfulness of Provider Website (SI only) — Somewhat helpful | 6 | — | — |
| Helpfulness of Provider Website (SI only) — A little helpful | 4 | — | — |
| Helpfulness of Provider Website (SI only) — Not at all helpful | 2 | — | — |
| Helpfulness of Instructions for Use flashcard — Very helpful | 8 | 12 | 15 |
| Helpfulness of Instructions for Use flashcard — Somewhat helpful | 10 | 3 | 2 |
| Helpfulness of Instructions for Use flashcard — A little helpful | 1 | 1 | 0 |
| Helpfulness of Instructions for Use flashcard — Not at all helpful | 1 | 0 | 0 |
| Helpfulness of Important Safety Information document — Very helpful | 10 | 10 | 12 |
| Helpfulness of Important Safety Information document — Somewhat helpful | 5 | 3 | 6 |
| Helpfulness of Important Safety Information document — A little helpful | 3 | 2 | 0 |
| Helpfulness of Important Safety Information document — Not at all helpful | 1 | 0 | 1 |
| Helpfulness of patient materials (e.g., welcome brochure) — Very helpful | 9 | 9 | 12 |
| Helpfulness of patient materials (e.g., welcome brochure) — Somewhat helpful | 4 | 4 | 2 |
| Helpfulness of patient materials (e.g., welcome brochure) — A little helpful | 4 | 1 | 2 |
| Helpfulness of patient materials (e.g., welcome brochure) — Not at all helpful | 1 | 0 | 1 |
| Helpfulness of Dosing and Administration Guide — Very helpful | 11 | 9 | 13 |
| Helpfulness of Dosing and Administration Guide — Somewhat helpful | 3 | 4 | 4 |
| Helpfulness of Dosing and Administration Guide — A little helpful | 3 | 1 | 0 |
| Helpfulness of Dosing and Administration Guide — Not at all helpful | 1 | 0 | 1 |
| Helpfulness of Implementation Guidance Video (ECI/EI only) — Very helpful | — | 8 | 9 |
| Helpfulness of Implementation Guidance Video (ECI/EI only) — Somewhat helpful | — | 3 | 2 |
| Helpfulness of Implementation Guidance Video (ECI/EI only) — A little helpful | — | 1 | 1 |
| Helpfulness of Implementation Guidance Video (ECI/EI only) — Not at all helpful | — | 1 | 0 |
| Helpfulness of Medication Administration Planner — Very helpful | 7 | 6 | 5 |
| Helpfulness of Medication Administration Planner — Somewhat helpful | 2 | 5 | 3 |
| Helpfulness of Medication Administration Planner — A little helpful | 2 | 1 | 0 |
| Helpfulness of Medication Administration Planner — Not at all helpful | 1 | 0 | 0 |
| Helpfulness of how to discuss sexual health (ECI/EI only) — Very helpful | — | 9 | 6 |
| Helpfulness of how to discuss sexual health (ECI/EI only) — Somewhat helpful | — | 4 | 3 |
| Helpfulness of how to discuss sexual health (ECI/EI only) — A little helpful | — | 1 | 0 |
| Helpfulness of how to discuss sexual health (ECI/EI only) — Not at all helpful | — | 0 | 0 |
| Helpfulness of EBONI Spot (ECI/EI only) — Very helpful | — | 10 | 11 |
| Helpfulness of EBONI Spot (ECI/EI only) — Somewhat helpful | — | 7 | 5 |
| Helpfulness of EBONI Spot (ECI/EI only) — A little helpful | — | 1 | 3 |
| Helpfulness of EBONI Spot (ECI/EI only) — Not at all helpful | — | 0 | 0 |
| Helpfulness of GSK Response Center — Very helpful | 1 | 5 | 1 |
| Helpfulness of GSK Response Center — Somewhat helpful | 5 | 2 | 4 |
| Helpfulness of GSK Response Center — A little helpful | 1 | 0 | 1 |
| Helpfulness of GSK Response Center — Not at all helpful | 1 | 0 | 0 |
| Helpfulness of ViiV Connect Video — Very helpful | 1 | 6 | 2 |
| Helpfulness of ViiV Connect Video — Somewhat helpful | 2 | 1 | 0 |
| Helpfulness of ViiV Connect Video — A little helpful | 0 | 1 | 1 |
| Helpfulness of ViiV Connect Video — Not at all helpful | 0 | 0 | 1 |
| Helpfulness of Medication Acquisition Tracker (EI only) — Very helpful | — | 3 | — |
| Helpfulness of Medication Acquisition Tracker (EI only) — Somewhat helpful | — | 0 | — |
| Helpfulness of Medication Acquisition Tracker (EI only) — A little helpful | — | 0 | — |
| Helpfulness of Medication Acquisition Tracker (EI only) — Not at all helpful | — | 2 | — |
PrEP training and tools were only available to selected arms (EI and/or ECI). Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients" (ECI only).
| Participants | EI - SSP | ECI - SSP |
|---|---|---|
| The PrEP training would be useful for my healthcare practice — Completely disagree | 0 | 0 |
| The PrEP training would be useful for my healthcare practice — Disagree | 0 | 0 |
| The PrEP training would be useful for my healthcare practice — Neither agree nor disagree | 0 | 3 |
| The PrEP training would be useful for my healthcare practice — Agree | 7 | 7 |
| The PrEP training would be useful for my healthcare practice — Completely agree | 7 | 7 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Completely disagree | 0 | 0 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Disagree | 0 | 1 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Neither agree nor disagree | 0 | 1 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Agree | 8 | 10 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Completely agree | 6 | 5 |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Completely disagree | 0 | — |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Disagree | 0 | — |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Neither agree nor disagree | 1 | — |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Agree | 8 | — |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Completely agree | 6 | — |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Completely disagree | — | 0 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Disagree | — | 0 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Neither agree nor disagree | — | 3 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Agree | — | 6 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Completely agree | — | 3 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Completely disagree | — | 0 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Disagree | — | 0 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Neither agree nor disagree | — | 4 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Agree | — | 4 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Completely agree | — | 4 |
Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).
| Participants | Women's Health Clinic - SSP | Primary Care Clinic - SSP | HIV Specialist Clinic - SSP |
|---|---|---|---|
| Used Frequently Asked Questions Brochure — Yes | 6 | 17 | 27 |
| Used Frequently Asked Questions Brochure — No | 3 | 2 | 15 |
| Used Frequently Asked Questions Brochure — I don't remember | 2 | 5 | 7 |
| Used Readiness Considerations Checklist — Yes | 5 | 15 | 28 |
| Used Readiness Considerations Checklist — No | 3 | 3 | 11 |
| Used Readiness Considerations Checklist — I don't remember | 3 | 6 | 10 |
| Used Getting Started Guide — Yes | 6 | 15 | 27 |
| Used Getting Started Guide — No | 3 | 3 | 13 |
| Used Getting Started Guide — I don't remember | 2 | 6 | 9 |
| Used Injection Education Video — Yes | 6 | 16 | 32 |
| Used Injection Education Video — No | 4 | 5 | 10 |
| Used Injection Education Video — I don't remember | 1 | 3 | 7 |
| Used Provider Website (SI only) — Yes | 0 | 8 | 11 |
| Used Provider Website (SI only) — No | 0 | 0 | 4 |
| Used Provider Website (SI only) — I don't remember | 0 | 1 | 2 |
| Used Instructions for Use flashcard — Yes | 5 | 18 | 30 |
| Used Instructions for Use flashcard — No | 4 | 3 | 11 |
| Used Instructions for Use flashcard — I don't remember | 2 | 3 | 8 |
| Used Important Safety Information document — Yes | 7 | 17 | 29 |
| Used Important Safety Information document — No | 2 | 3 | 12 |
| Used Important Safety Information document — I don't remember | 2 | 4 | 8 |
| Used patient materials (e.g., welcome brochure) — Yes | 5 | 15 | 29 |
| Used patient materials (e.g., welcome brochure) — No | 2 | 3 | 13 |
| Used patient materials (e.g., welcome brochure) — I don't remember | 4 | 6 | 7 |
| Used Dosing and Administration Guide — Yes | 8 | 15 | 27 |
| Used Dosing and Administration Guide — No | 2 | 4 | 14 |
| Used Dosing and Administration Guide — I don't remember | 1 | 5 | 8 |
| Used Implementation Guidance Video (ECI/EI only) — Yes | 5 | 6 | 14 |
| Used Implementation Guidance Video (ECI/EI only) — No | 2 | 6 | 9 |
| Used Implementation Guidance Video (ECI/EI only) — I don't remember | 4 | 3 | 9 |
| Used Medication Administration Planner — Yes | 4 | 10 | 18 |
| Used Medication Administration Planner — No | 3 | 8 | 20 |
| Used Medication Administration Planner — I don't remember | 4 | 6 | 11 |
| Used document on how to discuss sexual health (ECI/EI only) — Yes | 3 | 5 | 15 |
| Used document on how to discuss sexual health (ECI/EI only) — No | 3 | 6 | 13 |
| Used document on how to discuss sexual health (ECI/EI only) — I don't remember | 5 | 4 | 4 |
| Used EBONI Spot (ECI/EI only) — Yes | 6 | 10 | 21 |
| Used EBONI Spot (ECI/EI only) — No | 1 | 2 | 6 |
| Used EBONI Spot (ECI/EI only) — I don't remember | 4 | 3 | 5 |
| Used GSK Response Center — Yes | 2 | 7 | 12 |
| Used GSK Response Center — No | 9 | 16 | 30 |
| Used GSK Response Center — I don't remember | 0 | 1 | 7 |
| Used ViiV Connect Video — Yes | 2 | 2 | 11 |
| Used ViiV Connect Video — No | 1 | 4 | 4 |
| Used ViiV Connect Video — I don't remember | 0 | 2 | 2 |
| Used Medication Acquisition Tracker (EI only) — Yes | 0 | 0 | 5 |
| Used Medication Acquisition Tracker (EI only) — No | 0 | 0 | 3 |
| Used Medication Acquisition Tracker (EI only) — I don't remember | 0 | 1 | 1 |
| Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — Yes | 9 | 6 | 16 |
| Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — No | 1 | 6 | 11 |
| Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — I don't remember | 1 | 3 | 5 |
Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.
| Participants | Women's Health Clinic - SSP | Primary Care Clinic - SSP | HIV Specialist Clinic - SSP |
|---|---|---|---|
| Helpfulness of Frequently Asked Questions Brochure — Very helpful | 2 | 8 | 15 |
| Helpfulness of Frequently Asked Questions Brochure — Somewhat helpful | 2 | 6 | 7 |
| Helpfulness of Frequently Asked Questions Brochure — A little helpful | 2 | 3 | 3 |
| Helpfulness of Frequently Asked Questions Brochure — Not at all helpful | 0 | 0 | 2 |
| Helpfulness of Readiness Considerations Checklist — Very helpful | 2 | 9 | 17 |
| Helpfulness of Readiness Considerations Checklist — Somewhat helpful | 3 | 5 | 5 |
| Helpfulness of Readiness Considerations Checklist — A little helpful | 0 | 1 | 5 |
| Helpfulness of Readiness Considerations Checklist — Not at all helpful | 0 | 0 | 1 |
| Helpfulness of Getting Started Guide — Very helpful | 2 | 9 | 14 |
| Helpfulness of Getting Started Guide — Somewhat helpful | 3 | 3 | 7 |
| Helpfulness of Getting Started Guide — A little helpful | 1 | 3 | 5 |
| Helpfulness of Getting Started Guide — Not at all helpful | 0 | 0 | 1 |
| Helpfulness of Injection Education Video — Very helpful | 4 | 11 | 24 |
| Helpfulness of Injection Education Video — Somewhat helpful | 2 | 4 | 5 |
| Helpfulness of Injection Education Video — A little helpful | 0 | 1 | 2 |
| Helpfulness of Injection Education Video — Not at all helpful | 0 | 0 | 1 |
| Helpfulness of Provider Website (SI only) — Very helpful | — | 2 | 5 |
| Helpfulness of Provider Website (SI only) — Somewhat helpful | — | 4 | 2 |
| Helpfulness of Provider Website (SI only) — A little helpful | — | 2 | 2 |
| Helpfulness of Provider Website (SI only) — Not at all helpful | — | 0 | 2 |
| Helpfulness of Instructions for Use flashcard — Very helpful | 4 | 11 | 20 |
| Helpfulness of Instructions for Use flashcard — Somewhat helpful | 1 | 7 | 7 |
| Helpfulness of Instructions for Use flashcard — A little helpful | 0 | 0 | 2 |
| Helpfulness of Instructions for Use flashcard — Not at all helpful | 0 | 0 | 1 |
| Helpfulness of Important Safety Information document — Very helpful | 3 | 11 | 18 |
| Helpfulness of Important Safety Information document — Somewhat helpful | 3 | 5 | 6 |
| Helpfulness of Important Safety Information document — A little helpful | 0 | 1 | 4 |
| Helpfulness of Important Safety Information document — Not at all helpful | 1 | 0 | 1 |
| Helpfulness of patient materials (e.g., welcome brochure) — Very helpful | 3 | 10 | 17 |
| Helpfulness of patient materials (e.g., welcome brochure) — Somewhat helpful | 1 | 2 | 7 |
| Helpfulness of patient materials (e.g., welcome brochure) — A little helpful | 0 | 3 | 4 |
| Helpfulness of patient materials (e.g., welcome brochure) — Not at all helpful | 1 | 0 | 1 |
| Helpfulness of Dosing and Administration Guide — Very helpful | 5 | 12 | 16 |
| Helpfulness of Dosing and Administration Guide — Somewhat helpful | 2 | 2 | 7 |
| Helpfulness of Dosing and Administration Guide — A little helpful | 0 | 1 | 3 |
| Helpfulness of Dosing and Administration Guide — Not at all helpful | 1 | 0 | 1 |
| Helpfulness of Implementation Guidance Video (ECI/EI only) — Very helpful | 2 | 6 | 9 |
| Helpfulness of Implementation Guidance Video (ECI/EI only) — Somewhat helpful | 2 | 0 | 3 |
| Helpfulness of Implementation Guidance Video (ECI/EI only) — A little helpful | 1 | 0 | 1 |
| Helpfulness of Implementation Guidance Video (ECI/EI only) — Not at all helpful | 0 | 0 | 1 |
| Helpfulness of Medication Administration Planner — Very helpful | 2 | 7 | 9 |
| Helpfulness of Medication Administration Planner — Somewhat helpful | 2 | 2 | 6 |
| Helpfulness of Medication Administration Planner — A little helpful | 0 | 1 | 2 |
| Helpfulness of Medication Administration Planner — Not at all helpful | 0 | 0 | 1 |
| Helpfulness of how to discuss sexual health (ECI/EI only) — Very helpful | 1 | 5 | 9 |
| Helpfulness of how to discuss sexual health (ECI/EI only) — Somewhat helpful | 2 | 0 | 5 |
| Helpfulness of how to discuss sexual health (ECI/EI only) — A little helpful | 0 | 0 | 1 |
| Helpfulness of how to discuss sexual health (ECI/EI only) — Not at all helpful | 0 | 0 | 0 |
| Helpfulness of EBONI Spot (ECI/EI only) — Very helpful | 2 | 6 | 13 |
| Helpfulness of EBONI Spot (ECI/EI only) — Somewhat helpful | 2 | 3 | 7 |
| Helpfulness of EBONI Spot (ECI/EI only) — A little helpful | 2 | 1 | 1 |
| Helpfulness of EBONI Spot (ECI/EI only) — Not at all helpful | 0 | 0 | 0 |
| Helpfulness of GSK Response Center — Very helpful | 0 | 2 | 5 |
| Helpfulness of GSK Response Center — Somewhat helpful | 1 | 4 | 6 |
| Helpfulness of GSK Response Center — A little helpful | 1 | 1 | 0 |
| Helpfulness of GSK Response Center — Not at all helpful | 0 | 0 | 1 |
| Helpfulness of ViiV Connect Video — Very helpful | 0 | 2 | 7 |
| Helpfulness of ViiV Connect Video — Somewhat helpful | 0 | 0 | 3 |
| Helpfulness of ViiV Connect Video — A little helpful | 1 | 0 | 1 |
| Helpfulness of ViiV Connect Video — Not at all helpful | 1 | 0 | 0 |
| Helpfulness of Medication Acquisition Tracker (EI only) — Very helpful | — | — | 3 |
| Helpfulness of Medication Acquisition Tracker (EI only) — Somewhat helpful | — | — | 0 |
| Helpfulness of Medication Acquisition Tracker (EI only) — A little helpful | — | — | 0 |
| Helpfulness of Medication Acquisition Tracker (EI only) — Not at all helpful | — | — | 2 |
Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients (ECI only)".
| Participants | Women's Health Clinic - SSP | Primary Care Clinic - SSP | HIV Specialist Clinic - SSP |
|---|---|---|---|
| The PrEP training would be useful for my healthcare practice — Completely disagree | 0 | 0 | 0 |
| The PrEP training would be useful for my healthcare practice — Disagree | 0 | 0 | 0 |
| The PrEP training would be useful for my healthcare practice — Neither agree nor disagree | 3 | 0 | 0 |
| The PrEP training would be useful for my healthcare practice — Agree | 3 | 3 | 8 |
| The PrEP training would be useful for my healthcare practice — Completely agree | 3 | 3 | 8 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Completely disagree | 0 | 0 | 0 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Disagree | 1 | 0 | 0 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Neither agree nor disagree | 1 | 0 | 0 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Agree | 5 | 3 | 10 |
| The PrEP training helped me address my patients' HIV prevention concerns effectively — Completely agree | 2 | 3 | 6 |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Completely disagree | — | 0 | 0 |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Disagree | — | 0 | 0 |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Neither agree nor disagree | — | 1 | 0 |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Agree | — | 0 | 8 |
| The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Completely agree | — | 1 | 5 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Completely disagree | 0 | 0 | 0 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Disagree | 0 | 0 | 0 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Neither agree nor disagree | 1 | 0 | 2 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Agree | 2 | 3 | 1 |
| The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Completely agree | 1 | 1 | 1 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Completely disagree | 0 | 0 | 0 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Disagree | 0 | 0 | 0 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Neither agree nor disagree | 2 | 0 | 2 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Agree | 1 | 3 | 0 |
| The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Completely agree | 1 | 1 | 2 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Not at all useful | — | 0 | 2 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Not very useful | — | 3 | 0 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Somewhat useful | — | 4 | 1 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Useful | — | 8 | 3 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Very useful | — | 8 | 8 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — I did not use it or it was not provided | — | 11 | 9 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Missing | — | 1 | 1 |
| Text reminders about your injection — Not at all useful | 0 | 0 | 0 |
| Text reminders about your injection — Not very useful | 0 | 0 | 0 |
| Text reminders about your injection — Somewhat useful | 1 | 1 | 2 |
| Text reminders about your injection — Useful | 6 | 10 | 2 |
| Text reminders about your injection — Very useful | 30 | 19 | 15 |
| Text reminders about your injection — I did not use it or it was not provided | 2 | 4 | 4 |
| Text reminders about your injection — Missing | 1 | 1 | 1 |
| Email reminders about your injection — Not at all useful | 1 | 0 | 0 |
| Email reminders about your injection — Not very useful | 2 | 2 | 0 |
| Email reminders about your injection — Somewhat useful | 4 | 2 | 1 |
| Email reminders about your injection — Useful | 9 | 11 | 3 |
| Email reminders about your injection — Very useful | 19 | 11 | 16 |
| Email reminders about your injection — I did not use it or it was not provided | 4 | 8 | 3 |
| Email reminders about your injection — Missing | 1 | 1 | 1 |
| Phone call reminders about your injection — Not at all useful | 0 | 0 | 2 |
| Phone call reminders about your injection — Not very useful | 0 | 1 | 0 |
| Phone call reminders about your injection — Somewhat useful | 0 | 4 | 3 |
| Phone call reminders about your injection — Useful | 11 | 9 | 4 |
| Phone call reminders about your injection — Very useful | 24 | 14 | 12 |
| Phone call reminders about your injection — I did not use it or it was not provided | 4 | 6 | 2 |
| Phone call reminders about your injection — Missing | 1 | 1 | 1 |
| Postal mail reminders about your injection — Not at all useful | 3 | 0 | 4 |
| Postal mail reminders about your injection — Not very useful | 2 | 5 | 2 |
| Postal mail reminders about your injection — Somewhat useful | 2 | 2 | 2 |
| Postal mail reminders about your injection — Useful | 4 | 8 | 1 |
| Postal mail reminders about your injection — Very useful | 6 | 5 | 5 |
| Postal mail reminders about your injection — I did not use it or it was not provided | 22 | 14 | 9 |
| Postal mail reminders about your injection — Missing | 1 | 1 | 1 |
| EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Not at all useful | — | 1 | 1 |
| EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Not very useful | — | 1 | 1 |
| EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Somewhat useful | — | 4 | 3 |
| EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Useful | — | 11 | 5 |
| EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Very useful | — | 7 | 9 |
| EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — I did not use it or it was not provided | — | 10 | 4 |
| EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Missing | — | 1 | 1 |
| Patient Website: download toolkit materials to support you throughout the study (SI only) — Not at all useful | 0 | — | — |
| Patient Website: download toolkit materials to support you throughout the study (SI only) — Not very useful | 0 | — | — |
| Patient Website: download toolkit materials to support you throughout the study (SI only) — Somewhat useful | 3 | — | — |
| Patient Website: download toolkit materials to support you throughout the study (SI only) — Useful | 14 | — | — |
| Patient Website: download toolkit materials to support you throughout the study (SI only) — Very useful | 11 | — | — |
| Patient Website: download toolkit materials to support you throughout the study (SI only) — I did not use it or it was not provided | 11 | — | — |
| Patient Website: download toolkit materials to support you throughout the study (SI only) — Missing | 1 | — | — |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Not at all useful | 0 | 0 | 0 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Not very useful | 0 | 0 | 0 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Somewhat useful | 1 | 1 | 0 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Useful | 9 | 13 | 8 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Very useful | 25 | 18 | 13 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — I did not use it or it was not provided | 4 | 2 | 2 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Missing | 1 | 1 | 1 |
| Brochures and other print materials to educate you on APRETUDE — Not at all useful | 0 | 0 | 0 |
| Brochures and other print materials to educate you on APRETUDE — Not very useful | 1 | 1 | 1 |
| Brochures and other print materials to educate you on APRETUDE — Somewhat useful | 0 | 3 | 1 |
| Brochures and other print materials to educate you on APRETUDE — Useful | 12 | 13 | 5 |
| Brochures and other print materials to educate you on APRETUDE — Very useful | 23 | 12 | 12 |
| Brochures and other print materials to educate you on APRETUDE — I did not use it or it was not provided | 3 | 5 | 4 |
| Brochures and other print materials to educate you on APRETUDE — Missing | 1 | 1 | 1 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not at all useful | — | — | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not very useful | — | — | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Somewhat useful | — | — | 2 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Useful | — | — | 4 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Very useful | — | — | 14 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — I did not use it or it was not provided | — | — | 3 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Missing | — | — | 1 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Brochures and other written materials you received about APRETUDE — Not at all helpful | 0 | 2 | 0 |
| Brochures and other written materials you received about APRETUDE — Somewhat helpful | 6 | 7 | 2 |
| Brochures and other written materials you received about APRETUDE — Helpful | 11 | 11 | 6 |
| Brochures and other written materials you received about APRETUDE — Very helpful | 15 | 11 | 9 |
| Brochures and other written materials you received about APRETUDE — I did not use it or it was not provided | 7 | 3 | 6 |
| Brochures and other written materials you received about APRETUDE — Missing | 1 | 1 | 1 |
| Getting Started Brochure: overview of how to start APRETUDE — Not at all helpful | 0 | 1 | 0 |
| Getting Started Brochure: overview of how to start APRETUDE — Somewhat helpful | 4 | 3 | 2 |
| Getting Started Brochure: overview of how to start APRETUDE — Helpful | 10 | 12 | 5 |
| Getting Started Brochure: overview of how to start APRETUDE — Very helpful | 19 | 12 | 11 |
| Getting Started Brochure: overview of how to start APRETUDE — I did not use it or it was not provided | 6 | 6 | 5 |
| Getting Started Brochure: overview of how to start APRETUDE — Missing | 1 | 1 | 1 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Not at all helpful | 0 | 1 | 0 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Somewhat helpful | 5 | 5 | 2 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Helpful | 8 | 10 | 3 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Very helpful | 18 | 12 | 12 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — I did not use it or it was not provided | 8 | 6 | 6 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Missing | 0 | 1 | 0 |
| Study brochures — Not at all helpful | 0 | 1 | 0 |
| Study brochures — Somewhat helpful | 5 | 5 | 1 |
| Study brochures — Helpful | 8 | 9 | 6 |
| Study brochures — Very helpful | 18 | 12 | 10 |
| Study brochures — I did not use it or it was not provided | 8 | 7 | 6 |
| Study brochures — Missing | 1 | 1 | 1 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Not at all helpful | — | — | 1 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Somewhat helpful | — | — | 3 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Helpful | — | — | 6 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Very helpful | — | — | 10 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — I did not use it or it was not provided | — | — | 3 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Missing | — | — | 1 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Not at all helpful | — | — | 2 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Somewhat helpful | — | — | 2 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Helpful | — | — | 7 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Very helpful | — | — | 9 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — I did not use it or it was not provided | — | — | 3 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Missing | — | — | 1 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Not at all helpful | — | — | 1 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Somewhat helpful | — | — | 2 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Helpful | — | — | 7 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Very helpful | — | — | 10 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — I did not use it or it was not provided | — | — | 3 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Missing | — | — | 1 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Not at all helpful | — | 0 | — |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Somewhat helpful | — | 4 | — |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Helpful | — | 9 | — |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Very helpful | — | 10 | — |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — I did not use it or it was not provided | — | 11 | — |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Missing | — | 1 | — |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Not at all helpful | — | 1 | 2 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Somewhat helpful | — | 3 | 2 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Helpful | — | 10 | 4 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Very helpful | — | 8 | 8 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — I did not use it or it was not provided | — | 12 | 7 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Missing | — | 1 | 1 |
| Important Safety Information: details safety information relating to APRETUDE — Not at all helpful | 1 | 3 | 1 |
| Important Safety Information: details safety information relating to APRETUDE — Somewhat helpful | 3 | 3 | 2 |
| Important Safety Information: details safety information relating to APRETUDE — Helpful | 10 | 11 | 4 |
| Important Safety Information: details safety information relating to APRETUDE — Very helpful | 17 | 9 | 11 |
| Important Safety Information: details safety information relating to APRETUDE — I did not use it or it was not provided | 8 | 8 | 5 |
| Important Safety Information: details safety information relating to APRETUDE — Missing | 1 | 1 | 1 |
| Important facts - This document details important facts relating to APRETUDE — Not at all helpful | 0 | 0 | 1 |
| Important facts - This document details important facts relating to APRETUDE — Somewhat helpful | 4 | 5 | 2 |
| Important facts - This document details important facts relating to APRETUDE — Helpful | 9 | 13 | 5 |
| Important facts - This document details important facts relating to APRETUDE — Very helpful | 17 | 10 | 9 |
| Important facts - This document details important facts relating to APRETUDE — I did not use it or it was not provided | 9 | 6 | 6 |
| Important facts - This document details important facts relating to APRETUDE — Missing | 1 | 1 | 1 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Not at all helpful | 0 | 1 | 0 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Somewhat helpful | 3 | 5 | 1 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Helpful | 8 | 8 | 5 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Very helpful | 20 | 11 | 10 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — I did not use it or it was not provided | 8 | 9 | 7 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Missing | 1 | 1 | 1 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Not at all helpful | — | — | 0 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Somewhat helpful | — | — | 2 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Helpful | — | — | 5 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Very helpful | — | — | 11 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — I did not use it or it was not provided | — | — | 5 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Missing | — | — | 1 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Digital calendar for planning APRETUDE injections (EI/ECI only) — Not at all useful | 0 | 0 | 2 |
| Digital calendar for planning APRETUDE injections (EI/ECI only) — Not very useful | 0 | 0 | 3 |
| Digital calendar for planning APRETUDE injections (EI/ECI only) — Somewhat useful | 0 | 0 | 5 |
| Digital calendar for planning APRETUDE injections (EI/ECI only) — Useful | 0 | 3 | 8 |
| Digital calendar for planning APRETUDE injections (EI/ECI only) — Very useful | 6 | 2 | 8 |
| Digital calendar for planning APRETUDE injections (EI/ECI only) — I did not use it or it was not provided | 4 | 6 | 10 |
| Digital calendar for planning APRETUDE injections (EI/ECI only) — Missing | 0 | 0 | 2 |
| Text reminders about your injection — Not at all useful | 0 | 0 | 0 |
| Text reminders about your injection — Not very useful | 0 | 0 | 0 |
| Text reminders about your injection — Somewhat useful | 0 | 0 | 4 |
| Text reminders about your injection — Useful | 1 | 6 | 11 |
| Text reminders about your injection — Very useful | 8 | 25 | 31 |
| Text reminders about your injection — I did not use it or it was not provided | 1 | 3 | 6 |
| Text reminders about your injection — Missing | 0 | 1 | 2 |
| Email reminders about your injection — Not at all useful | 0 | 1 | 0 |
| Email reminders about your injection — Not very useful | 0 | 2 | 2 |
| Email reminders about your injection — Somewhat useful | 0 | 2 | 5 |
| Email reminders about your injection — Useful | 0 | 8 | 15 |
| Email reminders about your injection — Very useful | 9 | 18 | 19 |
| Email reminders about your injection — I did not use it or it was not provided | 1 | 3 | 11 |
| Email reminders about your injection — Missing | 0 | 1 | 2 |
| Phone call reminders about your injection — Not at all useful | 1 | 0 | 1 |
| Phone call reminders about your injection — Not very useful | 0 | 0 | 1 |
| Phone call reminders about your injection — Somewhat useful | 1 | 1 | 5 |
| Phone call reminders about your injection — Useful | 1 | 9 | 14 |
| Phone call reminders about your injection — Very useful | 7 | 19 | 24 |
| Phone call reminders about your injection — I did not use it or it was not provided | 0 | 5 | 7 |
| Phone call reminders about your injection — Missing | 0 | 1 | 2 |
| Postal mail reminders about your injection — Not at all useful | 2 | 1 | 4 |
| Postal mail reminders about your injection — Not very useful | 1 | 3 | 5 |
| Postal mail reminders about your injection — Somewhat useful | 0 | 1 | 5 |
| Postal mail reminders about your injection — Useful | 0 | 4 | 9 |
| Postal mail reminders about your injection — Very useful | 2 | 6 | 8 |
| Postal mail reminders about your injection — I did not use it or it was not provided | 5 | 19 | 21 |
| Postal mail reminders about your injection — Missing | 0 | 1 | 2 |
| EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Not at all useful | 1 | 0 | 1 |
| EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Not very useful | 1 | 0 | 1 |
| EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Somewhat useful | 0 | 2 | 5 |
| EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Useful | 1 | 1 | 14 |
| EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Very useful | 6 | 4 | 6 |
| EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — I did not use it or it was not provided | 1 | 4 | 9 |
| EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Missing | 0 | 0 | 2 |
| Patient Website: download toolkit materials to support you during the study (SI only) — Not at all useful | — | 0 | 0 |
| Patient Website: download toolkit materials to support you during the study (SI only) — Not very useful | — | 0 | 0 |
| Patient Website: download toolkit materials to support you during the study (SI only) — Somewhat useful | — | 1 | 2 |
| Patient Website: download toolkit materials to support you during the study (SI only) — Useful | — | 5 | 9 |
| Patient Website: download toolkit materials to support you during the study (SI only) — Very useful | — | 9 | 2 |
| Patient Website: download toolkit materials to support you during the study (SI only) — I did not use it or it was not provided | — | 8 | 3 |
| Patient Website: download toolkit materials to support you during the study (SI only) — Missing | — | 1 | 0 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Not at all useful | 0 | 0 | 0 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Not very useful | 0 | 0 | 0 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Somewhat useful | 0 | 0 | 2 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Useful | 3 | 9 | 18 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Very useful | 7 | 22 | 27 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — I did not use it or it was not provided | 0 | 3 | 5 |
| You and your doctor discuss pros and cons of PrEP options and choose the right one together — Missing | 0 | 1 | 2 |
| Brochures and other print materials to educate you on APRETUDE — Not at all useful | 0 | 0 | 0 |
| Brochures and other print materials to educate you on APRETUDE — Not very useful | 0 | 1 | 2 |
| Brochures and other print materials to educate you on APRETUDE — Somewhat useful | 0 | 1 | 3 |
| Brochures and other print materials to educate you on APRETUDE — Useful | 1 | 10 | 19 |
| Brochures and other print materials to educate you on APRETUDE — Very useful | 8 | 17 | 22 |
| Brochures and other print materials to educate you on APRETUDE — I did not use it or it was not provided | 1 | 5 | 6 |
| Brochures and other print materials to educate you on APRETUDE — Missing | 0 | 1 | 2 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not at all useful | 0 | 0 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not very useful | 0 | 0 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Somewhat useful | 0 | 0 | 2 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Useful | 1 | 1 | 2 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Very useful | 8 | 2 | 4 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — I did not use it or it was not provided | 1 | 1 | 1 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Missing | 0 | 0 | 1 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Brochures and other written materials you received about APRETUDE — Not at all helpful | 0 | 1 | 1 |
| Brochures and other written materials you received about APRETUDE — Somewhat helpful | 2 | 4 | 9 |
| Brochures and other written materials you received about APRETUDE — Helpful | 2 | 8 | 18 |
| Brochures and other written materials you received about APRETUDE — Very helpful | 5 | 15 | 15 |
| Brochures and other written materials you received about APRETUDE — I did not use it or it was not provided | 1 | 6 | 9 |
| Brochures and other written materials you received about APRETUDE — Missing | 0 | 1 | 2 |
| Getting Started Brochure: overview of starting APRETUDE — Not at all helpful | 0 | 0 | 1 |
| Getting Started Brochure: overview of starting APRETUDE — Somewhat helpful | 2 | 1 | 6 |
| Getting Started Brochure: overview of starting APRETUDE — Helpful | 1 | 8 | 18 |
| Getting Started Brochure: overview of starting APRETUDE — Very helpful | 7 | 17 | 18 |
| Getting Started Brochure: overview of starting APRETUDE — I did not use it or it was not provided | 0 | 8 | 9 |
| Getting Started Brochure: overview of starting APRETUDE — Missing | 0 | 1 | 2 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Not at all helpful | 0 | 0 | 1 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Somewhat helpful | 2 | 2 | 8 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Helpful | 0 | 7 | 14 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Very helpful | 7 | 17 | 18 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — I did not use it or it was not provided | 1 | 8 | 11 |
| Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Missing | 0 | 0 | 1 |
| Study brochures — Not at all helpful | 0 | 0 | 1 |
| Study brochures — Somewhat helpful | 1 | 2 | 8 |
| Study brochures — Helpful | 3 | 6 | 14 |
| Study brochures — Very helpful | 5 | 17 | 18 |
| Study brochures — I did not use it or it was not provided | 1 | 9 | 11 |
| Study brochures — Missing | 0 | 1 | 2 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Not at all helpful | 0 | 1 | 0 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Somewhat helpful | 3 | 0 | 0 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Helpful | 1 | 0 | 5 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Very helpful | 5 | 2 | 3 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — I did not use it or it was not provided | 1 | 1 | 1 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Missing | 0 | 0 | 1 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Not at all helpful | 0 | 1 | 1 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Somewhat helpful | 2 | 0 | 0 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Helpful | 3 | 0 | 4 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Very helpful | 4 | 2 | 3 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — I did not use it or it was not provided | 1 | 1 | 1 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Missing | 0 | 0 | 1 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Not at all helpful | 0 | 1 | 0 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Somewhat helpful | 2 | 0 | 0 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Helpful | 2 | 0 | 5 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Very helpful | 5 | 2 | 3 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — I did not use it or it was not provided | 1 | 1 | 1 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Missing | 0 | 0 | 1 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Not at all helpful | — | 0 | 0 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Somewhat helpful | — | 1 | 3 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Helpful | — | 0 | 9 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Very helpful | — | 3 | 7 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — I did not use it or it was not provided | — | 3 | 8 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Missing | — | 0 | 1 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Not at all helpful | 0 | 1 | 2 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Somewhat helpful | 2 | 1 | 2 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Helpful | 1 | 0 | 13 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Very helpful | 5 | 3 | 8 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — I did not use it or it was not provided | 2 | 6 | 11 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Missing | 0 | 0 | 2 |
| Important Safety Information: APRETUDE safety details — Not at all helpful | 0 | 4 | 1 |
| Important Safety Information: APRETUDE safety details — Somewhat helpful | 2 | 1 | 5 |
| Important Safety Information: APRETUDE safety details — Helpful | 2 | 6 | 17 |
| Important Safety Information: APRETUDE safety details — Very helpful | 6 | 16 | 15 |
| Important Safety Information: APRETUDE safety details — I did not use it or it was not provided | 0 | 7 | 14 |
| Important Safety Information: APRETUDE safety details — Missing | 0 | 1 | 2 |
| Important facts - This document details important facts relating to APRETUDE — Not at all helpful | 0 | 1 | 0 |
| Important facts - This document details important facts relating to APRETUDE — Somewhat helpful | 2 | 4 | 5 |
| Important facts - This document details important facts relating to APRETUDE — Helpful | 2 | 6 | 19 |
| Important facts - This document details important facts relating to APRETUDE — Very helpful | 5 | 15 | 16 |
| Important facts - This document details important facts relating to APRETUDE — I did not use it or it was not provided | 1 | 8 | 12 |
| Important facts - This document details important facts relating to APRETUDE — Missing | 0 | 1 | 2 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Not at all helpful | 0 | 1 | 0 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Somewhat helpful | 1 | 2 | 6 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Helpful | 1 | 4 | 16 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Very helpful | 6 | 18 | 17 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — I did not use it or it was not provided | 2 | 9 | 13 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Missing | 0 | 1 | 2 |
| Rewards: earn points for completing APRETUDE journey goals (ECI) — Not at all helpful | 0 | 0 | 0 |
| Rewards: earn points for completing APRETUDE journey goals (ECI) — Somewhat helpful | 1 | 0 | 1 |
| Rewards: earn points for completing APRETUDE journey goals (ECI) — Helpful | 1 | 0 | 4 |
| Rewards: earn points for completing APRETUDE journey goals (ECI) — Very helpful | 7 | 2 | 2 |
| Rewards: earn points for completing APRETUDE journey goals (ECI) — I did not use it or it was not provided | 1 | 2 | 2 |
| Rewards: earn points for completing APRETUDE journey goals (ECI) — Missing | 0 | 0 | 1 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only) — Yes | 7 | 1 | 6 |
| Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only) — No | 0 | 1 | 0 |
| Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only) — I don't know | 3 | 2 | 3 |
| Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only) — Missing | 0 | 0 | 1 |
| Did your provider or clinic staff discuss your assessment results with you? (ECI only) — Yes | 4 | 1 | 3 |
| Did your provider or clinic staff discuss your assessment results with you? (ECI only) — No | 0 | 0 | 2 |
| Did your provider or clinic staff discuss your assessment results with you? (ECI only) — I don't know | 3 | 0 | 1 |
| Did your provider or clinic staff discuss your assessment results with you? (ECI only) — Missing | 0 | 0 | 0 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question: "Who discussed the results of the assessment with you? (ECI only)".
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| My healthcare provider/doctor | 1 | 1 | 1 |
| A nurse | 2 | 0 | 2 |
| A social worker | 1 | 0 | 0 |
| A peer educator | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| I don't know | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Very helpful | 3 | 1 | 4 |
| Somewhat helpful | 2 | 0 | 1 |
| A little helpful | 1 | 0 | 0 |
| Not at all helpful | 1 | 0 | 1 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Clinic Characteristics | 0 | 1 | 0 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies by patient gender subgroups.
| Participants | Cisgender - PSP | Transgender - PSP |
|---|---|---|
| Digital calendar to plan APRETUDE injections (EI/ECI only) — Not at all useful | 2 | 0 |
| Digital calendar to plan APRETUDE injections (EI/ECI only) — Not very useful | 3 | 0 |
| Digital calendar to plan APRETUDE injections (EI/ECI only) — Somewhat useful | 1 | 4 |
| Digital calendar to plan APRETUDE injections (EI/ECI only) — Useful | 10 | 1 |
| Digital calendar to plan APRETUDE injections (EI/ECI only) — Very useful | 10 | 6 |
| Digital calendar to plan APRETUDE injections (EI/ECI only) — I did not use it or it was not provided | 15 | 5 |
| Digital calendar to plan APRETUDE injections (EI/ECI only) — Missing | 1 | 1 |
| Text reminders about your injection — Not at all useful | 0 | 0 |
| Text reminders about your injection — Not very useful | 0 | 0 |
| Text reminders about your injection — Somewhat useful | 3 | 1 |
| Text reminders about your injection — Useful | 15 | 3 |
| Text reminders about your injection — Very useful | 52 | 12 |
| Text reminders about your injection — I did not use it or it was not provided | 6 | 4 |
| Text reminders about your injection — Missing | 2 | 1 |
| Email reminders about your injection — Not at all useful | 1 | 0 |
| Email reminders about your injection — Not very useful | 4 | 0 |
| Email reminders about your injection — Somewhat useful | 5 | 2 |
| Email reminders about your injection — Useful | 19 | 4 |
| Email reminders about your injection — Very useful | 36 | 10 |
| Email reminders about your injection — I did not use it or it was not provided | 11 | 4 |
| Email reminders about your injection — Missing | 2 | 1 |
| Phone call reminders about your injection — Not at all useful | 0 | 2 |
| Phone call reminders about your injection — Not very useful | 1 | 0 |
| Phone call reminders about your injection — Somewhat useful | 4 | 3 |
| Phone call reminders about your injection — Useful | 22 | 2 |
| Phone call reminders about your injection — Very useful | 42 | 8 |
| Phone call reminders about your injection — I did not use it or it was not provided | 7 | 5 |
| Phone call reminders about your injection — Missing | 2 | 1 |
| Postal mail reminders about your injection — Not at all useful | 4 | 3 |
| Postal mail reminders about your injection — Not very useful | 8 | 1 |
| Postal mail reminders about your injection — Somewhat useful | 4 | 2 |
| Postal mail reminders about your injection — Useful | 10 | 3 |
| Postal mail reminders about your injection — Very useful | 12 | 4 |
| Postal mail reminders about your injection — I did not use it or it was not provided | 38 | 7 |
| Postal mail reminders about your injection — Missing | 2 | 1 |
| EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Not at all useful | 2 | 0 |
| EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Not very useful | 2 | 0 |
| EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Somewhat useful | 5 | 2 |
| EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Useful | 11 | 5 |
| EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Very useful | 13 | 3 |
| EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — I did not use it or it was not provided | 8 | 6 |
| EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Missing | 1 | 1 |
| Patient Website: download toolkit materials for study support (SI only) — Not at all useful | 0 | 0 |
| Patient Website: download toolkit materials for study support (SI only) — Not very useful | 0 | 0 |
| Patient Website: download toolkit materials for study support (SI only) — Somewhat useful | 3 | 0 |
| Patient Website: download toolkit materials for study support (SI only) — Useful | 14 | 0 |
| Patient Website: download toolkit materials for study support (SI only) — Very useful | 8 | 3 |
| Patient Website: download toolkit materials for study support (SI only) — I did not use it or it was not provided | 10 | 1 |
| Patient Website: download toolkit materials for study support (SI only) — Missing | 1 | 0 |
| You and your doctor discuss pros and cons of PrEP options and decide together — Not at all useful | 0 | 0 |
| You and your doctor discuss pros and cons of PrEP options and decide together — Not very useful | 0 | 0 |
| You and your doctor discuss pros and cons of PrEP options and decide together — Somewhat useful | 1 | 1 |
| You and your doctor discuss pros and cons of PrEP options and decide together — Useful | 25 | 5 |
| You and your doctor discuss pros and cons of PrEP options and decide together — Very useful | 45 | 11 |
| You and your doctor discuss pros and cons of PrEP options and decide together — I did not use it or it was not provided | 5 | 3 |
| You and your doctor discuss pros and cons of PrEP options and decide together — Missing | 2 | 1 |
| Brochures and other print materials to educate you on APRETUDE — Not at all useful | 0 | 0 |
| Brochures and other print materials to educate you on APRETUDE — Not very useful | 2 | 1 |
| Brochures and other print materials to educate you on APRETUDE — Somewhat useful | 2 | 2 |
| Brochures and other print materials to educate you on APRETUDE — Useful | 26 | 4 |
| Brochures and other print materials to educate you on APRETUDE — Very useful | 38 | 9 |
| Brochures and other print materials to educate you on APRETUDE — I did not use it or it was not provided | 8 | 4 |
| Brochures and other print materials to educate you on APRETUDE — Missing | 2 | 1 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not at all useful | 0 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not very useful | 0 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Somewhat useful | 2 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Useful | 4 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Very useful | 9 | 5 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — I did not use it or it was not provided | 1 | 2 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Missing | 1 | 0 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials by patient gender subgroups.
| Participants | Cisgender - PSP | Transgender - PSP |
|---|---|---|
| Brochures and other written materials you received about APRETUDE — Not at all helpful | 1 | 1 |
| Brochures and other written materials you received about APRETUDE — Somewhat helpful | 12 | 3 |
| Brochures and other written materials you received about APRETUDE — Helpful | 25 | 3 |
| Brochures and other written materials you received about APRETUDE — Very helpful | 27 | 8 |
| Brochures and other written materials you received about APRETUDE — I did not use it or it was not provided | 11 | 5 |
| Brochures and other written materials you received about APRETUDE — Missing | 2 | 1 |
| Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Not at all helpful | 1 | 0 |
| Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Somewhat helpful | 7 | 2 |
| Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Helpful | 23 | 4 |
| Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Very helpful | 33 | 9 |
| Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — I did not use it or it was not provided | 12 | 5 |
| Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Missing | 2 | 1 |
| Patient Brochure: explains APRETUDE injections, side effects, insurance info — Not at all helpful | 1 | 0 |
| Patient Brochure: explains APRETUDE injections, side effects, insurance info — Somewhat helpful | 10 | 2 |
| Patient Brochure: explains APRETUDE injections, side effects, insurance info — Helpful | 19 | 2 |
| Patient Brochure: explains APRETUDE injections, side effects, insurance info — Very helpful | 32 | 10 |
| Patient Brochure: explains APRETUDE injections, side effects, insurance info — I did not use it or it was not provided | 14 | 6 |
| Patient Brochure: explains APRETUDE injections, side effects, insurance info — Missing | 0 | 1 |
| Study brochures — Not at all helpful | 1 | 0 |
| Study brochures — Somewhat helpful | 9 | 2 |
| Study brochures — Helpful | 20 | 3 |
| Study brochures — Very helpful | 30 | 10 |
| Study brochures — I did not use it or it was not provided | 16 | 5 |
| Study brochures — Missing | 2 | 1 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Not at all helpful | 0 | 1 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Somewhat helpful | 3 | 0 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Helpful | 5 | 1 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Very helpful | 6 | 4 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — I did not use it or it was not provided | 2 | 1 |
| Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Missing | 1 | 0 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Not at all helpful | 1 | 1 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Somewhat helpful | 2 | 0 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Helpful | 5 | 2 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Very helpful | 6 | 3 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — I did not use it or it was not provided | 2 | 1 |
| The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Missing | 1 | 0 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Not at all helpful | 0 | 1 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Somewhat helpful | 2 | 0 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Helpful | 6 | 1 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Very helpful | 6 | 4 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — I did not use it or it was not provided | 2 | 1 |
| The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Missing | 1 | 0 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Not at all helpful | 0 | 0 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Somewhat helpful | 3 | 1 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Helpful | 5 | 4 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Very helpful | 8 | 2 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — I did not use it or it was not provided | 9 | 2 |
| The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Missing | 0 | 1 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Not at all helpful | 2 | 1 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Somewhat helpful | 5 | 0 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Helpful | 9 | 5 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Very helpful | 10 | 6 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — I did not use it or it was not provided | 15 | 4 |
| A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Missing | 1 | 1 |
| Important Safety Information: APRETUDE safety details — Not at all helpful | 3 | 2 |
| Important Safety Information: APRETUDE safety details — Somewhat helpful | 7 | 1 |
| Important Safety Information: APRETUDE safety details — Helpful | 21 | 4 |
| Important Safety Information: APRETUDE safety details — Very helpful | 29 | 8 |
| Important Safety Information: APRETUDE safety details — I did not use it or it was not provided | 16 | 5 |
| Important Safety Information: APRETUDE safety details — Missing | 2 | 1 |
| Important facts - This document details important facts relating to APRETUDE — Not at all helpful | 0 | 1 |
| Important facts - This document details important facts relating to APRETUDE — Somewhat helpful | 9 | 2 |
| Important facts - This document details important facts relating to APRETUDE — Helpful | 23 | 4 |
| Important facts - This document details important facts relating to APRETUDE — Very helpful | 28 | 8 |
| Important facts - This document details important facts relating to APRETUDE — I did not use it or it was not provided | 16 | 5 |
| Important facts - This document details important facts relating to APRETUDE — Missing | 2 | 1 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Not at all helpful | 1 | 0 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Somewhat helpful | 7 | 2 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Helpful | 19 | 2 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Very helpful | 31 | 10 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — I did not use it or it was not provided | 18 | 6 |
| The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Missing | 2 | 1 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Not at all helpful | 0 | 0 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Somewhat helpful | 2 | 0 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Helpful | 4 | 1 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Very helpful | 7 | 4 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — I did not use it or it was not provided | 3 | 2 |
| Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Missing | 1 | 0 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".
| Participants | Cisgender - PSP | Transgender - PSP |
|---|---|---|
| Have you completed a Sexual Health Assessment from your provider in last 12 months? (ECI only) — Yes | 10 | 4 |
| Have you completed a Sexual Health Assessment from your provider in last 12 months? (ECI only) — No | 0 | 1 |
| Have you completed a Sexual Health Assessment from your provider in last 12 months? (ECI only) — I don't know | 6 | 2 |
| Have you completed a Sexual Health Assessment from your provider in last 12 months? (ECI only) — Missing | 1 | 0 |
| Did your provider or clinic discuss your assessment results with you? (ECI only) — Yes | 5 | 3 |
| Did your provider or clinic discuss your assessment results with you? (ECI only) — No | 1 | 1 |
| Did your provider or clinic discuss your assessment results with you? (ECI only) — I don't know | 4 | 0 |
| Did your provider or clinic discuss your assessment results with you? (ECI only) — Missing | 0 | 0 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question regarding the sexual health assessment: "Who discussed the results of the assessment with you? (ECI only)".
| Participants | Cisgender - PSP | Transgender - PSP |
|---|---|---|
| My healthcare provider/doctor | 2 | 1 |
| A nurse | 3 | 1 |
| A social worker | 0 | 1 |
| A peer educator | 0 | 0 |
| Other | 0 | 0 |
| I don't know | 0 | 0 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".
| Participants | Cisgender - PSP | Transgender - PSP |
|---|---|---|
| Very helpful | 4 | 4 |
| Somewhat helpful | 3 | 0 |
| A little helpful | 1 | 0 |
| Not at all helpful | 2 | 0 |
PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.
| Participants | Cisgender - PSP | Transgender - PSP |
|---|---|---|
| Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Patient Subgroups | 0 | 1 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Used Getting Started Brochure Tool | 7 | 4 | 2 |
| Used Helpfulness of Patient Brochure Tool | 6 | 0 | 1 |
| Used Important Facts Document | 5 | 0 | 0 |
| Used Important Safety Information | 12 | 2 | 4 |
| Used Helpfulness of GSK Response Center Tool | 1 | 0 | 0 |
| Used Patient Website Tool (SI only) | 11 | 0 | 0 |
| Used The EBONI Spot Tool (ECI/EI only) | 0 | 7 | 9 |
| Used Intro to ViiVConnect Video Tool (EI only) | 0 | 2 | 0 |
| Engaged with SHE Ambassador (ECI only) | — | — | 4 |
PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies by patient gender subgroups.
| Participants | Cisgender - PSP | Transgender - PSP |
|---|---|---|
| Used Getting Started Brochure Tool | 12 | 1 |
| Used Helpfulness of Patient Brochure Tool | 7 | 0 |
| Used Important Facts Document | 4 | 1 |
| Used Important Safety Information | 16 | 2 |
| Used Helpfulness of GSK Response Center Tool | 1 | 0 |
| Used Patient Website Tool (SI only) | 10 | 1 |
| Used The EBONI Spot Tool (ECI/EI only) | 12 | 4 |
| Used Intro to ViiVConnect Video Tool (EI only) | 0 | 2 |
| Engaged with SHE Ambassador (ECI only) | 3 | 1 |
This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as +/- 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Injections | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Dose 2 | 51 | 47 | 33 |
| Dose 3 | 37 | 36 | 24 |
| Dose 4 | 33 | 23 | 19 |
| Dose 5 | 28 | 14 | 16 |
| Dose 6 | 24 | 13 | 12 |
| Dose 7 | 24 | 14 | 9 |
PSP perceptions of barriers and facilitators to fidelity to APRETUDE injection windows were gathered via the ISQ. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs responses to the following question: "How easy was it to understand the Target Appointment Date?"
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Easy | 15 | 36 | 52 |
| Somewhat easy | 1 | 3 | 11 |
| Neither easy nor difficult | 1 | 3 | 6 |
| Somewhat difficult | 0 | 0 | 0 |
| Difficult | 0 | 0 | 0 |
| I am not familiar/I don't remember | 5 | 6 | 12 |
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Have you missed any of your APRETUDE injection visits in the last 6 months?".
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| M4 - Have you missed any of your APRETUDE injection visits in the last 6 months? — Yes | 1 | 3 | 4 |
| M4 - Have you missed any of your APRETUDE injection visits in the last 6 months? — No | 17 | 36 | 67 |
| M4 - Have you missed any of your APRETUDE injection visits in the last 6 months? — Missing | 1 | 1 | 0 |
| M12 - Have you missed any of your APRETUDE injection visits in the last 6 months? — Yes | 2 | 2 | 5 |
| M12 - Have you missed any of your APRETUDE injection visits in the last 6 months? — No | 8 | 32 | 47 |
| M12 - Have you missed any of your APRETUDE injection visits in the last 6 months? — Missing | 0 | 1 | 2 |
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Was missing your APRETUDE injection visits planned or unplanned?".
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| M4 - Was missing your APRETUDE injection visits planned or unplanned? — All the injection visits I missed were planned | 0 | 0 | 1 |
| M4 - Was missing your APRETUDE injection visits planned or unplanned? — Some of the injection visits I missed were planned and some were unplanned | 1 | 1 | 1 |
| M4 - Was missing your APRETUDE injection visits planned or unplanned? — All the injection visits I missed were unplanned | 0 | 2 | 2 |
| M4 - Was missing your APRETUDE injection visits planned or unplanned? — I prefer not to answer | 0 | 0 | 0 |
| M12 - Was missing your APRETUDE injection visits planned or unplanned? — All the injection visits I missed were planned | 1 | 0 | 1 |
| M12 - Was missing your APRETUDE injection visits planned or unplanned? — Some of the injection visits I missed were planned and some were unplanned | 0 | 0 | 0 |
| M12 - Was missing your APRETUDE injection visits planned or unplanned? — All the injection visits I missed were unplanned | 1 | 2 | 4 |
| M12 - Was missing your APRETUDE injection visits planned or unplanned? — I prefer not to answer | 0 | 0 | 0 |
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Did you start oral PrEP after missing any of your injection visit?".
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| M4 - Did you start oral PrEP after missing any of your injection visit? — Yes | 1 | 1 | 2 |
| M4 - Did you start oral PrEP after missing any of your injection visit? — No | 0 | 2 | 2 |
| M12 - Did you start oral PrEP after missing any of your injection visit? — Yes | 0 | 0 | 1 |
| M12 - Did you start oral PrEP after missing any of your injection visit? — No | 2 | 2 | 4 |
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How easy or difficult was it to start oral PrEP after a missed injection visit?".
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Very easy | 0 | 0 | 1 |
| M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Somewhat easy | 0 | 0 | 0 |
| M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Neither easy nor difficult | 0 | 1 | 1 |
| M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Somewhat difficult | 1 | 0 | 0 |
| M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Very difficult | 0 | 0 | 0 |
| M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Very easy | 0 | 0 | 1 |
| M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Somewhat easy | 0 | 0 | 0 |
| M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Neither easy nor difficult | 0 | 0 | 0 |
| M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Somewhat difficult | 0 | 0 | 0 |
| M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Very difficult | 0 | 0 | 0 |
Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How acceptable was it to start oral PrEP after a missed injection visit?".
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| M4 - How acceptable was it to start oral PrEP after a missed injection visit? — Very acceptable | 0 | 0 | 1 |
| M4 - How acceptable was it to start oral PrEP after a missed injection visit? — Acceptable | 0 | 1 | 0 |
| M4 - How acceptable was it to start oral PrEP after a missed injection visit? — Somewhat acceptable | 1 | 0 | 1 |
| M4 - How acceptable was it to start oral PrEP after a missed injection visit? — A little acceptable | 0 | 0 | 0 |
| M4 - How acceptable was it to start oral PrEP after a missed injection visit? — Not at all acceptable | 0 | 0 | 0 |
| M12 - How acceptable was it to start oral PrEP after a missed injection visit? — Very acceptable | 0 | 0 | 1 |
| M12 - How acceptable was it to start oral PrEP after a missed injection visit? — Acceptable | 0 | 0 | 0 |
| M12 - How acceptable was it to start oral PrEP after a missed injection visit? — Somewhat acceptable | 0 | 0 | 0 |
| M12 - How acceptable was it to start oral PrEP after a missed injection visit? — A little acceptable | 0 | 0 | 0 |
| M12 - How acceptable was it to start oral PrEP after a missed injection visit? — Not at all acceptable | 0 | 0 | 0 |
Data below were collected via SSIs or interviews, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs understanding and access to the target appointment date. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Received an explanation of the target appointment date | 10 | 8 | 22 |
| Did not receive an explanation of the target appointment date | 1 | 4 | 9 |
| Unsure/don't remember receiving an explanation of the target appointment date | 2 | 3 | 8 |
| Found the explanation of the target appointment date was helpful | 2 | 3 | 6 |
| Isn't aware of or doesn't understand the target appointment date | 1 | 1 | 1 |
| Accurately explains the target appointment date | 3 | 2 | 9 |
| Accurately explains the injection window | 3 | 5 | 12 |
| Accurately explains the APRETUDE injection dosing schedule | 4 | 2 | 5 |
Data below were collected via SSIs or interviews, and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSP responses to the APRETUDE adherence and the specified barriers and facilitators to injection fidelity.
| Participants | Women's Health Clinic - PSP | Primary Care Clinic - PSP | HIV Specialist Clinic - PSP |
|---|---|---|---|
| Has not missed injection window | 5 | 10 | 18 |
| Understand target injection date | 2 | 7 | 18 |
| Unfamiliar with term specific "target injection date"- more familiar with "injection window" | 2 | 0 | 11 |
| Injection schedule fits with PSP's lifestyle | 3 | 8 | 15 |
| Likes how injections are scheduled | 1 | 6 | 14 |
| Appointment reminders and calendar tracking is helpful | 4 | 8 | 24 |
| Clinic staff work to help keep/maintain treatment schedule | 2 | 7 | 12 |
| Multiple injection visits scheduled at once | 0 | 4 | 6 |
| Injection appointments scheduled at the end of each visit | 4 | 3 | 21 |
| Clinic flexibility when (re)scheduling appointments is helpful | 0 | 3 | 5 |
| Bimonthly visits allowed screenings, vitals, and sexual health needs to be discussed | 2 | 4 | 11 |
| Unfavorable Injection schedule | 1 | 4 | 7 |
Data below were collected by ISQ and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses for the specified items regarding patient management challenges and injection fidelity for APRETUDE.
| Participants | Women's Health Clinic - SSP | Primary Care Clinic - SSP | HIV Specialist Clinic - SSP |
|---|---|---|---|
| BL - Understanding how to manage patients who miss an injection dose — Extremely concerned | 0 | 1 | 4 |
| BL - Understanding how to manage patients who miss an injection dose — Moderately concerned | 3 | 1 | 5 |
| BL - Understanding how to manage patients who miss an injection dose — Somewhat concerned | 3 | 5 | 12 |
| BL - Understanding how to manage patients who miss an injection dose — Slightly concerned | 2 | 14 | 16 |
| BL - Understanding how to manage patients who miss an injection dose — Not at all Concerned | 14 | 14 | 30 |
| M4 - Understanding how to manage patients who miss an injection dose — Extremely concerned | 0 | 0 | 0 |
| M4 - Understanding how to manage patients who miss an injection dose — Moderately concerned | 0 | 0 | 4 |
| M4 - Understanding how to manage patients who miss an injection dose — Somewhat concerned | 4 | 4 | 8 |
| M4 - Understanding how to manage patients who miss an injection dose — Slightly concerned | 5 | 9 | 10 |
| M4 - Understanding how to manage patients who miss an injection dose — Not at all Concerned | 7 | 14 | 34 |
| M12 - Understanding how to manage patients who miss an injection dose — Extremely concerned | 0 | 0 | 1 |
| M12 - Understanding how to manage patients who miss an injection dose — Moderately concerned | 4 | 0 | 4 |
| M12 - Understanding how to manage patients who miss an injection dose — Somewhat concerned | 1 | 6 | 2 |
| M12 - Understanding how to manage patients who miss an injection dose — Slightly concerned | 2 | 4 | 11 |
| M12 - Understanding how to manage patients who miss an injection dose — Not at all Concerned | 4 | 14 | 31 |
| BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Extremely concerned | 0 | 0 | 4 |
| BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Moderately concerned | 2 | 4 | 2 |
| BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Somewhat concerned | 2 | 6 | 8 |
| BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Slightly concerned | 4 | 10 | 13 |
| BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Not at all Concerned | 14 | 15 | 40 |
| M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Extremely concerned | 0 | 0 | 0 |
| M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Moderately concerned | 0 | 0 | 2 |
| M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Somewhat concerned | 4 | 4 | 8 |
| M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Slightly concerned | 4 | 6 | 9 |
| M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Not at all Concerned | 8 | 17 | 37 |
| M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Extremely concerned | 1 | 0 | 1 |
| M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Moderately concerned | 3 | 2 | 1 |
| M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Somewhat concerned | 1 | 2 | 6 |
| M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Slightly concerned | 1 | 4 | 8 |
| M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Not at all Concerned | 5 | 16 | 33 |
| BL - Understanding how to restart APRETUDE after a missed injection — Extremely concerned | 0 | 0 | 4 |
| BL - Understanding how to restart APRETUDE after a missed injection — Moderately concerned | 3 | 3 | 3 |
| BL - Understanding how to restart APRETUDE after a missed injection — Somewhat concerned | 1 | 5 | 9 |
| BL - Understanding how to restart APRETUDE after a missed injection — Slightly concerned | 5 | 14 | 14 |
| BL - Understanding how to restart APRETUDE after a missed injection — Not at all Concerned | 13 | 13 | 37 |
| M4 - Understanding how to restart APRETUDE after a missed injection — Extremely concerned | 0 | 0 | 0 |
| M4 - Understanding how to restart APRETUDE after a missed injection — Moderately concerned | 0 | 0 | 4 |
| M4 - Understanding how to restart APRETUDE after a missed injection — Somewhat concerned | 4 | 3 | 7 |
| M4 - Understanding how to restart APRETUDE after a missed injection — Slightly concerned | 4 | 8 | 9 |
| M4 - Understanding how to restart APRETUDE after a missed injection — Not at all Concerned | 8 | 16 | 36 |
| M12 - Understanding how to restart APRETUDE after a missed injection — Extremely concerned | 0 | 0 | 1 |
| M12 - Understanding how to restart APRETUDE after a missed injection — Moderately concerned | 2 | 1 | 2 |
| M12 - Understanding how to restart APRETUDE after a missed injection — Somewhat concerned | 2 | 2 | 5 |
| M12 - Understanding how to restart APRETUDE after a missed injection — Slightly concerned | 2 | 4 | 10 |
| M12 - Understanding how to restart APRETUDE after a missed injection — Not at all Concerned | 5 | 17 | 31 |
| BL - HIV monitoring requirements associated with APRETUDE — Extremely concerned | 0 | 0 | 3 |
| BL - HIV monitoring requirements associated with APRETUDE — Moderately concerned | 1 | 0 | 1 |
| BL - HIV monitoring requirements associated with APRETUDE — Somewhat concerned | 2 | 1 | 3 |
| BL - HIV monitoring requirements associated with APRETUDE — Slightly concerned | 2 | 11 | 12 |
| BL - HIV monitoring requirements associated with APRETUDE — Not at all Concerned | 17 | 23 | 48 |
| M4 - HIV monitoring requirements associated with APRETUDE — Extremely concerned | 0 | 0 | 1 |
| M4 - HIV monitoring requirements associated with APRETUDE — Moderately concerned | 0 | 0 | 2 |
| M4 - HIV monitoring requirements associated with APRETUDE — Somewhat concerned | 0 | 3 | 4 |
| M4 - HIV monitoring requirements associated with APRETUDE — Slightly concerned | 5 | 5 | 5 |
| M4 - HIV monitoring requirements associated with APRETUDE — Not at all Concerned | 11 | 19 | 44 |
| M12 - HIV monitoring requirements associated with APRETUDE — Extremely concerned | 0 | 0 | 1 |
| M12 - HIV monitoring requirements associated with APRETUDE — Moderately concerned | 1 | 1 | 1 |
| M12 - HIV monitoring requirements associated with APRETUDE — Somewhat concerned | 1 | 2 | 2 |
| M12 - HIV monitoring requirements associated with APRETUDE — Slightly concerned | 2 | 3 | 6 |
| M12 - HIV monitoring requirements associated with APRETUDE — Not at all Concerned | 7 | 18 | 39 |
| M4 - How to transition patients off of APRETUDE who want to stop taking it — Extremely concerned | 0 | 0 | 1 |
| M4 - How to transition patients off of APRETUDE who want to stop taking it — Moderately concerned | 1 | 1 | 4 |
| M4 - How to transition patients off of APRETUDE who want to stop taking it — Somewhat concerned | 2 | 4 | 7 |
| M4 - How to transition patients off of APRETUDE who want to stop taking it — Slightly concerned | 4 | 8 | 4 |
| M4 - How to transition patients off of APRETUDE who want to stop taking it — Not at all Concerned | 9 | 14 | 40 |
| M12 - How to transition patients off of APRETUDE who want to stop taking it — Extremely concerned | 0 | 1 | 2 |
| M12 - How to transition patients off of APRETUDE who want to stop taking it — Moderately concerned | 0 | 2 | 2 |
| M12 - How to transition patients off of APRETUDE who want to stop taking it — Somewhat concerned | 3 | 4 | 5 |
| M12 - How to transition patients off of APRETUDE who want to stop taking it — Slightly concerned | 3 | 3 | 6 |
| M12 - How to transition patients off of APRETUDE who want to stop taking it — Not at all Concerned | 5 | 14 | 34 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Data displayed represent injection fidelity topics discussed by SSPs while describing the APRETUDE implementation process. SSIs were not conducted with SSPs at baseline. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).
| Participants | Women's Health Clinic - SSP | Primary Care Clinic - SSP | HIV Specialist Clinic - SSP |
|---|---|---|---|
| Injection visits | 10 | 19 | 43 |
| Managing patient adherence | 6 | 17 | 24 |
| Managing missed doses | 9 | 17 | 40 |
Data below were collected via SSIs, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents topics surrounding managing adherence and missed doses as discussed by SSPs during SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
| Participants | Women's Health Clinic - SSP | Primary Care Clinic - SSP | HIV Specialist Clinic - SSP |
|---|---|---|---|
| Appointment reminders | 5 | 7 | 21 |
| Scheduling strategies | 4 | 4 | 22 |
| Supporting patient needs | 2 | 1 | 7 |
| No missed doses outside of window | 2 | 5 | 10 |
| Yes, missed doses outside of window | 2 | 5 | 17 |
| Have not switched patients to oral PrEP | 2 | 7 | 19 |
| Patients discontinued APRETUDE | 3 | 3 | 5 |
| Bridging with oral PrEP until restart | 2 | 3 | 5 |
| Having a workflow for missed doses | 3 | 8 | 10 |
IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to barriers and facilitators to fidelity to APRETUDE injection windows as discussed during IMC calls. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Clinics | Women's Health Clinic | Primary Care Clinic | HIV Specialist Clinic |
|---|---|---|---|
| Consistent/Regular Communication with Patient | 1 | 1 | 5 |
| Past experiences with injectables and/or APRETUDE | 2 | 2 | — |
| Established and Clear Protocol and Procedures in Place | 1 | 1 | 1 |
| Advance and/or Flexible Scheduling | — | 1 | 2 |
| Patient Supportive Resources (i.e., educational brochures, transportation arrangements) | 2 | — | 1 |
| Funding Supports Implementation for AREPTUDE | — | — | 1 |
| Roles Assigned among Clinic Staff | — | — | 1 |
| Patient-Clinic Relationship Established and/or strengthened | — | — | 1 |
| Staff knowledge/perception/motivation/attitudes | — | — | 2 |
| Lack of training/education | — | — | 1 |
| Time constraints & care prioritization | — | — | 1 |
| Issues related to insurance coverage/reimbursement or financial-assistance programs | — | 1 | 1 |
| Insufficient staff to work on this | — | 2 | — |
| Insufficient time to work on this | — | — | 1 |
| Challenges reaching patients or patients missing appointments | 2 | 3 | 2 |
| Patient scheduling challenges | 1 | 3 | 5 |
| Patient requested changes | — | 1 | 1 |
Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Cisgender - PSP | Transgender - PSP |
|---|---|---|
| Number of PSPs Completing Target Number of Injections by Patient Subgroups | 29 | 8 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified APRETUDE implementation and patient management. Only a selection of items are applicable for BL timepoint.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Ability to provide HIV screening at each injection visit and follow up based on results — Extremely concerned | 1 | 2 | 0 |
| BL - Ability to provide HIV screening at each injection visit and follow up based on results — Moderately concerned | 0 | 4 | 0 |
| BL - Ability to provide HIV screening at each injection visit and follow up based on results — Somewhat concerned | 3 | 2 | 3 |
| BL - Ability to provide HIV screening at each injection visit and follow up based on results — Slightly concerned | 6 | 9 | 11 |
| BL - Ability to provide HIV screening at each injection visit and follow up based on results — Not at all Concerned | 30 | 35 | 26 |
| BL - Provider time to discuss HIV prevention with all eligible patients — Extremely concerned | 1 | 2 | 1 |
| BL - Provider time to discuss HIV prevention with all eligible patients — Moderately concerned | 1 | 4 | 2 |
| BL - Provider time to discuss HIV prevention with all eligible patients — Somewhat concerned | 1 | 2 | 2 |
| BL - Provider time to discuss HIV prevention with all eligible patients — Slightly concerned | 13 | 9 | 8 |
| BL - Provider time to discuss HIV prevention with all eligible patients — Not at all Concerned | 24 | 35 | 27 |
| BL - Patients' ability to keep injection appointments — Extremely concerned | 7 | 10 | 2 |
| BL - Patients' ability to keep injection appointments — Moderately concerned | 8 | 13 | 7 |
| BL - Patients' ability to keep injection appointments — Somewhat concerned | 12 | 8 | 13 |
| BL - Patients' ability to keep injection appointments — Slightly concerned | 7 | 15 | 12 |
| BL - Patients' ability to keep injection appointments — Not at all Concerned | 6 | 6 | 6 |
| BL - Keeping a patient engaged and motivated to continue APRETUDE — Extremely concerned | 2 | 9 | 3 |
| BL - Keeping a patient engaged and motivated to continue APRETUDE — Moderately concerned | 7 | 10 | 7 |
| BL - Keeping a patient engaged and motivated to continue APRETUDE — Somewhat concerned | 10 | 10 | 9 |
| BL - Keeping a patient engaged and motivated to continue APRETUDE — Slightly concerned | 12 | 10 | 12 |
| BL - Keeping a patient engaged and motivated to continue APRETUDE — Not at all Concerned | 9 | 13 | 9 |
| BL - Worried that a patient will feel stigmatized if offered APRETUDE — Extremely concerned | 2 | 6 | 0 |
| BL - Worried that a patient will feel stigmatized if offered APRETUDE — Moderately concerned | 3 | 4 | 1 |
| BL - Worried that a patient will feel stigmatized if offered APRETUDE — Somewhat concerned | 4 | 8 | 3 |
| BL - Worried that a patient will feel stigmatized if offered APRETUDE — Slightly concerned | 9 | 10 | 15 |
| BL - Worried that a patient will feel stigmatized if offered APRETUDE — Not at all Concerned | 22 | 24 | 21 |
| BL - Patients' willingness to travel every 2 months for an injection appointment — Extremely concerned | 4 | 6 | 2 |
| BL - Patients' willingness to travel every 2 months for an injection appointment — Moderately concerned | 5 | 11 | 8 |
| BL - Patients' willingness to travel every 2 months for an injection appointment — Somewhat concerned | 7 | 8 | 9 |
| BL - Patients' willingness to travel every 2 months for an injection appointment — Slightly concerned | 16 | 15 | 15 |
| BL - Patients' willingness to travel every 2 months for an injection appointment — Not at all Concerned | 8 | 12 | 6 |
| BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Extremely concerned | 1 | 2 | 1 |
| BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Moderately concerned | 3 | 3 | 2 |
| BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Somewhat concerned | 3 | 5 | 2 |
| BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Slightly concerned | 9 | 10 | 9 |
| BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Not at all Concerned | 24 | 32 | 26 |
| M4 - Patients' ability to keep injection appointments — Extremely concerned | 4 | 2 | 0 |
| M4 - Patients' ability to keep injection appointments — Moderately concerned | 7 | 5 | 6 |
| M4 - Patients' ability to keep injection appointments — Somewhat concerned | 4 | 8 | 12 |
| M4 - Patients' ability to keep injection appointments — Slightly concerned | 9 | 10 | 12 |
| M4 - Patients' ability to keep injection appointments — Not at all Concerned | 5 | 7 | 8 |
| M4 - Keeping a patient engaged and motivated to continue APRETUDE — Extremely concerned | 4 | 2 | 2 |
| M4 - Keeping a patient engaged and motivated to continue APRETUDE — Moderately concerned | 5 | 5 | 0 |
| M4 - Keeping a patient engaged and motivated to continue APRETUDE — Somewhat concerned | 6 | 5 | 10 |
| M4 - Keeping a patient engaged and motivated to continue APRETUDE — Slightly concerned | 7 | 10 | 19 |
| M4 - Keeping a patient engaged and motivated to continue APRETUDE — Not at all Concerned | 7 | 10 | 7 |
| M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Extremely concerned | 1 | 0 | 0 |
| M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Moderately concerned | 2 | 0 | 1 |
| M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Somewhat concerned | 2 | 1 | 4 |
| M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Slightly concerned | 8 | 9 | 8 |
| M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Not at all Concerned | 16 | 22 | 25 |
| M4 - Patients' willingness to travel every 2 months for an injection appointment — Extremely concerned | 2 | 0 | 1 |
| M4 - Patients' willingness to travel every 2 months for an injection appointment — Moderately concerned | 4 | 3 | 4 |
| M4 - Patients' willingness to travel every 2 months for an injection appointment — Somewhat concerned | 5 | 7 | 8 |
| M4 - Patients' willingness to travel every 2 months for an injection appointment — Slightly concerned | 8 | 13 | 17 |
| M4 - Patients' willingness to travel every 2 months for an injection appointment — Not at all Concerned | 10 | 9 | 8 |
| M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Extremely concerned | 0 | 0 | 0 |
| M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Moderately concerned | 0 | 1 | 1 |
| M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Somewhat concerned | 7 | 3 | 2 |
| M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Slightly concerned | 4 | 4 | 10 |
| M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Not at all Concerned | 18 | 24 | 25 |
| M4 - Provider time to discuss HIV prevention with all eligible patients — Extremely concerned | 0 | 0 | 0 |
| M4 - Provider time to discuss HIV prevention with all eligible patients — Moderately concerned | 3 | 1 | 0 |
| M4 - Provider time to discuss HIV prevention with all eligible patients — Somewhat concerned | 4 | 4 | 4 |
| M4 - Provider time to discuss HIV prevention with all eligible patients — Slightly concerned | 3 | 6 | 8 |
| M4 - Provider time to discuss HIV prevention with all eligible patients — Not at all Concerned | 19 | 21 | 26 |
| M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Extremely concerned | 1 | 0 | 0 |
| M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Moderately concerned | 1 | 1 | 2 |
| M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Somewhat concerned | 3 | 4 | 5 |
| M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Slightly concerned | 5 | 4 | 6 |
| M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Not at all Concerned | 19 | 23 | 25 |
| M12 - Patients' ability to keep injection appointments — Extremely concerned | 5 | 1 | 1 |
| M12 - Patients' ability to keep injection appointments — Moderately concerned | 2 | 3 | 9 |
| M12 - Patients' ability to keep injection appointments — Somewhat concerned | 7 | 5 | 11 |
| M12 - Patients' ability to keep injection appointments — Slightly concerned | 8 | 8 | 6 |
| M12 - Patients' ability to keep injection appointments — Not at all Concerned | 4 | 9 | 5 |
| M12 - Keeping a patient engaged and motivated to continue APRETUDE — Extremely concerned | 2 | 1 | 4 |
| M12 - Keeping a patient engaged and motivated to continue APRETUDE — Moderately concerned | 5 | 4 | 2 |
| M12 - Keeping a patient engaged and motivated to continue APRETUDE — Somewhat concerned | 7 | 3 | 11 |
| M12 - Keeping a patient engaged and motivated to continue APRETUDE — Slightly concerned | 6 | 10 | 8 |
| M12 - Keeping a patient engaged and motivated to continue APRETUDE — Not at all Concerned | 6 | 8 | 7 |
| M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Extremely concerned | 2 | 0 | 1 |
| M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Moderately concerned | 0 | 1 | 1 |
| M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Somewhat concerned | 6 | 2 | 3 |
| M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Slightly concerned | 8 | 5 | 8 |
| M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Not at all Concerned | 10 | 18 | 19 |
| M12 - Patients' willingness to travel every 2 months for an injection appointment — Extremely concerned | 3 | 1 | 4 |
| M12 - Patients' willingness to travel every 2 months for an injection appointment — Moderately concerned | 1 | 3 | 4 |
| M12 - Patients' willingness to travel every 2 months for an injection appointment — Somewhat concerned | 10 | 5 | 6 |
| M12 - Patients' willingness to travel every 2 months for an injection appointment — Slightly concerned | 6 | 5 | 11 |
| M12 - Patients' willingness to travel every 2 months for an injection appointment — Not at all Concerned | 6 | 12 | 7 |
| M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Extremely concerned | 1 | 0 | 0 |
| M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Moderately concerned | 2 | 0 | 1 |
| M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Somewhat concerned | 3 | 2 | 2 |
| M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Slightly concerned | 1 | 2 | 4 |
| M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Not at all Concerned | 19 | 22 | 25 |
| M12 - Provider time to discuss HIV prevention with all eligible patients — Extremely concerned | 1 | 0 | 0 |
| M12 - Provider time to discuss HIV prevention with all eligible patients — Moderately concerned | 1 | 0 | 2 |
| M12 - Provider time to discuss HIV prevention with all eligible patients — Somewhat concerned | 3 | 1 | 4 |
| M12 - Provider time to discuss HIV prevention with all eligible patients — Slightly concerned | 5 | 6 | 5 |
| M12 - Provider time to discuss HIV prevention with all eligible patients — Not at all Concerned | 16 | 19 | 21 |
| M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Extremely concerned | 2 | 0 | 0 |
| M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Moderately concerned | 2 | 0 | 3 |
| M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Somewhat concerned | 2 | 1 | 8 |
| M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Slightly concerned | 5 | 4 | 5 |
| M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Not at all Concerned | 15 | 21 | 16 |
Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs response to the specified items regarding to the clinic climate and change readiness as implementation barriers and facilitators.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - People at all levels openly talk about what is and isn't working — Completely disagree | 0 | 1 | 0 |
| BL - People at all levels openly talk about what is and isn't working — Disagree | 2 | 1 | 0 |
| BL - People at all levels openly talk about what is and isn't working — Neither agree nor disagree | 8 | 8 | 4 |
| BL - People at all levels openly talk about what is and isn't working — Agree | 19 | 20 | 17 |
| BL - People at all levels openly talk about what is and isn't working — Completely agree | 11 | 22 | 19 |
| BL - Most people in this clinic are willing to change their practices based on feedback — Completely disagree | 0 | 0 | 0 |
| BL - Most people in this clinic are willing to change their practices based on feedback — Disagree | 3 | 4 | 3 |
| BL - Most people in this clinic are willing to change their practices based on feedback — Neither agree nor disagree | 7 | 8 | 5 |
| BL - Most people in this clinic are willing to change their practices based on feedback — Agree | 20 | 23 | 22 |
| BL - Most people in this clinic are willing to change their practices based on feedback — Completely agree | 10 | 17 | 10 |
| BL - It is hard to get things to change in our clinic — Completely disagree | 8 | 8 | 7 |
| BL - It is hard to get things to change in our clinic — Disagree | 15 | 24 | 17 |
| BL - It is hard to get things to change in our clinic — Neither agree nor disagree | 11 | 7 | 7 |
| BL - It is hard to get things to change in our clinic — Agree | 5 | 7 | 7 |
| BL - It is hard to get things to change in our clinic — Completely agree | 1 | 6 | 2 |
| BL - People in this clinic operate as a real team — Completely disagree | 0 | 0 | 0 |
| BL - People in this clinic operate as a real team — Disagree | 2 | 2 | 0 |
| BL - People in this clinic operate as a real team — Neither agree nor disagree | 7 | 7 | 2 |
| BL - People in this clinic operate as a real team — Agree | 14 | 21 | 20 |
| BL - People in this clinic operate as a real team — Completely agree | 17 | 22 | 18 |
| BL - Staff members often show signs of stress and strain — Completely disagree | 2 | 9 | 1 |
| BL - Staff members often show signs of stress and strain — Disagree | 12 | 13 | 8 |
| BL - Staff members often show signs of stress and strain — Neither agree nor disagree | 12 | 12 | 16 |
| BL - Staff members often show signs of stress and strain — Agree | 10 | 13 | 14 |
| BL - Staff members often show signs of stress and strain — Completely agree | 4 | 5 | 1 |
| BL - We regularly take time to consider ways to improve how we do things — Completely disagree | 0 | 0 | 0 |
| BL - We regularly take time to consider ways to improve how we do things — Disagree | 2 | 2 | 1 |
| BL - We regularly take time to consider ways to improve how we do things — Neither agree nor disagree | 6 | 7 | 1 |
| BL - We regularly take time to consider ways to improve how we do things — Agree | 18 | 19 | 27 |
| BL - We regularly take time to consider ways to improve how we do things — Completely agree | 14 | 24 | 11 |
| BL - Leadership strongly supports clinic change efforts — Completely disagree | 0 | 0 | 0 |
| BL - Leadership strongly supports clinic change efforts — Disagree | 2 | 2 | 1 |
| BL - Leadership strongly supports clinic change efforts — Neither agree nor disagree | 11 | 9 | 4 |
| BL - Leadership strongly supports clinic change efforts — Agree | 10 | 16 | 22 |
| BL - Leadership strongly supports clinic change efforts — Completely agree | 17 | 25 | 13 |
| M4 - People at all levels openly talk about what is and isn't working — Completely disagree | 1 | 1 | 1 |
| M4 - People at all levels openly talk about what is and isn't working — Disagree | 3 | 0 | 1 |
| M4 - People at all levels openly talk about what is and isn't working — Neither agree nor disagree | 6 | 3 | 7 |
| M4 - People at all levels openly talk about what is and isn't working — Agree | 10 | 15 | 20 |
| M4 - People at all levels openly talk about what is and isn't working — Completely agree | 9 | 13 | 9 |
| M4 - Most people in this clinic are willing to change their practices based on feedback — Completely disagree | 1 | 1 | 0 |
| M4 - Most people in this clinic are willing to change their practices based on feedback — Disagree | 1 | 0 | 1 |
| M4 - Most people in this clinic are willing to change their practices based on feedback — Neither agree nor disagree | 4 | 4 | 9 |
| M4 - Most people in this clinic are willing to change their practices based on feedback — Agree | 16 | 15 | 20 |
| M4 - Most people in this clinic are willing to change their practices based on feedback — Completely agree | 7 | 12 | 8 |
| M4 - It is hard to get things to change in our clinic — Completely disagree | 7 | 6 | 6 |
| M4 - It is hard to get things to change in our clinic — Disagree | 5 | 12 | 10 |
| M4 - It is hard to get things to change in our clinic — Neither agree nor disagree | 8 | 7 | 10 |
| M4 - It is hard to get things to change in our clinic — Agree | 7 | 3 | 7 |
| M4 - It is hard to get things to change in our clinic — Completely agree | 2 | 4 | 5 |
| M4 - People in this clinic operate as a real team — Completely disagree | 0 | 0 | 0 |
| M4 - People in this clinic operate as a real team — Disagree | 0 | 1 | 1 |
| M4 - People in this clinic operate as a real team — Neither agree nor disagree | 5 | 5 | 4 |
| M4 - People in this clinic operate as a real team — Agree | 18 | 14 | 17 |
| M4 - People in this clinic operate as a real team — Completely agree | 6 | 12 | 16 |
| M4 - Staff members often show signs of stress and strain — Completely disagree | 2 | 6 | 1 |
| M4 - Staff members often show signs of stress and strain — Disagree | 4 | 6 | 5 |
| M4 - Staff members often show signs of stress and strain — Neither agree nor disagree | 6 | 9 | 15 |
| M4 - Staff members often show signs of stress and strain — Agree | 9 | 7 | 12 |
| M4 - Staff members often show signs of stress and strain — Completely agree | 8 | 4 | 5 |
| M4 - We regularly take time to consider ways to improve how we do things — Completely disagree | 1 | 0 | 1 |
| M4 - We regularly take time to consider ways to improve how we do things — Disagree | 2 | 0 | 2 |
| M4 - We regularly take time to consider ways to improve how we do things — Neither agree nor disagree | 4 | 6 | 5 |
| M4 - We regularly take time to consider ways to improve how we do things — Agree | 15 | 14 | 20 |
| M4 - We regularly take time to consider ways to improve how we do things — Completely agree | 7 | 12 | 10 |
| M4 - Leadership strongly supports clinic change efforts — Completely disagree | 1 | 0 | 1 |
| M4 - Leadership strongly supports clinic change efforts — Disagree | 0 | 1 | 2 |
| M4 - Leadership strongly supports clinic change efforts — Neither agree nor disagree | 10 | 6 | 5 |
| M4 - Leadership strongly supports clinic change efforts — Agree | 8 | 13 | 18 |
| M4 - Leadership strongly supports clinic change efforts — Completely agree | 10 | 12 | 12 |
| M12 - People at all levels openly talk about what is and isn't working — Completely disagree | 1 | 0 | 0 |
| M12 - People at all levels openly talk about what is and isn't working — Disagree | 2 | 1 | 1 |
| M12 - People at all levels openly talk about what is and isn't working — Neither agree nor disagree | 4 | 3 | 4 |
| M12 - People at all levels openly talk about what is and isn't working — Agree | 10 | 8 | 22 |
| M12 - People at all levels openly talk about what is and isn't working — Completely agree | 9 | 14 | 5 |
| M12 - Most people in this clinic are willing to change their practices based on feedback — Completely disagree | 1 | 0 | 1 |
| M12 - Most people in this clinic are willing to change their practices based on feedback — Disagree | 1 | 0 | 0 |
| M12 - Most people in this clinic are willing to change their practices based on feedback — Neither agree nor disagree | 7 | 2 | 4 |
| M12 - Most people in this clinic are willing to change their practices based on feedback — Agree | 10 | 9 | 22 |
| M12 - Most people in this clinic are willing to change their practices based on feedback — Completely agree | 7 | 15 | 5 |
| M12 - It is hard to get things to change in our clinic — Completely disagree | 7 | 6 | 3 |
| M12 - It is hard to get things to change in our clinic — Disagree | 4 | 8 | 13 |
| M12 - It is hard to get things to change in our clinic — Neither agree nor disagree | 6 | 5 | 7 |
| M12 - It is hard to get things to change in our clinic — Agree | 5 | 2 | 7 |
| M12 - It is hard to get things to change in our clinic — Completely agree | 4 | 5 | 2 |
| M12 - People in this clinic operate as a real team — Completely disagree | 1 | 0 | 1 |
| M12 - People in this clinic operate as a real team — Disagree | 1 | 0 | 0 |
| M12 - People in this clinic operate as a real team — Neither agree nor disagree | 4 | 2 | 2 |
| M12 - People in this clinic operate as a real team — Agree | 11 | 8 | 17 |
| M12 - People in this clinic operate as a real team — Completely agree | 9 | 16 | 12 |
| M12 - Staff members often show signs of stress and strain — Completely disagree | 2 | 6 | 1 |
| M12 - Staff members often show signs of stress and strain — Disagree | 4 | 5 | 7 |
| M12 - Staff members often show signs of stress and strain — Neither agree nor disagree | 8 | 8 | 8 |
| M12 - Staff members often show signs of stress and strain — Agree | 8 | 4 | 13 |
| M12 - Staff members often show signs of stress and strain — Completely agree | 4 | 3 | 3 |
| M12 - We regularly take time to consider ways to improve how we do things — Completely disagree | 1 | 1 | 1 |
| M12 - We regularly take time to consider ways to improve how we do things — Disagree | 2 | 0 | 4 |
| M12 - We regularly take time to consider ways to improve how we do things — Neither agree nor disagree | 7 | 1 | 5 |
| M12 - We regularly take time to consider ways to improve how we do things — Agree | 9 | 11 | 16 |
| M12 - We regularly take time to consider ways to improve how we do things — Completely agree | 7 | 13 | 6 |
| M12 - Leadership strongly supports clinic change efforts — Completely disagree | 1 | 0 | 1 |
| M12 - Leadership strongly supports clinic change efforts — Disagree | 2 | 0 | 1 |
| M12 - Leadership strongly supports clinic change efforts — Neither agree nor disagree | 11 | 3 | 7 |
| M12 - Leadership strongly supports clinic change efforts — Agree | 4 | 7 | 14 |
| M12 - Leadership strongly supports clinic change efforts — Completely agree | 8 | 16 | 9 |
Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs perception of the bi-monthly injection benefits.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| No benefits for every two months injections (exclusive) | 1 | 3 | 2 |
| Confirmation of PrEP use | 21 | 15 | 21 |
| Confirmation of HIV testing | 22 | 17 | 16 |
| More opportunities to discuss medication concerns or manage side effect | 18 | 15 | 18 |
| More opportunities to screen for other comorbidities | 16 | 13 | 12 |
| Additional opportunity to screen for STIs | 20 | 20 | 21 |
| Additional change to provide other health or psychological care | 13 | 8 | 9 |
| Another benefit | 0 | 0 | 1 |
| Missing | 0 | 1 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified questions regarding prior knowledge of HIV/PrEP. For each timepoint assessed for this outcome measure only specific questions were applied.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| BL - Do you personally know of someone or some people living with HIV? — Yes | 33 | 34 | 26 |
| BL - Do you personally know of someone or some people living with HIV? — No | 17 | 20 | 14 |
| BL - Do you personally know of someone or some people living with HIV? — I don't know | 2 | 2 | 2 |
| BL - Do you personally know of someone or some people living with HIV? — Missing | 1 | 0 | 0 |
| BL - Before enrolling, had you heard of APRETUDE, the long-acting injectable form of PrEP? — Yes | 31 | 25 | 23 |
| BL - Before enrolling, had you heard of APRETUDE, the long-acting injectable form of PrEP? — No | 21 | 30 | 19 |
| BL - Before enrolling, had you heard of APRETUDE, the long-acting injectable form of PrEP? — I don't know | 1 | 1 | 0 |
| BL - Before enrolling, had you heard of APRETUDE, the long-acting injectable form of PrEP? — Missing | 0 | 0 | 0 |
| BL - Before enrolling, had you heard of people without HIV taking daily oral PrEP? — Yes | 39 | 41 | 33 |
| BL - Before enrolling, had you heard of people without HIV taking daily oral PrEP? — No | 11 | 13 | 7 |
| BL - Before enrolling, had you heard of people without HIV taking daily oral PrEP? — I don't know | 3 | 2 | 2 |
| BL - Before enrolling, had you heard of people without HIV taking daily oral PrEP? — Missing | 0 | 0 | 0 |
| BL - Do you personally know of a person or people who have ever taken oral PrEP? — Yes | 30 | 23 | 25 |
| BL - Do you personally know of a person or people who have ever taken oral PrEP? — No | 9 | 18 | 7 |
| BL - Do you personally know of a person or people who have ever taken oral PrEP? — I don't know | 0 | 0 | 1 |
| BL - Do you personally know of a person or people who have ever taken oral PrEP? — Missing | 0 | 0 | 0 |
| M4 - Do you personally know of someone or some people living with HIV? — Yes | 36 | 27 | 19 |
| M4 - Do you personally know of someone or some people living with HIV? — No | 11 | 11 | 15 |
| M4 - Do you personally know of someone or some people living with HIV? — I don't know | 3 | 5 | 2 |
| M4 - Do you personally know of someone or some people living with HIV? — Missing | 0 | 0 | 1 |
| M12 - Do you personally know of someone or some people living with HIV? — Yes | 27 | 21 | 16 |
| M12 - Do you personally know of someone or some people living with HIV? — No | 10 | 12 | 6 |
| M12 - Do you personally know of someone or some people living with HIV? — I don't know | 3 | 1 | 1 |
| M12 - Do you personally know of someone or some people living with HIV? — Missing | 0 | 1 | 1 |
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified items regarding HIV knowledge and misconceptions.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| BL - A person who has HIV can look healthy — True | 52 | 55 | 42 |
| BL - A person who has HIV can look healthy — False | 1 | 1 | 0 |
| BL - A person who has HIV can look healthy — Missing | 0 | 0 | 0 |
| BL - There is a vaccine that can stop you from getting HIV — True | 34 | 35 | 23 |
| BL - There is a vaccine that can stop you from getting HIV — False | 19 | 21 | 19 |
| BL - There is a vaccine that can stop you from getting HIV — Missing | 0 | 0 | 0 |
| BL - A person will NOT get HIV if they are taking antibiotics — True | 7 | 7 | 7 |
| BL - A person will NOT get HIV if they are taking antibiotics — False | 46 | 49 | 35 |
| BL - A person will NOT get HIV if they are taking antibiotics — Missing | 0 | 0 | 0 |
| BL - If you only have sex once with a partner, you cannot get HIV from them — True | 0 | 2 | 3 |
| BL - If you only have sex once with a partner, you cannot get HIV from them — False | 53 | 54 | 39 |
| BL - If you only have sex once with a partner, you cannot get HIV from them — Missing | 0 | 0 | 0 |
| BL - People on HIV medications cannot spread HIV — True | 17 | 23 | 18 |
| BL - People on HIV medications cannot spread HIV — False | 36 | 33 | 24 |
| BL - People on HIV medications cannot spread HIV — Missing | 0 | 0 | 0 |
| BL - Everybody who has HIV knows that they have HIV — True | 4 | 2 | 2 |
| BL - Everybody who has HIV knows that they have HIV — False | 49 | 54 | 40 |
| BL - Everybody who has HIV knows that they have HIV — Missing | 0 | 0 | 0 |
| BL - A natural skin [lamb skin] condom works better against HIV than does a latex condom — True | 3 | 6 | 8 |
| BL - A natural skin [lamb skin] condom works better against HIV than does a latex condom — False | 50 | 50 | 34 |
| BL - A natural skin [lamb skin] condom works better against HIV than does a latex condom — Missing | 0 | 0 | 0 |
| BL - It is safer to use water-based lubricants than oil-based lubricants when using condoms — True | 43 | 41 | 35 |
| BL - It is safer to use water-based lubricants than oil-based lubricants when using condoms — False | 10 | 15 | 7 |
| BL - It is safer to use water-based lubricants than oil-based lubricants when using condoms — Missing | 0 | 0 | 0 |
| M4 - A person who has HIV can look healthy — True | 50 | 42 | 36 |
| M4 - A person who has HIV can look healthy — False | 0 | 1 | 0 |
| M4 - A person who has HIV can look healthy — Missing | 0 | 0 | 1 |
| M4 - There is a vaccine that can stop you from getting HIV — True | 29 | 22 | 20 |
| M4 - There is a vaccine that can stop you from getting HIV — False | 21 | 21 | 16 |
| M4 - There is a vaccine that can stop you from getting HIV — Missing | 0 | 0 | 1 |
| M4 - A person will NOT get HIV if they are taking antibiotics — True | 5 | 3 | 4 |
| M4 - A person will NOT get HIV if they are taking antibiotics — False | 45 | 40 | 32 |
| M4 - A person will NOT get HIV if they are taking antibiotics — Missing | 0 | 0 | 1 |
| M4 - If you only have sex once with a partner, you cannot get HIV from them — True | 0 | 0 | 1 |
| M4 - If you only have sex once with a partner, you cannot get HIV from them — False | 50 | 43 | 35 |
| M4 - If you only have sex once with a partner, you cannot get HIV from them — Missing | 0 | 0 | 1 |
| M4 - People on HIV medications cannot spread HIV — True | 19 | 13 | 18 |
| M4 - People on HIV medications cannot spread HIV — False | 31 | 30 | 18 |
| M4 - People on HIV medications cannot spread HIV — Missing | 0 | 0 | 1 |
| M4 - Everybody who has HIV knows that they have HIV — True | 3 | 3 | 2 |
| M4 - Everybody who has HIV knows that they have HIV — False | 47 | 40 | 34 |
| M4 - Everybody who has HIV knows that they have HIV — Missing | 0 | 0 | 1 |
| M4 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — True | 4 | 5 | 4 |
| M4 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — False | 46 | 38 | 32 |
| M4 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — Missing | 0 | 0 | 1 |
| M4 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — True | 40 | 34 | 31 |
| M4 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — False | 10 | 9 | 5 |
| M4 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — Missing | 0 | 0 | 1 |
| M12 - A person who has HIV can look healthy — True | 40 | 34 | 23 |
| M12 - A person who has HIV can look healthy — False | 0 | 0 | 0 |
| M12 - A person who has HIV can look healthy — Missing | 0 | 1 | 1 |
| M12 - There is a vaccine that can stop you from getting HIV — True | 23 | 21 | 11 |
| M12 - There is a vaccine that can stop you from getting HIV — False | 17 | 13 | 12 |
| M12 - There is a vaccine that can stop you from getting HIV — Missing | 0 | 1 | 1 |
| M12 - A person will NOT get HIV if they are taking antibiotics — True | 1 | 2 | 1 |
| M12 - A person will NOT get HIV if they are taking antibiotics — False | 39 | 32 | 22 |
| M12 - A person will NOT get HIV if they are taking antibiotics — Missing | 0 | 1 | 1 |
| M12 - If you only have sex once with a partner, you cannot get HIV from them — True | 1 | 0 | 0 |
| M12 - If you only have sex once with a partner, you cannot get HIV from them — False | 39 | 34 | 23 |
| M12 - If you only have sex once with a partner, you cannot get HIV from them — Missing | 0 | 1 | 1 |
| M12 - People on HIV medications cannot spread HIV — True | 12 | 15 | 14 |
| M12 - People on HIV medications cannot spread HIV — False | 28 | 19 | 9 |
| M12 - People on HIV medications cannot spread HIV — Missing | 0 | 1 | 1 |
| M12 - Everybody who has HIV knows that they have HIV — True | 2 | 1 | 1 |
| M12 - Everybody who has HIV knows that they have HIV — False | 38 | 33 | 22 |
| M12 - Everybody who has HIV knows that they have HIV — Missing | 0 | 1 | 1 |
| M12 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — True | 1 | 5 | 2 |
| M12 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — False | 39 | 29 | 21 |
| M12 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — Missing | 0 | 1 | 1 |
| M12 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — True | 34 | 26 | 22 |
| M12 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — False | 6 | 8 | 1 |
| M12 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — Missing | 0 | 1 | 1 |
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement regarding the social and personal perceptions (support, stigma, attitude) towards PrEP use.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| BL - My friends would be supportive of me taking PrEP — Completely disagree | 3 | 2 | 1 |
| BL - My friends would be supportive of me taking PrEP — Disagree | 2 | 2 | 1 |
| BL - My friends would be supportive of me taking PrEP — Neither agree nor disagree | 10 | 10 | 6 |
| BL - My friends would be supportive of me taking PrEP — Agree | 13 | 16 | 11 |
| BL - My friends would be supportive of me taking PrEP — Completely agree | 25 | 26 | 23 |
| BL - My friends would be supportive of me taking PrEP — Missing | 0 | 0 | 0 |
| BL - My family would be supportive of me taking PrEP — Completely disagree | 8 | 2 | 0 |
| BL - My family would be supportive of me taking PrEP — Disagree | 4 | 3 | 2 |
| BL - My family would be supportive of me taking PrEP — Neither agree nor disagree | 8 | 14 | 10 |
| BL - My family would be supportive of me taking PrEP — Agree | 14 | 10 | 9 |
| BL - My family would be supportive of me taking PrEP — Completely agree | 19 | 27 | 21 |
| BL - My family would be supportive of me taking PrEP — Missing | 0 | 0 | 0 |
| BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely disagree | 6 | 8 | 7 |
| BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Disagree | 13 | 11 | 7 |
| BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Neither agree nor disagree | 21 | 23 | 14 |
| BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Agree | 8 | 12 | 11 |
| BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely agree | 5 | 2 | 3 |
| BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Missing | 0 | 0 | 0 |
| BL - People experience negative judgment because they take PrEP — Completely disagree | 4 | 8 | 6 |
| BL - People experience negative judgment because they take PrEP — Disagree | 8 | 9 | 6 |
| BL - People experience negative judgment because they take PrEP — Neither agree nor disagree | 18 | 21 | 14 |
| BL - People experience negative judgment because they take PrEP — Agree | 17 | 17 | 13 |
| BL - People experience negative judgment because they take PrEP — Completely agree | 6 | 1 | 3 |
| BL - People experience negative judgment because they take PrEP — Missing | 0 | 0 | 0 |
| BL - People taking PrEP receive praise for being responsible — Completely disagree | 1 | 1 | 2 |
| BL - People taking PrEP receive praise for being responsible — Disagree | 5 | 7 | 4 |
| BL - People taking PrEP receive praise for being responsible — Neither agree nor disagree | 22 | 24 | 13 |
| BL - People taking PrEP receive praise for being responsible — Agree | 17 | 16 | 13 |
| BL - People taking PrEP receive praise for being responsible — Completely agree | 8 | 8 | 10 |
| BL - People taking PrEP receive praise for being responsible — Missing | 0 | 0 | 0 |
| BL - I would feel ashamed to take PrEP in front of others — Completely disagree | 27 | 22 | 26 |
| BL - I would feel ashamed to take PrEP in front of others — Disagree | 15 | 19 | 8 |
| BL - I would feel ashamed to take PrEP in front of others — Neither agree nor disagree | 7 | 9 | 3 |
| BL - I would feel ashamed to take PrEP in front of others — Agree | 4 | 6 | 3 |
| BL - I would feel ashamed to take PrEP in front of others — Completely agree | 0 | 0 | 2 |
| BL - I would feel ashamed to take PrEP in front of others — Missing | 0 | 0 | 0 |
| BL - Someone taking PrEP may be seen as having sex with many different people — Completely disagree | 3 | 4 | 6 |
| BL - Someone taking PrEP may be seen as having sex with many different people — Disagree | 7 | 13 | 4 |
| BL - Someone taking PrEP may be seen as having sex with many different people — Neither agree nor disagree | 18 | 16 | 14 |
| BL - Someone taking PrEP may be seen as having sex with many different people — Agree | 19 | 19 | 11 |
| BL - Someone taking PrEP may be seen as having sex with many different people — Completely agree | 6 | 4 | 7 |
| BL - Someone taking PrEP may be seen as having sex with many different people — Missing | 0 | 0 | 0 |
| BL - People on PrEP are taking care of their health — Completely disagree | 1 | 1 | 0 |
| BL - People on PrEP are taking care of their health — Disagree | 1 | 0 | 0 |
| BL - People on PrEP are taking care of their health — Neither agree nor disagree | 5 | 6 | 1 |
| BL - People on PrEP are taking care of their health — Agree | 14 | 20 | 9 |
| BL - People on PrEP are taking care of their health — Completely agree | 32 | 29 | 32 |
| BL - People on PrEP are taking care of their health — Missing | 0 | 0 | 0 |
| BL - People taking PrEP experience verbal harassment — Completely disagree | 7 | 7 | 9 |
| BL - People taking PrEP experience verbal harassment — Disagree | 12 | 15 | 6 |
| BL - People taking PrEP experience verbal harassment — Neither agree nor disagree | 32 | 24 | 21 |
| BL - People taking PrEP experience verbal harassment — Agree | 2 | 7 | 5 |
| BL - People taking PrEP experience verbal harassment — Completely agree | 0 | 3 | 1 |
| BL - People taking PrEP experience verbal harassment — Missing | 0 | 0 | 0 |
| BL - I would not want others to know if I was taking PrEP — Completely disagree | 16 | 15 | 19 |
| BL - I would not want others to know if I was taking PrEP — Disagree | 20 | 14 | 10 |
| BL - I would not want others to know if I was taking PrEP — Neither agree nor disagree | 14 | 16 | 7 |
| BL - I would not want others to know if I was taking PrEP — Agree | 2 | 8 | 4 |
| BL - I would not want others to know if I was taking PrEP — Completely agree | 1 | 3 | 2 |
| BL - I would not want others to know if I was taking PrEP — Missing | 0 | 0 | 0 |
| BL - Someone taking PrEP should keep their pills hidden — Completely disagree | 16 | 12 | 17 |
| BL - Someone taking PrEP should keep their pills hidden — Disagree | 17 | 15 | 10 |
| BL - Someone taking PrEP should keep their pills hidden — Neither agree nor disagree | 19 | 22 | 7 |
| BL - Someone taking PrEP should keep their pills hidden — Agree | 1 | 6 | 5 |
| BL - Someone taking PrEP should keep their pills hidden — Completely agree | 0 | 1 | 3 |
| BL - Someone taking PrEP should keep their pills hidden — Missing | 0 | 0 | 0 |
| BL - I would feel proud to take PrEP — Completely disagree | 2 | 1 | 0 |
| BL - I would feel proud to take PrEP — Disagree | 0 | 0 | 0 |
| BL - I would feel proud to take PrEP — Neither agree nor disagree | 7 | 6 | 5 |
| BL - I would feel proud to take PrEP — Agree | 19 | 25 | 10 |
| BL - I would feel proud to take PrEP — Completely agree | 25 | 24 | 27 |
| BL - I would feel proud to take PrEP — Missing | 0 | 0 | 0 |
| BL - I would have sex with someone who is taking PrEP — Completely disagree | 1 | 0 | 0 |
| BL - I would have sex with someone who is taking PrEP — Disagree | 0 | 1 | 0 |
| BL - I would have sex with someone who is taking PrEP — Neither agree nor disagree | 7 | 9 | 6 |
| BL - I would have sex with someone who is taking PrEP — Agree | 18 | 24 | 12 |
| BL - I would have sex with someone who is taking PrEP — Completely agree | 27 | 22 | 24 |
| BL - I would have sex with someone who is taking PrEP — Missing | 0 | 0 | 0 |
| M4 - My friends would be supportive of me taking PrEP — Completely disagree | 1 | 1 | 4 |
| M4 - My friends would be supportive of me taking PrEP — Disagree | 1 | 2 | 0 |
| M4 - My friends would be supportive of me taking PrEP — Neither agree nor disagree | 10 | 5 | 7 |
| M4 - My friends would be supportive of me taking PrEP — Agree | 14 | 17 | 7 |
| M4 - My friends would be supportive of me taking PrEP — Completely agree | 24 | 18 | 18 |
| M4 - My friends would be supportive of me taking PrEP — Missing | 0 | 0 | 1 |
| M4 - My family would be supportive of me taking PrEP — Completely disagree | 3 | 2 | 1 |
| M4 - My family would be supportive of me taking PrEP — Disagree | 3 | 2 | 2 |
| M4 - My family would be supportive of me taking PrEP — Neither agree nor disagree | 8 | 7 | 10 |
| M4 - My family would be supportive of me taking PrEP — Agree | 13 | 15 | 7 |
| M4 - My family would be supportive of me taking PrEP — Completely agree | 23 | 17 | 16 |
| M4 - My family would be supportive of me taking PrEP — Missing | 0 | 0 | 1 |
| M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely disagree | 8 | 3 | 7 |
| M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Disagree | 6 | 8 | 7 |
| M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Neither agree nor disagree | 22 | 20 | 14 |
| M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Agree | 12 | 8 | 6 |
| M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely agree | 2 | 4 | 2 |
| M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Missing | 0 | 0 | 1 |
| M4 - People experience negative judgment because they take PrEP — Completely disagree | 8 | 2 | 7 |
| M4 - People experience negative judgment because they take PrEP — Disagree | 6 | 9 | 7 |
| M4 - People experience negative judgment because they take PrEP — Neither agree nor disagree | 18 | 17 | 12 |
| M4 - People experience negative judgment because they take PrEP — Agree | 15 | 12 | 7 |
| M4 - People experience negative judgment because they take PrEP — Completely agree | 3 | 3 | 3 |
| M4 - People experience negative judgment because they take PrEP — Missing | 0 | 0 | 1 |
| M4 - People taking PrEP receive praise for being responsible — Completely disagree | 2 | 1 | 3 |
| M4 - People taking PrEP receive praise for being responsible — Disagree | 3 | 4 | 2 |
| M4 - People taking PrEP receive praise for being responsible — Neither agree nor disagree | 25 | 15 | 14 |
| M4 - People taking PrEP receive praise for being responsible — Agree | 14 | 15 | 11 |
| M4 - People taking PrEP receive praise for being responsible — Completely agree | 6 | 8 | 6 |
| M4 - People taking PrEP receive praise for being responsible — Missing | 0 | 0 | 1 |
| M4 - I would feel ashamed to take PrEP in front of others — Completely disagree | 21 | 15 | 19 |
| M4 - I would feel ashamed to take PrEP in front of others — Disagree | 14 | 17 | 7 |
| M4 - I would feel ashamed to take PrEP in front of others — Neither agree nor disagree | 7 | 8 | 8 |
| M4 - I would feel ashamed to take PrEP in front of others — Agree | 7 | 3 | 0 |
| M4 - I would feel ashamed to take PrEP in front of others — Completely agree | 1 | 0 | 2 |
| M4 - I would feel ashamed to take PrEP in front of others — Missing | 0 | 0 | 1 |
| M4 - Someone taking PrEP may be seen as having sex with many different people — Completely disagree | 4 | 3 | 7 |
| M4 - Someone taking PrEP may be seen as having sex with many different people — Disagree | 9 | 12 | 7 |
| M4 - Someone taking PrEP may be seen as having sex with many different people — Neither agree nor disagree | 14 | 12 | 10 |
| M4 - Someone taking PrEP may be seen as having sex with many different people — Agree | 14 | 12 | 10 |
| M4 - Someone taking PrEP may be seen as having sex with many different people — Completely agree | 9 | 4 | 2 |
| M4 - Someone taking PrEP may be seen as having sex with many different people — Missing | 0 | 0 | 1 |
| M4 - People on PrEP are taking care of their health — Completely disagree | 0 | 1 | 1 |
| M4 - People on PrEP are taking care of their health — Disagree | 0 | 1 | 0 |
| M4 - People on PrEP are taking care of their health — Neither agree nor disagree | 3 | 5 | 0 |
| M4 - People on PrEP are taking care of their health — Agree | 21 | 20 | 12 |
| M4 - People on PrEP are taking care of their health — Completely agree | 26 | 16 | 23 |
| M4 - People on PrEP are taking care of their health — Missing | 0 | 0 | 1 |
| M4 - People taking PrEP experience verbal harassment — Completely disagree | 8 | 8 | 8 |
| M4 - People taking PrEP experience verbal harassment — Disagree | 10 | 13 | 7 |
| M4 - People taking PrEP experience verbal harassment — Neither agree nor disagree | 26 | 19 | 15 |
| M4 - People taking PrEP experience verbal harassment — Agree | 5 | 3 | 5 |
| M4 - People taking PrEP experience verbal harassment — Completely agree | 1 | 0 | 1 |
| M4 - People taking PrEP experience verbal harassment — Missing | 0 | 0 | 1 |
| M4 - I would not want others to know if I was taking PrEP — Completely disagree | 19 | 8 | 17 |
| M4 - I would not want others to know if I was taking PrEP — Disagree | 9 | 17 | 7 |
| M4 - I would not want others to know if I was taking PrEP — Neither agree nor disagree | 13 | 10 | 9 |
| M4 - I would not want others to know if I was taking PrEP — Agree | 7 | 7 | 3 |
| M4 - I would not want others to know if I was taking PrEP — Completely agree | 2 | 1 | 0 |
| M4 - I would not want others to know if I was taking PrEP — Missing | 0 | 0 | 1 |
| M4 - Someone taking PrEP should keep their pills hidden — Completely disagree | 15 | 10 | 15 |
| M4 - Someone taking PrEP should keep their pills hidden — Disagree | 14 | 11 | 8 |
| M4 - Someone taking PrEP should keep their pills hidden — Neither agree nor disagree | 17 | 17 | 9 |
| M4 - Someone taking PrEP should keep their pills hidden — Agree | 4 | 5 | 2 |
| M4 - Someone taking PrEP should keep their pills hidden — Completely agree | 0 | 0 | 2 |
| M4 - Someone taking PrEP should keep their pills hidden — Missing | 0 | 0 | 1 |
| M4 - I would feel proud to take PrEP — Completely disagree | 1 | 1 | 2 |
| M4 - I would feel proud to take PrEP — Disagree | 0 | 2 | 0 |
| M4 - I would feel proud to take PrEP — Neither agree nor disagree | 5 | 3 | 3 |
| M4 - I would feel proud to take PrEP — Agree | 19 | 18 | 15 |
| M4 - I would feel proud to take PrEP — Completely agree | 25 | 19 | 16 |
| M4 - I would feel proud to take PrEP — Missing | 0 | 0 | 1 |
| M4 - I would have sex with someone who is taking PrEP — Completely disagree | 0 | 1 | 1 |
| M4 - I would have sex with someone who is taking PrEP — Disagree | 0 | 1 | 0 |
| M4 - I would have sex with someone who is taking PrEP — Neither agree nor disagree | 8 | 9 | 6 |
| M4 - I would have sex with someone who is taking PrEP — Agree | 16 | 16 | 14 |
| M4 - I would have sex with someone who is taking PrEP — Completely agree | 26 | 16 | 15 |
| M4 - I would have sex with someone who is taking PrEP — Missing | 0 | 0 | 1 |
| M12 - My friends would be supportive of me taking PrEP — Completely disagree | 0 | 1 | 1 |
| M12 - My friends would be supportive of me taking PrEP — Disagree | 1 | 0 | 0 |
| M12 - My friends would be supportive of me taking PrEP — Neither agree nor disagree | 12 | 6 | 5 |
| M12 - My friends would be supportive of me taking PrEP — Agree | 13 | 13 | 5 |
| M12 - My friends would be supportive of me taking PrEP — Completely agree | 14 | 14 | 12 |
| M12 - My friends would be supportive of me taking PrEP — Missing | 0 | 1 | 1 |
| M12 - My family would be supportive of me taking PrEP — Completely disagree | 1 | 1 | 1 |
| M12 - My family would be supportive of me taking PrEP — Disagree | 3 | 0 | 0 |
| M12 - My family would be supportive of me taking PrEP — Neither agree nor disagree | 12 | 9 | 6 |
| M12 - My family would be supportive of me taking PrEP — Agree | 11 | 9 | 4 |
| M12 - My family would be supportive of me taking PrEP — Completely agree | 13 | 15 | 12 |
| M12 - My family would be supportive of me taking PrEP — Missing | 0 | 1 | 1 |
| M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely disagree | 6 | 3 | 4 |
| M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Disagree | 3 | 2 | 4 |
| M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Neither agree nor disagree | 21 | 17 | 9 |
| M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Agree | 8 | 7 | 6 |
| M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely agree | 2 | 5 | 0 |
| M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Missing | 0 | 1 | 1 |
| M12 - People experience negative judgment because they take PrEP — Completely disagree | 5 | 3 | 5 |
| M12 - People experience negative judgment because they take PrEP — Disagree | 5 | 3 | 3 |
| M12 - People experience negative judgment because they take PrEP — Neither agree nor disagree | 13 | 15 | 3 |
| M12 - People experience negative judgment because they take PrEP — Agree | 15 | 5 | 11 |
| M12 - People experience negative judgment because they take PrEP — Completely agree | 2 | 8 | 1 |
| M12 - People experience negative judgment because they take PrEP — Missing | 0 | 1 | 1 |
| M12 - People taking PrEP receive praise for being responsible — Completely disagree | 1 | 0 | 0 |
| M12 - People taking PrEP receive praise for being responsible — Disagree | 6 | 1 | 2 |
| M12 - People taking PrEP receive praise for being responsible — Neither agree nor disagree | 20 | 15 | 9 |
| M12 - People taking PrEP receive praise for being responsible — Agree | 8 | 10 | 8 |
| M12 - People taking PrEP receive praise for being responsible — Completely agree | 5 | 8 | 4 |
| M12 - People taking PrEP receive praise for being responsible — Missing | 0 | 1 | 1 |
| M12 - I would feel ashamed to take PrEP in front of others — Completely disagree | 19 | 14 | 16 |
| M12 - I would feel ashamed to take PrEP in front of others — Disagree | 14 | 14 | 5 |
| M12 - I would feel ashamed to take PrEP in front of others — Neither agree nor disagree | 7 | 5 | 1 |
| M12 - I would feel ashamed to take PrEP in front of others — Agree | 0 | 0 | 0 |
| M12 - I would feel ashamed to take PrEP in front of others — Completely agree | 0 | 1 | 1 |
| M12 - I would feel ashamed to take PrEP in front of others — Missing | 0 | 1 | 1 |
| M12 - Someone taking PrEP may be seen as having sex with many different people — Completely disagree | 4 | 5 | 7 |
| M12 - Someone taking PrEP may be seen as having sex with many different people — Disagree | 8 | 7 | 0 |
| M12 - Someone taking PrEP may be seen as having sex with many different people — Neither agree nor disagree | 13 | 7 | 6 |
| M12 - Someone taking PrEP may be seen as having sex with many different people — Agree | 12 | 9 | 9 |
| M12 - Someone taking PrEP may be seen as having sex with many different people — Completely agree | 3 | 6 | 1 |
| M12 - Someone taking PrEP may be seen as having sex with many different people — Missing | 0 | 1 | 1 |
| M12 - People on PrEP are taking care of their health — Completely disagree | 1 | 0 | 0 |
| M12 - People on PrEP are taking care of their health — Disagree | 0 | 0 | 0 |
| M12 - People on PrEP are taking care of their health — Neither agree nor disagree | 2 | 3 | 0 |
| M12 - People on PrEP are taking care of their health — Agree | 13 | 11 | 4 |
| M12 - People on PrEP are taking care of their health — Completely agree | 24 | 20 | 19 |
| M12 - People on PrEP are taking care of their health — Missing | 0 | 1 | 1 |
| M12 - People taking PrEP experience verbal harassment — Completely disagree | 7 | 7 | 7 |
| M12 - People taking PrEP experience verbal harassment — Disagree | 7 | 8 | 5 |
| M12 - People taking PrEP experience verbal harassment — Neither agree nor disagree | 24 | 14 | 10 |
| M12 - People taking PrEP experience verbal harassment — Agree | 2 | 3 | 1 |
| M12 - People taking PrEP experience verbal harassment — Completely agree | 0 | 2 | 0 |
| M12 - People taking PrEP experience verbal harassment — Missing | 0 | 1 | 1 |
| M12 - I would not want others to know if I was taking PrEP — Completely disagree | 16 | 9 | 16 |
| M12 - I would not want others to know if I was taking PrEP — Disagree | 14 | 6 | 2 |
| M12 - I would not want others to know if I was taking PrEP — Neither agree nor disagree | 9 | 12 | 3 |
| M12 - I would not want others to know if I was taking PrEP — Agree | 0 | 1 | 1 |
| M12 - I would not want others to know if I was taking PrEP — Completely agree | 1 | 6 | 1 |
| M12 - I would not want others to know if I was taking PrEP — Missing | 0 | 1 | 1 |
| M12 - Someone taking PrEP should keep their pills hidden — Completely disagree | 13 | 3 | 10 |
| M12 - Someone taking PrEP should keep their pills hidden — Disagree | 13 | 12 | 5 |
| M12 - Someone taking PrEP should keep their pills hidden — Neither agree nor disagree | 12 | 13 | 6 |
| M12 - Someone taking PrEP should keep their pills hidden — Agree | 2 | 1 | 1 |
| M12 - Someone taking PrEP should keep their pills hidden — Completely agree | 0 | 5 | 1 |
| M12 - Someone taking PrEP should keep their pills hidden — Missing | 0 | 1 | 1 |
| M12 - I would feel proud to take PrEP — Completely disagree | 0 | 1 | 0 |
| M12 - I would feel proud to take PrEP — Disagree | 0 | 1 | 0 |
| M12 - I would feel proud to take PrEP — Neither agree nor disagree | 6 | 6 | 0 |
| M12 - I would feel proud to take PrEP — Agree | 13 | 8 | 6 |
| M12 - I would feel proud to take PrEP — Completely agree | 21 | 18 | 17 |
| M12 - I would feel proud to take PrEP — Missing | 0 | 1 | 1 |
| M12 - I would have sex with someone who is taking PrEP — Completely disagree | 0 | 1 | 0 |
| M12 - I would have sex with someone who is taking PrEP — Disagree | 0 | 2 | 2 |
| M12 - I would have sex with someone who is taking PrEP — Neither agree nor disagree | 7 | 5 | 2 |
| M12 - I would have sex with someone who is taking PrEP — Agree | 12 | 12 | 5 |
| M12 - I would have sex with someone who is taking PrEP — Completely agree | 21 | 14 | 14 |
| M12 - I would have sex with someone who is taking PrEP — Missing | 0 | 1 | 1 |
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs response to the following question: "In general, what kind of attitude do you think your community has toward PrEP?".
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Positive | 10 | 17 | 10 |
| Somewhat positive | 8 | 9 | 9 |
| Neither negative nor positive | 10 | 8 | 8 |
| Somewhat negative | 10 | 6 | 5 |
| Negative | 1 | 1 | 1 |
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs response to the following question: "How often are you worried that people may find out that you are taking APRETUDE?".
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - How often are you worried that people may find out that you are taking APRETUDE? — Never | 37 | 31 | 29 |
| M4 - How often are you worried that people may find out that you are taking APRETUDE? — Rarely | 6 | 7 | 3 |
| M4 - How often are you worried that people may find out that you are taking APRETUDE? — Sometimes | 7 | 5 | 3 |
| M4 - How often are you worried that people may find out that you are taking APRETUDE? — Often | 0 | 0 | 1 |
| M4 - How often are you worried that people may find out that you are taking APRETUDE? — All the time | 0 | 0 | 0 |
| M4 - How often are you worried that people may find out that you are taking APRETUDE? — Missing | 0 | 0 | 1 |
| M12 - How often are you worried that people may find out that you are taking APRETUDE? — Never | 30 | 27 | 19 |
| M12 - How often are you worried that people may find out that you are taking APRETUDE? — Rarely | 8 | 4 | 4 |
| M12 - How often are you worried that people may find out that you are taking APRETUDE? — Sometimes | 2 | 3 | 0 |
| M12 - How often are you worried that people may find out that you are taking APRETUDE? — Often | 0 | 0 | 0 |
| M12 - How often are you worried that people may find out that you are taking APRETUDE? — All the time | 0 | 0 | 0 |
| M12 - How often are you worried that people may find out that you are taking APRETUDE? — Missing | 0 | 1 | 1 |
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the sources of information for APRETUDE pre-enrollment. This outcome measure presents the PSPs response to the following question: "If you have questions about APRETUDE, where do you find information?" The answer "the study app/website" was inconsistently displayed to study arms at different time points due to a programming error.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - Product website | 15 | 7 | 11 |
| M4 - Written materials such as the study handbook from my healthcare provider | 21 | 7 | 7 |
| M4 - Speaking to a healthcare provider | 27 | 26 | 24 |
| M4 - Social Media | 1 | 0 | 1 |
| M4 - Internet search | 7 | 9 | 7 |
| M4 - Friends | 2 | 1 | 0 |
| M4 - Family | 1 | 1 | 1 |
| M4 - The study app/website (EI/ECI) | — | 7 | 8 |
| M4 - I have not had any questions so far | 8 | 4 | 4 |
| M4 - I did not find answers to my questions | 1 | 2 | 0 |
| M4 - Missing | 1 | 1 | 1 |
| M12 - Product website | 13 | 9 | 10 |
| M12 - Written materials such as the study handbook from my healthcare provider | 15 | 6 | 9 |
| M12 - Speaking to a healthcare provider | 25 | 23 | 14 |
| M12 - Social Media | 3 | 0 | 1 |
| M12 - Internet search | 8 | 7 | 9 |
| M12 - Friends | 2 | 1 | 1 |
| M12 - Family | 1 | 0 | 0 |
| M12 - The study app/website | 10 | 3 | 9 |
| M12 - I have not had any questions so far | 3 | 4 | 1 |
| M12 - I did not find answers to my questions | 0 | 1 | 0 |
| M12 - Missing | 1 | 1 | 1 |
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the PSPs perception of the benefits of in-person APRETUDE injection visits.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| I have more opportunities to discuss APRETUDE concerns or manage side effects | 27 | 22 | 19 |
| I can discuss other sexual health issues like STIs or contraception during visits | 23 | 18 | 12 |
| I have more opportunities to discuss non-sexual healthcare issues or concerns | 11 | 12 | 8 |
| I have more opportunities for health screenings like diabetes and high blood pressure | 12 | 10 | 12 |
| I am more engaged in my sexual health | 21 | 15 | 7 |
| I feel like I have a better relationship with my care provider | 15 | 18 | 9 |
| Another benefit | 0 | 0 | 0 |
| There are no benefits | 2 | 0 | 1 |
| I have only received injections at home or an alternative site (e.g., infusion center) | 0 | 1 | 0 |
| Missing | 1 | 1 | 1 |
Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Overall, how are you feeling about getting APRETUDE?".
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| BL - Overall, how are you feeling about getting APRETUDE? — Very positive | 47 | 44 | 38 |
| BL - Overall, how are you feeling about getting APRETUDE? — Somewhat positive | 3 | 10 | 3 |
| BL - Overall, how are you feeling about getting APRETUDE? — Neither positive nor negative | 3 | 2 | 0 |
| BL - Overall, how are you feeling about getting APRETUDE? — Somewhat negative | 0 | 0 | 0 |
| BL - Overall, how are you feeling about getting APRETUDE? — Very negative | 0 | 0 | 1 |
| BL - Overall, how are you feeling about getting APRETUDE? — Missing | 0 | 0 | 0 |
| M4 - Overall, how are you feeling about getting APRETUDE? — Very positive | 45 | 36 | 31 |
| M4 - Overall, how are you feeling about getting APRETUDE? — Somewhat positive | 4 | 2 | 3 |
| M4 - Overall, how are you feeling about getting APRETUDE? — Neither positive nor negative | 0 | 2 | 1 |
| M4 - Overall, how are you feeling about getting APRETUDE? — Somewhat negative | 0 | 1 | 0 |
| M4 - Overall, how are you feeling about getting APRETUDE? — Very negative | 0 | 1 | 0 |
| M4 - Overall, how are you feeling about getting APRETUDE? — Missing | 1 | 1 | 2 |
| M12 - Overall, how are you feeling about getting APRETUDE? — Very positive | 36 | 28 | 21 |
| M12 - Overall, how are you feeling about getting APRETUDE? — Somewhat positive | 3 | 4 | 2 |
| M12 - Overall, how are you feeling about getting APRETUDE? — Neither positive nor negative | 0 | 2 | 0 |
| M12 - Overall, how are you feeling about getting APRETUDE? — Somewhat negative | 0 | 0 | 0 |
| M12 - Overall, how are you feeling about getting APRETUDE? — Very negative | 0 | 0 | 0 |
| M12 - Overall, how are you feeling about getting APRETUDE? — Missing | 1 | 1 | 1 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Structural Characteristics as Facilitators | 3 | 8 | 9 |
| Structural Characteristics as Barriers | 4 | 2 | 9 |
| Climate-Culture as Facilitators | 23 | 21 | 25 |
| Climate-Culture as Barriers | 7 | 7 | 16 |
| Staff Ed and Training as a Facilitator | 4 | 5 | 8 |
| Supportive key players | 3 | 12 | 7 |
| Engaging participants | 24 | 22 | 25 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Staff generally supportive | 16 | 10 | 10 |
| Specific roles supportive | 7 | 8 | 5 |
| Alignment with clinic priorities | 8 | 3 | 5 |
| Supportive clinic leadership | 6 | 3 | 3 |
| Strain of new workflow | 3 | 2 | 8 |
| Strain of insurance and acquisition processes | 4 | 1 | 4 |
| Injection aversion | 10 | 4 | 6 |
| Patient beliefs | 7 | 2 | 1 |
| Comfort with oral PrEP | 2 | 2 | 4 |
| Injection schedule unappealing | 1 | 4 | 1 |
| Injection side effects | 12 | 7 | 6 |
| Adhering to bimonthly visits | 4 | 5 | 6 |
| Lack of resources | 6 | 1 | 6 |
| Absence of daily pill regimen | 12 | 8 | 12 |
| Privacy | 5 | 4 | 2 |
| Perceived protection from HIV | 3 | 5 | 1 |
| Good experience: no challenges | 9 | 5 | 7 |
| Convenience of appointments | 3 | 3 | 2 |
| Routine clinic visits | 13 | 11 | 11 |
| Print outreach | 12 | 7 | 6 |
| Community partnerships-events | 6 | 7 | 4 |
| Social media-web | 6 | 3 | 6 |
| Patients ask about it | 6 | 1 | 4 |
| Directed outreach | 3 | 2 | 1 |
| Communication efforts successful | 13 | 11 | 10 |
| No challenges engaging Black women | 4 | 5 | 8 |
| Challenge: risk awareness | 9 | 4 | 4 |
| Challenge: Misconceptions | 3 | 2 | 1 |
| Challenge: small population | 4 | 0 | 2 |
| Need: community and provider education | 7 | 4 | 3 |
| Patients drive decision-making | 7 | 2 | 4 |
| Shared decision-making | 6 | 3 | 3 |
| Providing information for patients to decide | 3 | 2 | 5 |
| Increase provider understanding | 5 | 2 | 5 |
| Educate Black women about risk | 3 | 4 | 4 |
| Increase trust, decrease stigma | 3 | 2 | 4 |
| Community outreach and representation | 2 | 0 | 4 |
| Offer HIV prevention to all women | 5 | 1 | 1 |
IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to overall SSP perceptions of facilitators and barriers to APRETUDE implementation discussed during IMC calls. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to qualitative data collection.
| Clinics | SI - Clinics | EI - Clinics | ECI - Clinics |
|---|---|---|---|
| Practice Preparations - Past experiences with injectables and/or APRETUDE | 1 | 2 | 3 |
| Practice Preparations - Leadership Support/Staff buy in for APRETUDE | 2 | — | 2 |
| Practice Preparations - Staff Expertise and Role Specialization | 1 | — | 2 |
| Practice Preparations - Workflow tools developed (i.e., tracking tools) | 2 | — | — |
| Practice Preparations - Building patient rapport | — | — | 1 |
| Practice Preparations - Training and Capacity Building | — | — | 1 |
| Practice Preparations - Support from SMA/Viiv | — | 1 | — |
| Practice Preparations - Current workflows will need to be restructured | — | — | 3 |
| Practice Preparations - Need to develop certain tools/documentation from scratch | — | 1 | 2 |
| Practice Preparations - Need to develop new processes | — | — | 1 |
| Practice Preparations - Staff knowledge/perception/motivation/attitudes | 1 | — | 2 |
| Practice Preparations - Lack of leadership support | — | — | 1 |
| Practice Preparations- Insufficient staff to work on setting up practice operations | — | 1 | 2 |
| Practice Preparations - Insufficient time to work on setting up practice operations | 1 | — | 3 |
| Patient Selection - Clinic tools and strategies | 2 | 3 | 4 |
| Patient Selection - Community outreach event/partnerships with community organizations | 5 | 7 | 5 |
| Patient Selection - Dedicated Staff and Role Assignment | 3 | 5 | 3 |
| Patient Selection - EBONI tools (e.g., health questionnaire, SHE Ambassadors, videos, etc.) | 1 | — | 1 |
| Patient Selection - External Support and Collaboration with other clinics | 2 | 2 | 2 |
| Patient Selection - Marketing APRETUDE | 3 | 3 | 5 |
| Patient Selection - Past experiences with injectables and/or APRETUDE | 3 | 3 | 5 |
| Patient Selection - Patient Supportive Resources | 2 | 5 | 4 |
| Patient-Clinic Trust or Relationship established and/or strengthened | 1 | 4 | 1 |
| Patient Selection - Trained or knowledgeable staff | 3 | 2 | 3 |
| Patient Selection - Staff knowledge/perception/motivation/attitudes | — | 3 | 1 |
| Patient Selection - Lack of training/education | 3 | 2 | 1 |
| Patient Selection - Time constraints and care prioritization among providers | 1 | 1 | 4 |
| Patient Selection - Insufficient staff to work on this | 2 | 2 | 2 |
| Patient Selection - Insufficient time to work on this | — | 1 | 2 |
| Patient Selection - Insufficient resources/funding to work on this | 2 | 1 | 2 |
| Patient Selection - APRETUDE product concerns | 3 | — | 1 |
| Patient Selection - Patient factors (e.g., lack of interest, historical adherence to appointments) | 7 | 9 | 6 |
| Injection Visits - Assigned staff roles | — | 2 | 3 |
| Injection visits - Pre-established protocols or experience with injectables/APRETUDE | 1 | 1 | 2 |
| Injection Visits - Scheduling and injection visit coordination | 1 | 1 | 1 |
| Injection Visits - Site's engagement and support with patients | 1 | 1 | 1 |
| Injection Visits - Iterative learning and adapting | — | — | 2 |
| Injection Visits - Training Staff | — | — | 1 |
| Injection Visits - Space/length of visits for patients | — | 1 | 2 |
| Injection Visits - Staff knowledge/perception/motivation/attitudes | — | — | 2 |
| Injection Visits - Lack of training/education | — | — | 1 |
| Injection Visits - Lack of established process or workflow concerns | — | — | 1 |
| Injection Visits - Time constraints & care prioritization | — | 1 | — |
| Injection visits - Insurance, reimbursement, or financial assistance issues | — | — | 3 |
| Injection Visits - Insufficient staff to work on this | — | 1 | 1 |
| Injection Visits - Lack of coordination between pharmacy and clinic/practice | — | — | 1 |
| Injection Visits - Insufficient time to work on this | — | — | 2 |
| Injection Visits - Challenges reaching patients or patients missing appointments | — | 3 | 2 |
| Injection Visits - Patient scheduling challenges | 2 | 1 | 3 |
| Injection Visits - Patient requested changes | — | 1 | — |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| PSP had a low awareness of PrEP | 2 | 5 | 4 |
| PSP was aware of PrEP | 17 | 10 | 15 |
| Knowledge about HIV protection: safe sex does not protect against STIs | 12 | 9 | 10 |
| Did not want to take oral PrEP anymore | 1 | 4 | 4 |
| More individuals should be on PrEP | 1 | 1 | 1 |
| There needs to be more info shared about PrEP | 1 | 0 | 3 |
| PSP was aware of APRETUDE | 13 | 10 | 9 |
| PSP was unaware of APRETUDE | 2 | 4 | 3 |
| Knowledge of the ease and convenience of injection | 15 | 12 | 15 |
| Knowledge that APRETUDE protects against HIV | 10 | 11 | 12 |
| Learned about APRETUDE from provider | 5 | 2 | 6 |
| APRETUDE provider is not the same as general medical care provider | 18 | 5 | 12 |
| APRETUDE provider is the same as general medical care provider | 4 | 8 | 8 |
| APRETUDE suggested by clinic staff/provider knowledgeable about PrEP | 7 | 13 | 18 |
| PSP asked provider/initiated discussions about APRETUDE | 7 | 5 | 3 |
| Provider involved in decision-making | 13 | 8 | 11 |
| Provider not involved in decision-making | 7 | 6 | 6 |
| Received counselling on sexual health services and HIV prevention options available | 12 | 9 | 12 |
| Was not counselled on sexual health services and HIV prevention options available | 8 | 7 | 7 |
| Discussed HIV prevention with provider | 6 | 5 | 9 |
| Was only counselled about sexual health services after PSP mentioned APRETUDE | 0 | 2 | 3 |
| Said they did not receive counseling, but described counseling services | 2 | 2 | 0 |
| Noted that they already know a lot about sexual health/PrEP | 2 | 3 | 1 |
| Found counselling on sexual health services and HIV prevention helpful for questions | 9 | 6 | 11 |
| Did not find counselling on sexual health services and HIV prevention helpful | 0 | 0 | 0 |
| Discussed counselling from non-study providers | 2 | 1 | 2 |
| Discussed condoms with provider | 7 | 4 | 6 |
| Discussed both oral and injectable PrEP with provider | 4 | 0 | 6 |
| Only discussed APRETUDE during counseling | 0 | 0 | 3 |
| Discussed abstinence or celibacy with provider | 1 | 0 | 2 |
| Discussed STD/STI testing services available to them | 2 | 0 | 0 |
| More public awareness and knowledge of APRETUDE | 0 | 3 | 3 |
| Assistance with insurance coverage and APRETUDE costs | 4 | 2 | 2 |
| Support from peers and community members | 3 | 2 | 0 |
| More time between injections | 3 | 2 | 2 |
| Ability to receive injections at more location/self-administer | 2 | 2 | 2 |
| More information about APRETUDE's efficacy, how it works, and side effects | 2 | 3 | 3 |
| Learning about the experiences of other APRETUDE patients | 1 | 1 | 1 |
| PrEP is known in PSPs community | 8 | 9 | 13 |
| PrEP is not well known in PSPs community | 18 | 11 | 10 |
| APRETUDE is known in PSPs community | 4 | 5 | 6 |
| APRETUDE is not known in PSPs community | 15 | 10 | 15 |
| Believes APRETUDE is a good fit for many members of their community | 0 | 3 | 3 |
| Discussed APRETUDE with peers/community members | 0 | 2 | 2 |
| High PrEP awareness due to community engagement | 2 | 4 | 7 |
| Lack of community knowledge about PrEP | 0 | 2 | 1 |
| There is PrEP/HIV stigma in Black community and among Black women | 1 | 2 | 3 |
| Experienced stigma from medical staff | 2 | 1 | 0 |
| Mentioned belief that PrEP can give HIV or is for people who already have HIV | 1 | 1 | 1 |
| Mentioned personal efforts to reduce stigma in their community | 1 | 2 | 2 |
| Mentioned stigma associated with going to a specialty clinic to receive APRETUDE | 1 | 2 | 2 |
| Discussed the existing sentiment that PrEP is only for gay people | 1 | 0 | 2 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Sees another healthcare provider at least once or twice a year | 3 | 4 | 5 |
| APRETUDE appointments do not conflict with other medical appointments | 14 | 3 | 11 |
| Confusion/ misunderstanding from other providers about APRETUDE | 3 | 1 | 1 |
| Primary interaction is with nurse/doctor during appointments | 2 | 0 | 4 |
| Doctor/nurse as the point of contact for questions/concerns | 5 | 7 | 6 |
| Believe that providers should be informing patients about APRETUDE | 2 | 1 | 2 |
| Stigma associated with APRETUDE and HIV | 4 | 2 | 3 |
| Discretion with APRETUDE | 3 | 2 | 3 |
| Misinformation and stigma about HIV prevention can affect perceptions of APRETUDE | 3 | 2 | 3 |
The AIM was used to assess among PSPs the acceptability of APRETUDE using a four-item measure (1. I believe APRETUDE will meet my approval for preventing HIV, 2. APRETUDE for the prevention of HIV is appealing to me, 3. I think I will like APRETUDE for the prevention of HIV, 4. I welcome APRETUDE for the prevention of HIV) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI)
| Scores on a scale | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| At Baseline | 4.3 ± 0.78 | 4.3 ± 0.67 | 4.6 ± 0.51 |
| At Month 4 | 4.6 ± 0.52 | 4.3 ± 0.59 | 4.7 ± 0.47 |
| At Month 12 | 4.7 ± 0.42 | 4.5 ± 0.60 | 4.7 ± 0.40 |
The FIM was used to assess among PSPs the feasibility of APRETUDE using a four-item measure (1. Receiving APRETUDE injections every 2 months seems workable in my life, 2. Receiving APRETUDE injections every 2 months seems possible for me, 3. Receiving APRETUDE injections every 2 months seems doable in my life, 4. Receiving APRETUDE injections every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).
| Scores on a scale | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| At Baseline | 4.3 ± 0.73 | 4.3 ± 0.75 | 4.6 ± 0.49 |
| At Month 4 | 4.5 ± 0.59 | 4.4 ± 0.64 | 4.7 ± 0.49 |
| At Month 12 | 4.5 ± 0.64 | 4.3 ± 0.76 | 4.7 ± 0.45 |
The AIM was used to assess the acceptability of APRETUDE using a four-item measure (1. APRETUDE in our clinic/practice meets my approval, 2. APRETUDE in our clinic/practice is appealing to me, 3. I like APRETUDE in our clinic/practice, 4. I welcome APRETUDE in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Scores on a scale | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| At Baseline | 4.6 ± 0.57 | 4.6 ± 0.54 | 4.5 ± 0.61 |
| At Month 4 | 4.3 ± 0.84 | 4.5 ± 0.52 | 4.4 ± 0.58 |
| At Month 12 | 4.4 ± 0.86 | 4.7 ± 0.44 | 4.4 ± 0.61 |
The FIM was used to assess the feasibility of APRETUDE using a four-item measure (1. APRETUDE seems implementable in our clinic/practice, 2. APRETUDE seems possible in our clinic/practice, 3. APRETUDE seems doable in our clinic/practice, 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Scores on a scale | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| At Baseline | 4.4 ± 0.76 | 4.6 ± 0.50 | 4.4 ± 0.59 |
| At Month 4 | 4.2 ± 0.86 | 4.6 ± 0.55 | 4.2 ± 0.63 |
| At Month 12 | 4.4 ± 0.91 | 4.6 ± 0.46 | 4.3 ± 0.58 |
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding feasibility of APRETUDE implementation.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Difficulty of giving the gluteal medial injection — Extremely concerned | 4 | 2 | 0 |
| BL - Difficulty of giving the gluteal medial injection — Moderately concerned | 0 | 5 | 3 |
| BL - Difficulty of giving the gluteal medial injection — Somewhat concerned | 1 | 5 | 3 |
| BL - Difficulty of giving the gluteal medial injection — Slightly concerned | 4 | 7 | 5 |
| BL - Difficulty of giving the gluteal medial injection — Not at all Concerned | 31 | 33 | 29 |
| BL - Managing scheduling of injection appointments every 2 months within dosing windows — Extremely concerned | 1 | 2 | 1 |
| BL - Managing scheduling of injection appointments every 2 months within dosing windows — Moderately concerned | 0 | 5 | 4 |
| BL - Managing scheduling of injection appointments every 2 months within dosing windows — Somewhat concerned | 3 | 3 | 4 |
| BL - Managing scheduling of injection appointments every 2 months within dosing windows — Slightly concerned | 8 | 9 | 12 |
| BL - Managing scheduling of injection appointments every 2 months within dosing windows — Not at all Concerned | 28 | 33 | 19 |
| BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Extremely concerned | 2 | 2 | 1 |
| BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Moderately concerned | 0 | 5 | 6 |
| BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Somewhat concerned | 4 | 5 | 3 |
| BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Slightly concerned | 11 | 10 | 10 |
| BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Not at all Concerned | 23 | 30 | 20 |
| BL - Staff time for counseling and support, including answering questions and motivation — Extremely concerned | 2 | 4 | 3 |
| BL - Staff time for counseling and support, including answering questions and motivation — Moderately concerned | 3 | 2 | 1 |
| BL - Staff time for counseling and support, including answering questions and motivation — Somewhat concerned | 4 | 3 | 8 |
| BL - Staff time for counseling and support, including answering questions and motivation — Slightly concerned | 12 | 9 | 13 |
| BL - Staff time for counseling and support, including answering questions and motivation — Not at all Concerned | 19 | 34 | 15 |
| M4 - Difficulty of giving the gluteal medial injection — Extremely concerned | 1 | 0 | 0 |
| M4 - Difficulty of giving the gluteal medial injection — Moderately concerned | 2 | 0 | 0 |
| M4 - Difficulty of giving the gluteal medial injection — Somewhat concerned | 3 | 3 | 4 |
| M4 - Difficulty of giving the gluteal medial injection — Slightly concerned | 4 | 4 | 7 |
| M4 - Difficulty of giving the gluteal medial injection — Not at all Concerned | 19 | 25 | 27 |
| M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Extremely concerned | 0 | 0 | 0 |
| M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Moderately concerned | 1 | 1 | 2 |
| M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Somewhat concerned | 4 | 2 | 5 |
| M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Slightly concerned | 8 | 7 | 7 |
| M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Not at all Concerned | 16 | 22 | 24 |
| M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Extremely concerned | 0 | 1 | 1 |
| M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Moderately concerned | 2 | 2 | 4 |
| M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Somewhat concerned | 4 | 2 | 5 |
| M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Slightly concerned | 9 | 6 | 5 |
| M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Not at all Concerned | 14 | 21 | 23 |
| M4 - Staff time for counseling and support, including answering questions and motivation — Extremely concerned | 0 | 0 | 0 |
| M4 - Staff time for counseling and support, including answering questions and motivation — Moderately concerned | 1 | 2 | 5 |
| M4 - Staff time for counseling and support, including answering questions and motivation — Somewhat concerned | 4 | 3 | 5 |
| M4 - Staff time for counseling and support, including answering questions and motivation — Slightly concerned | 8 | 8 | 8 |
| M4 - Staff time for counseling and support, including answering questions and motivation — Not at all Concerned | 16 | 19 | 20 |
| M12 - Difficulty of giving the gluteal medial injection — Extremely concerned | 3 | 0 | 0 |
| M12 - Difficulty of giving the gluteal medial injection — Moderately concerned | 0 | 0 | 2 |
| M12 - Difficulty of giving the gluteal medial injection — Somewhat concerned | 3 | 2 | 5 |
| M12 - Difficulty of giving the gluteal medial injection — Slightly concerned | 2 | 2 | 9 |
| M12 - Difficulty of giving the gluteal medial injection — Not at all Concerned | 18 | 22 | 16 |
| M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Extremely concerned | 1 | 0 | 0 |
| M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Moderately concerned | 1 | 0 | 3 |
| M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Somewhat concerned | 3 | 2 | 4 |
| M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Slightly concerned | 4 | 6 | 10 |
| M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Not at all Concerned | 17 | 18 | 15 |
| M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Extremely concerned | 2 | 0 | 0 |
| M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Moderately concerned | 3 | 0 | 3 |
| M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Somewhat concerned | 1 | 2 | 4 |
| M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Slightly concerned | 4 | 5 | 8 |
| M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Not at all Concerned | 16 | 19 | 17 |
| M12 - Staff time for counseling and support, including answering questions and motivation — Extremely concerned | 2 | 0 | 2 |
| M12 - Staff time for counseling and support, including answering questions and motivation — Moderately concerned | 1 | 0 | 3 |
| M12 - Staff time for counseling and support, including answering questions and motivation — Somewhat concerned | 3 | 1 | 4 |
| M12 - Staff time for counseling and support, including answering questions and motivation — Slightly concerned | 6 | 7 | 8 |
| M12 - Staff time for counseling and support, including answering questions and motivation — Not at all Concerned | 14 | 18 | 15 |
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding clinic capacity for APRETUDE patient management (i.e. "Number of APRETUDE patients that the clinic can manage per week").
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Number of APRETUDE patients that the clinic can manage per week — 0-10 patients | 17 | 22 | 18 |
| BL - Number of APRETUDE patients that the clinic can manage per week — 11-25 patients | 15 | 13 | 9 |
| BL - Number of APRETUDE patients that the clinic can manage per week — 26-50 patients | 4 | 8 | 4 |
| BL - Number of APRETUDE patients that the clinic can manage per week — 51-100 patients | 2 | 0 | 2 |
| BL - Number of APRETUDE patients that the clinic can manage per week — 101-200 patients | 0 | 0 | 0 |
| BL - Number of APRETUDE patients that the clinic can manage per week — > 200 patients | 0 | 0 | 0 |
| BL - Number of APRETUDE patients that the clinic can manage per week — Does not know | 2 | 9 | 7 |
| M4 - Number of APRETUDE patients that the clinic can manage per week — 0-10 patients | 6 | 3 | 1 |
| M4 - Number of APRETUDE patients that the clinic can manage per week — 11-25 patients | 4 | 5 | 8 |
| M4 - Number of APRETUDE patients that the clinic can manage per week — 26-50 patients | 4 | 8 | 9 |
| M4 - Number of APRETUDE patients that the clinic can manage per week — 51-100 patients | 7 | 6 | 10 |
| M4 - Number of APRETUDE patients that the clinic can manage per week — 101-200 patients | 2 | 4 | 1 |
| M4 - Number of APRETUDE patients that the clinic can manage per week — > 200 patients | 5 | 3 | 2 |
| M4 - Number of APRETUDE patients that the clinic can manage per week — Does not know | 1 | 3 | 7 |
| M12 - Number of APRETUDE patients that the clinic can manage per week — 0-10 patients | 7 | 2 | 4 |
| M12 - Number of APRETUDE patients that the clinic can manage per week — 11-25 patients | 6 | 3 | 8 |
| M12 - Number of APRETUDE patients that the clinic can manage per week — 26-50 patients | 2 | 9 | 6 |
| M12 - Number of APRETUDE patients that the clinic can manage per week — 51-100 patients | 1 | 2 | 5 |
| M12 - Number of APRETUDE patients that the clinic can manage per week — 101-200 patients | 7 | 3 | 2 |
| M12 - Number of APRETUDE patients that the clinic can manage per week — > 200 patients | 2 | 2 | 5 |
| M12 - Number of APRETUDE patients that the clinic can manage per week — Does not know | 1 | 5 | 2 |
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This endpoint presents the results on mean number of staff needed to incorporate APRETUDE into clinics per week.
| Number of participants per week | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| At Baseline | 3.9 ± 1.93 | 5.0 ± 7.98 | 4.5 ± 1.90 |
| At Month 4 | 3.0 ± 1.78 | 2.8 ± 1.23 | 4.1 ± 2.48 |
| At Month 12 | 2.8 ± 1.38 | 4.8 ± 5.87 | 4.3 ± 2.81 |
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to staff time/FTE requirements per week to incorporate APRETUDE.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 1-20% FTE or 0.4-8hrs of staff time | 7 | 8 | 4 |
| BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 21-40% FTE or 8.4-16hrs of staff time | 10 | 15 | 10 |
| BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 41-60% FTE or 16.4-24hrs of staff time | 1 | 3 | 4 |
| BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 61-80% FTE or 24.4-32hrs of staff time | 5 | 0 | 3 |
| BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 81%-100% FTE or 32.4-40hrs of staff | 4 | 2 | 0 |
| BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — Does not know | 13 | 24 | 19 |
| M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 1-20% FTE or 0.4-8hrs of staff time | 8 | 5 | 1 |
| M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 21-40% FTE or 8.4-16hrs of staff time | 7 | 9 | 7 |
| M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 41-60% FTE or 16.4-24hrs of staff time | 5 | 3 | 5 |
| M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 61-80% FTE or 24.4-32hrs of staff time | 2 | 1 | 2 |
| M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 81%-100% FTE or 32.4-40hrs of staff | 3 | 1 | 2 |
| M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — Does not know | 4 | 13 | 21 |
| M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 1-20% FTE or 0.4-8hrs of staff time | 8 | 4 | 2 |
| M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 21-40% FTE or 8.4-16hrs of staff time | 6 | 2 | 5 |
| M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 41-60% FTE or 16.4-24hrs of staff time | 2 | 1 | 3 |
| M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 61-80% FTE or 24.4-32hrs of staff time | 2 | 1 | 0 |
| M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 81%-100% FTE or 32.4-40hrs of staff | 2 | 1 | 5 |
| M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — Does not know | 6 | 17 | 17 |
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods for patient tracking.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Use a spreadsheet such as MS Excel | 20 | 19 | 20 |
| BL - Assign specific staff to track patients | 19 | 24 | 14 |
| BL - Have providers track their own patients | 1 | 1 | 4 |
| BL - Create alerts in electronic medical records (EMRs) | 13 | 12 | 16 |
| BL - Other | 1 | 0 | 6 |
| BL - Does not know | 7 | 16 | 9 |
| M4 - Use a spreadsheet such as MS Excel | 17 | 15 | 19 |
| M4 - Assign specific staff to track patients | 12 | 16 | 14 |
| M4 - Have providers track their own patients | 3 | 5 | 4 |
| M4 - Create alerts in electronic medical records (EMRs) | 8 | 9 | 12 |
| M4 - Other | 2 | 0 | 3 |
| M4 - Does not know | 2 | 4 | 8 |
| M12 - Use a spreadsheet such as MS Excel | 14 | 11 | 19 |
| M12 - Assign specific staff to track patients | 9 | 12 | 14 |
| M12 - Have providers track their own patients | 2 | 3 | 5 |
| M12 - Create alerts in electronic medical records (EMRs) | 10 | 10 | 13 |
| M12 - Other | 3 | 0 | 0 |
| M12 - Does not know | 2 | 5 | 7 |
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods to remind patients of an upcoming appointment
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Phone call from Staff | 35 | 34 | 20 |
| BL - Automated phone call | 14 | 25 | 25 |
| BL - Text message | 29 | 24 | 30 |
| BL - Email | 20 | 8 | 20 |
| BL - Postal Mail | 3 | 4 | 0 |
| BL - Phone app notification | 6 | 10 | 8 |
| BL - Other | 0 | 1 | 1 |
| BL - Does not know | 1 | 7 | 3 |
| M4 - Phone call from Staff | 24 | 24 | 24 |
| M4 - Automated phone call | 14 | 13 | 26 |
| M4 - Text message | 19 | 22 | 21 |
| M4 - Email | 11 | 9 | 14 |
| M4 - Postal Mail | 1 | 0 | 1 |
| M4 - Phone app notification | 6 | 2 | 6 |
| M4 - Other | 0 | 0 | 1 |
| M4 - Does not know | 1 | 4 | 5 |
| M12 - Phone call from Staff | 22 | 20 | 22 |
| M12 - Automated phone call | 11 | 13 | 27 |
| M12 - Text message | 14 | 17 | 25 |
| M12 - Email | 3 | 8 | 12 |
| M12 - Postal Mail | 0 | 1 | 1 |
| M12 - Phone app notification | 1 | 3 | 6 |
| M12 - Other | 0 | 0 | 1 |
| M12 - Does not know | 2 | 3 | 0 |
| M12 - Missing | 0 | 1 | 0 |
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice approaches for offering injection appointments.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - Appointments each day of the week | 24 | 20 | 18 |
| BL - Appointments only on certain days of the week | 11 | 16 | 8 |
| BL - Appointments spread out over the month | 4 | 7 | 5 |
| BL - Injection-only appointments | 17 | 20 | 20 |
| BL - Allow patients to drop-in for injections on any day without an appointment | 5 | 1 | 2 |
| BL - Allow patients to drop-in with little advance notice (e.g., 24 hr notice) | 9 | 8 | 5 |
| BL - Allow patients to drop-in on a specific injection day without an appointment | 4 | 1 | 1 |
| BL - After hours appointments | 8 | 8 | 2 |
| BL - Before hours appointment | 6 | 3 | 1 |
| BL - Weekend appointments | 4 | 5 | 4 |
| BL - Home nursing appointments | 0 | 1 | 0 |
| BL - Mobile clinic option | 1 | 0 | 0 |
| BL - Alternate site appointments | 2 | 2 | 2 |
| BL - Depends on the schedule of the injection nurse | 8 | 6 | 4 |
| BL - Depends on the schedule of the APRETUDE provider | 5 | 4 | 3 |
| BL - Other | 0 | 0 | 1 |
| BL - Don't know | 1 | 15 | 7 |
| M4 - Appointments each day of the week | 20 | 20 | 21 |
| M4 - Appointments only on certain days of the week | 8 | 7 | 7 |
| M4 - Appointments spread out over the month | 2 | 2 | 4 |
| M4 - Injection-only appointments | 13 | 15 | 14 |
| M4 - Allow patients to drop-in for injections on any day without an appointment | 1 | 3 | 2 |
| M4 - Allow patients to drop-in with little advance notice (e.g., 24 hr notice) | 5 | 3 | 7 |
| M4 - Allow patients to drop-in on a specific injection day without an appointment | 1 | 1 | 2 |
| M4 - After hours appointments | 3 | 2 | 2 |
| M4 - Before hours appointment | 2 | 0 | 1 |
| M4 - Weekend appointments | 0 | 5 | 4 |
| M4 - Home nursing appointments | 0 | 0 | 0 |
| M4 - Mobile clinic option | 0 | 0 | 0 |
| M4 - Alternate site appointments | 1 | 3 | 3 |
| M4 - Depends on the schedule of the injection nurse | 3 | 1 | 2 |
| M4 - Depends on the schedule of the APRETUDE provider | 2 | 3 | 4 |
| M4 - Other | 0 | 0 | 1 |
| M4 - Unsure | 1 | 4 | 9 |
| M12 - Appointments each day of the week | 16 | 16 | 24 |
| M12 - Appointments only on certain days of the week | 9 | 6 | 7 |
| M12 - Appointments spread out over the month | 4 | 3 | 2 |
| M12 - Injection-only appointments | 9 | 11 | 16 |
| M12 - Allow patients to drop-in for injections on any day without an appointment | 2 | 3 | 5 |
| M12 - Allow patients to drop-in with little advance notice (e.g., 24 hr notice) | 3 | 6 | 7 |
| M12 - Allow patients to drop-in on a specific injection day without an appointment | 0 | 1 | 3 |
| M12 - After hours appointments | 0 | 4 | 5 |
| M12 - Before hours appointment | 0 | 0 | 3 |
| M12 - Weekend appointments | 0 | 3 | 5 |
| M12 - Home nursing appointments | 0 | 1 | 0 |
| M12 - Mobile clinic option | 0 | 0 | 0 |
| M12 - Alternate site appointments | 0 | 1 | 1 |
| M12 - Depends on the schedule of the injection nurse | 2 | 2 | 1 |
| M12 - Depends on the schedule of the APRETUDE provider | 1 | 2 | 3 |
| M12 - Other | 0 | 0 | 0 |
| M12 - Unsure | 1 | 2 | 0 |
The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived ease/difficulty of implementing APRETUDE in clinics.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very easy | 13 | 22 | 11 |
| BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat easy | 14 | 14 | 16 |
| BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Neither easy nor difficult | 11 | 13 | 10 |
| BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat difficult | 1 | 3 | 3 |
| BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very difficult | 1 | 0 | 0 |
| BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Missing | 0 | 0 | 0 |
| M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very easy | 10 | 15 | 7 |
| M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat easy | 12 | 10 | 13 |
| M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Neither easy nor difficult | 3 | 7 | 8 |
| M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat difficult | 3 | 0 | 10 |
| M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very difficult | 1 | 0 | 0 |
| M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Missing | 0 | 0 | 0 |
| M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very easy | 7 | 13 | 6 |
| M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat easy | 14 | 8 | 14 |
| M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Neither easy nor difficult | 2 | 2 | 6 |
| M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat difficult | 2 | 2 | 5 |
| M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very difficult | 1 | 0 | 1 |
| M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Missing | 0 | 1 | 0 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to acceptability of APRETUDE implementation.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL- Risk of drug resistance for patients not adherent to injection visits — Extremely concerned | 7 | 12 | 7 |
| BL- Risk of drug resistance for patients not adherent to injection visits — Moderately concerned | 7 | 12 | 5 |
| BL- Risk of drug resistance for patients not adherent to injection visits — Somewhat concerned | 10 | 7 | 11 |
| BL- Risk of drug resistance for patients not adherent to injection visits — Slightly concerned | 9 | 16 | 10 |
| BL- Risk of drug resistance for patients not adherent to injection visits — Not at all concerned | 7 | 5 | 7 |
| BL - Cost of APRETUDE — Extremely concerned | 9 | 16 | 6 |
| BL - Cost of APRETUDE — Moderately concerned | 5 | 8 | 11 |
| BL - Cost of APRETUDE — Somewhat concerned | 10 | 14 | 9 |
| BL - Cost of APRETUDE — Slightly concerned | 7 | 5 | 9 |
| BL - Cost of APRETUDE — Not at all concerned | 9 | 9 | 5 |
| BL - Cost of ancillary services to provide APRETUDE — Extremely concerned | 5 | 8 | 4 |
| BL - Cost of ancillary services to provide APRETUDE — Moderately concerned | 5 | 11 | 6 |
| BL - Cost of ancillary services to provide APRETUDE — Somewhat concerned | 7 | 15 | 10 |
| BL - Cost of ancillary services to provide APRETUDE — Slightly concerned | 12 | 7 | 11 |
| BL - Cost of ancillary services to provide APRETUDE — Not at all concerned | 11 | 11 | 9 |
| BL - Staff belief in the efficacy of APRETUDE — Extremely concerned | 1 | 2 | 0 |
| BL - Staff belief in the efficacy of APRETUDE — Moderately concerned | 0 | 2 | 0 |
| BL - Staff belief in the efficacy of APRETUDE — Somewhat concerned | 4 | 3 | 2 |
| BL - Staff belief in the efficacy of APRETUDE — Slightly concerned | 6 | 6 | 5 |
| BL - Staff belief in the efficacy of APRETUDE — Not at all concerned | 29 | 39 | 33 |
| M4 - Risk of drug resistance for patients not adherent to injection visits — Extremely concerned | 5 | 2 | 5 |
| M4 - Risk of drug resistance for patients not adherent to injection visits — Moderately concerned | 6 | 3 | 4 |
| M4 - Risk of drug resistance for patients not adherent to injection visits — Somewhat concerned | 5 | 8 | 10 |
| M4 - Risk of drug resistance for patients not adherent to injection visits — Slightly concerned | 6 | 9 | 10 |
| M4 - Risk of drug resistance for patients not adherent to injection visits — Not at all concerned | 7 | 10 | 9 |
| M4 - Cost of APRETUDE — Extremely concerned | 8 | 5 | 8 |
| M4 - Cost of APRETUDE — Moderately concerned | 3 | 8 | 2 |
| M4 - Cost of APRETUDE — Somewhat concerned | 3 | 6 | 9 |
| M4 - Cost of APRETUDE — Slightly concerned | 4 | 6 | 9 |
| M4 - Cost of APRETUDE — Not at all concerned | 11 | 7 | 10 |
| M4 - Cost of ancillary services to provide APRETUDE — Extremely concerned | 4 | 3 | 5 |
| M4 - Cost of ancillary services to provide APRETUDE — Moderately concerned | 6 | 5 | 1 |
| M4 - Cost of ancillary services to provide APRETUDE — Somewhat concerned | 3 | 8 | 10 |
| M4 - Cost of ancillary services to provide APRETUDE — Slightly concerned | 4 | 7 | 11 |
| M4 - Cost of ancillary services to provide APRETUDE — Not at all concerned | 12 | 9 | 11 |
| M4 - Staff belief in the efficacy of APRETUDE — Extremely concerned | 0 | 0 | 0 |
| M4 - Staff belief in the efficacy of APRETUDE — Moderately concerned | 0 | 1 | 0 |
| M4 - Staff belief in the efficacy of APRETUDE — Somewhat concerned | 3 | 0 | 4 |
| M4 - Staff belief in the efficacy of APRETUDE — Slightly concerned | 3 | 3 | 3 |
| M4 - Staff belief in the efficacy of APRETUDE — Not at all concerned | 23 | 28 | 31 |
| M12 - Risk of drug resistance for patients not adherent to injection visits — Extremely concerned | 4 | 0 | 7 |
| M12 - Risk of drug resistance for patients not adherent to injection visits — Moderately concerned | 3 | 4 | 7 |
| M12 - Risk of drug resistance for patients not adherent to injection visits — Somewhat concerned | 6 | 3 | 7 |
| M12 - Risk of drug resistance for patients not adherent to injection visits — Slightly concerned | 8 | 6 | 5 |
| M12 - Risk of drug resistance for patients not adherent to injection visits — Not at all concerned | 5 | 13 | 6 |
| M12 - Cost of APRETUDE — Extremely concerned | 8 | 3 | 10 |
| M12 - Cost of APRETUDE — Moderately concerned | 6 | 2 | 4 |
| M12 - Cost of APRETUDE — Somewhat concerned | 5 | 7 | 5 |
| M12 - Cost of APRETUDE — Slightly concerned | 2 | 4 | 6 |
| M12 - Cost of APRETUDE — Not at all concerned | 5 | 10 | 7 |
| M12 - Cost of ancillary services to provide APRETUDE — Extremely concerned | 5 | 2 | 4 |
| M12 - Cost of ancillary services to provide APRETUDE — Moderately concerned | 5 | 1 | 9 |
| M12 - Cost of ancillary services to provide APRETUDE — Somewhat concerned | 5 | 4 | 9 |
| M12 - Cost of ancillary services to provide APRETUDE — Slightly concerned | 5 | 6 | 5 |
| M12 - Cost of ancillary services to provide APRETUDE — Not at all concerned | 6 | 13 | 5 |
| M12 - Staff belief in the efficacy of APRETUDE — Extremely concerned | 1 | 0 | 0 |
| M12 - Staff belief in the efficacy of APRETUDE — Moderately concerned | 2 | 0 | 0 |
| M12 - Staff belief in the efficacy of APRETUDE — Somewhat concerned | 2 | 1 | 1 |
| M12 - Staff belief in the efficacy of APRETUDE — Slightly concerned | 3 | 4 | 5 |
| M12 - Staff belief in the efficacy of APRETUDE — Not at all concerned | 18 | 21 | 26 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived positive perception of implementing APRETUDE.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| BL - How do you feel about implementing APRETUDE at your clinic/practice? — Extremely positive | 25 | 30 | 17 |
| BL - How do you feel about implementing APRETUDE at your clinic/practice? — Positive | 14 | 19 | 18 |
| BL - How do you feel about implementing APRETUDE at your clinic/practice? — Somewhat positive | 1 | 1 | 3 |
| BL - How do you feel about implementing APRETUDE at your clinic/practice? — A little positive | 0 | 2 | 1 |
| BL - How do you feel about implementing APRETUDE at your clinic/practice? — Not at all positive | 0 | 0 | 1 |
| BL - How do you feel about implementing APRETUDE at your clinic/practice? — Missing | 0 | 0 | 0 |
| M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Extremely positive | 19 | 20 | 14 |
| M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Positive | 7 | 10 | 18 |
| M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Somewhat positive | 3 | 2 | 4 |
| M4 - How do you feel about implementing APRETUDE at your clinic/practice? — A little positive | 0 | 0 | 2 |
| M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Not at all positive | 0 | 0 | 0 |
| M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Missing | 0 | 0 | 0 |
| M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Extremely positive | 12 | 18 | 10 |
| M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Positive | 12 | 7 | 17 |
| M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Somewhat positive | 1 | 0 | 4 |
| M12 - How do you feel about implementing APRETUDE at your clinic/practice? — A little positive | 0 | 0 | 1 |
| M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Not at all positive | 1 | 0 | 0 |
| M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Missing | 0 | 1 | 0 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to patient time in waiting room and exam room for APRETUDE injection visits.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — Up to 20 minutes | 24 | 18 | 22 |
| On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — 21-40 minutes | 0 | 2 | 2 |
| On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — 41-60 minutes | 0 | 0 | 1 |
| On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — 61- 90 minutes (1hr-1.5hrs) | 0 | 0 | 0 |
| On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — More than 90 minutes (more than 1.5hrs) | 0 | 0 | 0 |
| On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — I don't know | 2 | 5 | 7 |
| On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — Missing | 0 | 1 | 0 |
| On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — Up to 20 minutes | 18 | 16 | 17 |
| On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — 21-40 minutes | 4 | 3 | 11 |
| On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — 41-60 minutes | 2 | 1 | 0 |
| On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — 61- 90 minutes (1hr-1.5hrs) | 0 | 0 | 0 |
| On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — More than 90 minutes (more than 1.5hrs) | 0 | 0 | 0 |
| On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — I don't know | 2 | 5 | 4 |
| On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — Missing | 0 | 1 | 0 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to post-injection observation period for patients after APRETUDE.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| No observation period | 4 | 4 | 8 |
| Up to 10 minutes | 18 | 8 | 3 |
| 11 to 20 minutes | 3 | 6 | 15 |
| 21-30 minutes | 0 | 0 | 1 |
| More than 30 minutes | 0 | 0 | 0 |
| I don't know | 1 | 7 | 5 |
| Missing | 0 | 1 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to convenience level of clinic hours.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| BL - How convenient are your clinic's hours? — Very convenient | 21 | 33 | 26 |
| BL - How convenient are your clinic's hours? — Convenient | 13 | 16 | 9 |
| BL - How convenient are your clinic's hours? — Somewhat Convenient | 13 | 5 | 4 |
| BL - How convenient are your clinic's hours? — A little Convenient | 5 | 2 | 3 |
| BL - How convenient are your clinic's hours? — Not at all Convenient | 1 | 0 | 0 |
| BL - How convenient are your clinic's hours? — Missing | 0 | 0 | 0 |
| M4 - How convenient are your clinic's hours? — Very convenient | 29 | 25 | 25 |
| M4 - How convenient are your clinic's hours? — Convenient | 11 | 11 | 6 |
| M4 - How convenient are your clinic's hours? — Somewhat Convenient | 6 | 3 | 3 |
| M4 - How convenient are your clinic's hours? — A little Convenient | 3 | 3 | 1 |
| M4 - How convenient are your clinic's hours? — Not at all Convenient | 1 | 0 | 1 |
| M4 - How convenient are your clinic's hours? — Missing | 0 | 1 | 0 |
| M12 - How convenient are your clinic's hours? — Very convenient | 21 | 17 | 16 |
| M12 - How convenient are your clinic's hours? — Convenient | 13 | 8 | 4 |
| M12 - How convenient are your clinic's hours? — Somewhat Convenient | 2 | 6 | 2 |
| M12 - How convenient are your clinic's hours? — A little Convenient | 3 | 1 | 1 |
| M12 - How convenient are your clinic's hours? — Not at all Convenient | 0 | 1 | 0 |
| M12 - How convenient are your clinic's hours? — Missing | 1 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to sources of first injection appointment reminders at baseline.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Phone calls | 31 | 32 | 27 |
| Texts/SMS messages | 42 | 31 | 24 |
| Existing clinic app reminder | 12 | 4 | 8 |
| E-mails | 23 | 24 | 19 |
| Reminder in the postal mail | 1 | 0 | 1 |
| Face-to-face reminder from a healthcare provider | 3 | 5 | 7 |
| Written reminder/appointment card with date and time | 1 | 6 | 5 |
| The study app (ECI) | 0 | 0 | 0 |
| I did not receive reminders | 1 | 1 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to sources of injection appointment reminders at Month 12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Phone calls | 19 | 16 | 11 |
| Text/SMS messages | 33 | 23 | 13 |
| Existing clinic app reminder | 11 | 3 | 6 |
| E-mails | 9 | 7 | 11 |
| Reminder in the postal mail | 1 | 1 | 0 |
| Face-to-face reminder from a healthcare provider | 4 | 6 | 1 |
| Written reminder/appointment card with date and time | 0 | 2 | 5 |
| The study app/website | 0 | 0 | 0 |
| Another type of reminder | 1 | 1 | 0 |
| I have not received any reminders | 1 | 0 | 1 |
| Missing | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to preferred appointment reminder types at baseline (Month 1).
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Phone calls | 25 | 28 | 16 |
| Texts/SMS messages | 49 | 47 | 34 |
| Existing clinic app reminder | 10 | 4 | 8 |
| App notifications | 9 | 6 | 6 |
| E-mails | 25 | 27 | 21 |
| Reminder in the postal mail | 1 | 1 | 0 |
| Face-to-face reminder from a healthcare provider | 1 | 3 | 3 |
| Written reminder/appointment card with date and time | 2 | 4 | 1 |
| Another type of reminder | 0 | 1 | 0 |
| I do not wish to receive reminders | 0 | 1 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to most helpful types of appointment reminders at M4 and M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - I have not received any reminders | 1 | 1 | 0 |
| M4 - Phone calls | 21 | 23 | 19 |
| M4 - Text/SMS messages | 38 | 35 | 27 |
| M4 - Existing clinic app reminder | 12 | 13 | 7 |
| M4 - E-mails | 14 | 17 | 14 |
| M4 - Reminder in the mail | 0 | 0 | 0 |
| M4 - Face-to-face reminder from a healthcare provider | 1 | 4 | 4 |
| M4 - Written reminder/appointment card with date and time | 5 | 3 | 2 |
| M4 - The study app/website (EI/ECI) | 0 | 1 | 1 |
| M4 - Another type of reminder | 0 | 0 | 0 |
| M4 - I did not think any of the reminders were helpful | 0 | 0 | 0 |
| M4 - Missing | 2 | 1 | 1 |
| M12 - Phone calls | 16 | 15 | 15 |
| M12 - Text/SMS messages | 36 | 23 | 17 |
| M12 - Existing clinic app reminder | 7 | 3 | 4 |
| M12 - E-mails | 10 | 13 | 12 |
| M12 - Reminder in the mail | 1 | 0 | 0 |
| M12 - Face-to-face reminder from a healthcare provider | 3 | 6 | 2 |
| M12 - Written reminder/appointment card with date and time | 1 | 2 | 1 |
| M12 - The study app/website (EI/ECI) | 0 | 0 | 0 |
| M12 - Another type of reminder | 2 | 2 | 1 |
| M12 - I did not think any of the reminders were helpful | 0 | 0 | 0 |
| M12 - Missing | 0 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to need for additional care for injection visits.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| BL - Will you need additional childcare, eldercare, or other care for injection visits? — Yes | 2 | 6 | 4 |
| BL - Will you need additional childcare, eldercare, or other care for injection visits? — No | 44 | 34 | 26 |
| BL - Will you need additional childcare, eldercare, or other care for injection visits? — I am not caring for others right now (N/A) | 7 | 16 | 12 |
| BL - Will you need additional childcare, eldercare, or other care for injection visits? — Missing | 0 | 0 | 0 |
| M4 - Have you needed additional childcare, eldercare, or other care for injection visits? — Yes | 0 | 4 | 3 |
| M4 - Have you needed additional childcare, eldercare, or other care for injection visits? — No | 40 | 31 | 22 |
| M4 - Have you needed additional childcare, eldercare, or other care for injection visits? — I am not caring for others right now (N/A) | 10 | 7 | 11 |
| M4 - Have you needed additional childcare, eldercare, or other care for injection visits? — Missing | 0 | 1 | 0 |
| M12 - Have you needed additional childcare, eldercare, or other care for injection visits? — Yes | 4 | 5 | 2 |
| M12 - Have you needed additional childcare, eldercare, or other care for injection visits? — No | 25 | 25 | 14 |
| M12 - Have you needed additional childcare, eldercare, or other care for injection visits? — I am not caring for others right now (N/A) | 10 | 3 | 7 |
| M12 - Have you needed additional childcare, eldercare, or other care for injection visits? — Missing | 1 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to anticipated time off work for APRETUDE injections at baseline.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| I am not working right now | 8 | 26 | 13 |
| I will not need to take time off work for injections | 24 | 11 | 15 |
| I will probably need to take a whole day off work for each injection | 6 | 5 | 5 |
| I will probably need to take a whole day off work for some injections | 0 | 2 | 1 |
| I will probably need to take a partial day off work for each injection | 8 | 6 | 4 |
| I will probably need to take a partial day off work for some injections | 6 | 4 | 4 |
| Other | 1 | 2 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to time off work for APRETUDE injections at M4 and M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - Have you taken any time off from work to receive your injections? — Yes | 17 | 10 | 7 |
| M4 - Have you taken any time off from work to receive your injections? — No | 30 | 23 | 23 |
| M4 - Have you taken any time off from work to receive your injections? — I am not working right now | 3 | 9 | 6 |
| M4 - Have you taken any time off from work to receive your injections? — Missing | 0 | 1 | 0 |
| M12 - Have you taken any time off from work to receive your injections? — Yes | 17 | 12 | 5 |
| M12 - Have you taken any time off from work to receive your injections? — No | 18 | 16 | 15 |
| M12 - Have you taken any time off from work to receive your injections? — I am not working right now | 4 | 6 | 3 |
| M12 - Have you taken any time off from work to receive your injections? — Missing | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to amount of time off work taken for injections at M4 and M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - How much time did you take off work to receive your injections? — I needed to take a whole day off work for each injection | 1 | 1 | 2 |
| M4 - How much time did you take off work to receive your injections? — I needed to take a whole day off work for some injections | 0 | 0 | 0 |
| M4 - How much time did you take off work to receive your injections? — I needed to take a partial day off work for each injection | 8 | 7 | 2 |
| M4 - How much time did you take off work to receive your injections? — I needed to take a partial day off work for some injections | 3 | 1 | 3 |
| M4 - How much time did you take off work to receive your injections? — Other | 5 | 1 | 0 |
| M12 - How much time did you take off work to receive your injections? — I needed to take a whole day off work for each injection | 2 | 3 | 1 |
| M12 - How much time did you take off work to receive your injections? — I needed to take a whole day off work for some injections | 0 | 2 | 2 |
| M12 - How much time did you take off work to receive your injections? — I needed to take a partial day off work for each injection | 10 | 3 | 0 |
| M12 - How much time did you take off work to receive your injections? — I needed to take a partial day off work for some injections | 4 | 3 | 1 |
| M12 - How much time did you take off work to receive your injections? — Other | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to status of time off work for injections at M4 and M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - Was your time off work for injections generally paid or unpaid? — Paid | 4 | 2 | 2 |
| M4 - Was your time off work for injections generally paid or unpaid? — Unpaid | 12 | 8 | 4 |
| M4 - Was your time off work for injections generally paid or unpaid? — Other | 1 | 0 | 1 |
| M12 - Was your time off work for injections generally paid or unpaid? — Paid | 5 | 1 | 3 |
| M12 - Was your time off work for injections generally paid or unpaid? — Unpaid | 12 | 10 | 2 |
| M12 - Was your time off work for injections generally paid or unpaid? — Other | 0 | 1 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to frequency of worry about forgetting APRETUDE injections.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - How often are you worried about forgetting your APRETUDE injections? — Never | 31 | 30 | 26 |
| M4 - How often are you worried about forgetting your APRETUDE injections? — Rarely | 12 | 5 | 5 |
| M4 - How often are you worried about forgetting your APRETUDE injections? — Sometimes | 5 | 5 | 4 |
| M4 - How often are you worried about forgetting your APRETUDE injections? — Often | 2 | 2 | 1 |
| M4 - How often are you worried about forgetting your APRETUDE injections? — All the time | 0 | 1 | 0 |
| M4 - How often are you worried about forgetting your APRETUDE injections? — Missing | 0 | 0 | 1 |
| M12 - How often are you worried about forgetting your APRETUDE injections? — Never | 27 | 17 | 13 |
| M12 - How often are you worried about forgetting your APRETUDE injections? — Rarely | 7 | 9 | 3 |
| M12 - How often are you worried about forgetting your APRETUDE injections? — Sometimes | 5 | 3 | 5 |
| M12 - How often are you worried about forgetting your APRETUDE injections? — Often | 1 | 1 | 1 |
| M12 - How often are you worried about forgetting your APRETUDE injections? — All the time | 0 | 4 | 1 |
| M12 - How often are you worried about forgetting your APRETUDE injections? — Missing | 0 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of scheduling injection appointments.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Very easy | 43 | 34 | 28 |
| M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Somewhat easy | 3 | 3 | 7 |
| M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Neither easy nor difficult | 4 | 4 | 0 |
| M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Somewhat difficult | 0 | 2 | 1 |
| M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Very difficult | 0 | 0 | 0 |
| M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — I have not scheduled any appointments at the clinic/practice | 0 | 0 | 0 |
| M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Missing | 0 | 0 | 1 |
| M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Very easy | 30 | 23 | 17 |
| M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Somewhat easy | 8 | 7 | 3 |
| M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Neither easy nor difficult | 1 | 1 | 1 |
| M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Somewhat difficult | 1 | 3 | 2 |
| M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Very difficult | 0 | 0 | 0 |
| M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — I have not scheduled any appointments at the clinic/practice | 0 | 0 | 0 |
| M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Missing | 0 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of rescheduling injection appointments.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Very easy | 31 | 27 | 24 |
| M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Somewhat easy | 5 | 4 | 5 |
| M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Neither easy nor difficult | 3 | 5 | 0 |
| M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Somewhat difficult | 0 | 1 | 1 |
| M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Very difficult | 0 | 0 | 1 |
| M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — I have not needed to reschedule any appointments | 11 | 6 | 5 |
| M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Very easy | 27 | 21 | 16 |
| M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Somewhat easy | 4 | 6 | 4 |
| M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Neither easy nor difficult | 4 | 1 | 0 |
| M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Somewhat difficult | 1 | 5 | 1 |
| M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Very difficult | 0 | 0 | 1 |
| M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — I have not needed to reschedule any appointments | 4 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to how easy or difficult it has been to get to the clinic every 2 months at M4 and M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Very easy | 29 | 23 | 23 |
| M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Easy | 14 | 12 | 8 |
| M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Neither easy or difficult | 7 | 5 | 3 |
| M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Difficult | 0 | 2 | 1 |
| M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Very difficult | 0 | 0 | 1 |
| M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Missing | 0 | 1 | 0 |
| M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Very easy | 21 | 17 | 16 |
| M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Easy | 9 | 4 | 3 |
| M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Neither easy or difficult | 3 | 10 | 3 |
| M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Difficult | 6 | 2 | 1 |
| M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Very difficult | 0 | 0 | 0 |
| M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Missing | 1 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to "Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?" at M12.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| Up to 20 minutes | 18 | 10 | 11 |
| 21-40 minutes | 11 | 18 | 10 |
| 41-60 minute | 7 | 2 | 1 |
| 61- 90 minutes | 2 | 3 | 1 |
| More than 90 minutes | 1 | 0 | 0 |
| Missing | 1 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to concerns about APRETUDE.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| BL- Do you have any concerns about APRETUDE — Yes | 6 | 9 | 4 |
| BL- Do you have any concerns about APRETUDE — No | 47 | 47 | 38 |
| BL- Do you have any concerns about APRETUDE — Missing | 0 | 0 | 0 |
| M4- Do you have any concerns about APRETUDE — Yes | 7 | 7 | 4 |
| M4- Do you have any concerns about APRETUDE — No | 43 | 36 | 32 |
| M4- Do you have any concerns about APRETUDE — Missing | 0 | 0 | 1 |
| M12- Do you have any concerns about APRETUDE — Yes | 1 | 1 | 1 |
| M12- Do you have any concerns about APRETUDE — No | 39 | 33 | 22 |
| M12- Do you have any concerns about APRETUDE — Missing | 0 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at baseline (M1).
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Pain or soreness from the injection | 3 | 3 | 2 |
| Other side effects from APRETUDE | 4 | 7 | 2 |
| Fear of needles | 1 | 1 | 1 |
| Being approved by my insurance to take it | 3 | 2 | 0 |
| Having to take oral PrEP first before I take APRETUDE injections | 0 | 0 | 1 |
| Possible long-term effects of the medicine | 5 | 5 | 3 |
| How it affects other medications I take | 3 | 2 | 0 |
| Scheduling or rescheduling injection visits | 1 | 2 | 1 |
| Forgetting my appointment for the injection visits | 1 | 3 | 1 |
| Missing an injection visit and then getting HIV | 0 | 2 | 0 |
| Missing work for the injection visits | 1 | 2 | 0 |
| Making time to go to the clinic/practice for the injection every 2 months | 1 | 2 | 1 |
| Travelling to the clinic/practice for the injection visits | 0 | 1 | 1 |
| Limited clinic/practice hours for injection visits | 1 | 0 | 0 |
| Childcare/caregiver responsibilities during injection visits | 0 | 0 | 1 |
| Lack of privacy at injection visits | 0 | 1 | 1 |
| My dignity not being respected during injection visits | 0 | 0 | 0 |
| People asking why I go to the clinic/doctor every 2 months | 0 | 0 | 0 |
| My hectic lifestyle | 1 | 0 | 0 |
| My travel or holiday schedules | 1 | 1 | 0 |
| Taking medication during times when I am not having sex | 1 | 0 | 1 |
| The medication not being effective at preventing HIV | 1 | 2 | 0 |
| Worrying that people would think I have HIV | 3 | 1 | 1 |
| Worry that people think I have many sexual partners because I use CAB-LA for PrEP | 1 | 1 | 1 |
| Worrying about my privacy because I live with someone | 0 | 1 | 0 |
| Worrying about my privacy because I'm on my parent's health insurance | 0 | 0 | 0 |
| Other | 1 | 2 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M4.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Pain or soreness from the injection | 4 | 1 | 1 |
| Other side effects from APRETUDE | 3 | 5 | 2 |
| Fear of needles | 1 | 0 | 0 |
| Possible long-term effects of the medicine | 3 | 6 | 1 |
| The medication not being effective at preventing HIV | 2 | 3 | 0 |
| How it affects other medications I take | 0 | 4 | 0 |
| Being approved by my insurance to take it | 2 | 1 | 1 |
| Scheduling or rescheduling injection visits | 0 | 1 | 0 |
| Forgetting my appointment for the injection visits | 0 | 1 | 0 |
| Missing an injection visit and then getting HIV | 1 | 0 | 1 |
| Missing work for the injection visits | 1 | 1 | 0 |
| Making time to go to the clinic/practice for the injection every 2 months | 0 | 2 | 0 |
| Travelling to the clinic/practice for the injection visits | 0 | 1 | 0 |
| Limited clinic/practice hours for injection visits | 1 | 2 | 0 |
| Childcare/caregiver responsibilities during injection visits | 0 | 1 | 0 |
| Lack of privacy at injection visits | 1 | 0 | 0 |
| My dignity not being respected during injection visits | 0 | 0 | 0 |
| People asking why I go to the clinic/doctor every 2 months | 0 | 0 | 1 |
| My hectic lifestyle | 0 | 2 | 0 |
| My travel or holiday schedules | 1 | 1 | 0 |
| Taking medication during times when I am not having sex | 0 | 2 | 1 |
| Worrying about forgetting my APRETUDE injection | 1 | 0 | 0 |
| Worrying that people would think I have HIV | 0 | 0 | 1 |
| Worrying that people would think I have a lot of sexual partners because I am on APRETUDE | 0 | 1 | 0 |
| Worrying about my privacy because I live with someone | 0 | 1 | 1 |
| Worrying about my privacy because I'm on my parent's health insurance | 0 | 0 | 0 |
| Other | 2 | 0 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Pain or soreness from the injection | 1 | 1 | 0 |
| Other side effects from APRETUDE | 0 | 0 | 1 |
| Fear of needles | 1 | 0 | 0 |
| Possible long-term effects of the medicine | 0 | 0 | 1 |
| The medication not being effective at preventing HIV | 0 | 0 | 0 |
| How it affects other medications I take | 0 | 1 | 1 |
| Change in my insurance coverage for APRETUDE | 0 | 0 | 0 |
| Scheduling or rescheduling injection visits | 0 | 0 | 0 |
| Forgetting my appointment for the injection visits | 0 | 0 | 0 |
| Missing an injection visit and then getting HIV | 0 | 0 | 0 |
| Missing work for the injection visits | 0 | 0 | 0 |
| Making time to go to the clinic/practice for the injection every 2 months | 1 | 1 | 0 |
| Travelling to the clinic/practice for the injection visits | 0 | 1 | 0 |
| Limited clinic/practice hours for injection visits | 0 | 0 | 0 |
| Childcare/caregiver responsibilities during injection visits | 0 | 0 | 0 |
| Lack of privacy at injection visits | 0 | 0 | 0 |
| My dignity not being respected during injection visits | 0 | 0 | 0 |
| People asking why I go to the clinic/doctor every 2 months | 0 | 0 | 0 |
| My hectic lifestyle | 0 | 1 | 0 |
| My travel or holiday schedules | 0 | 0 | 0 |
| Taking medication during times when I am not having sex | 0 | 0 | 0 |
| Worrying about forgetting my APRETUDE injection | 0 | 0 | 0 |
| Worrying that people would think I have HIV | 0 | 0 | 0 |
| Worrying that people would think I have a lot of sexual partners because I am on APRETUDE | 0 | 0 | 0 |
| Worrying about my privacy because I live with someone | 0 | 0 | 0 |
| Worrying about my privacy because I'm on my parent's health insurance | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of bi-monthly clinic visits for injections.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| At Baseline — Very acceptable | 30 | 36 | 29 |
| At Baseline — Acceptable | 19 | 19 | 10 |
| At Baseline — Somewhat Acceptable | 3 | 1 | 3 |
| At Baseline — A little Acceptable | 1 | 0 | 0 |
| At Baseline — Not at all Acceptable | 0 | 0 | 0 |
| At Baseline — Missing | 0 | 0 | 0 |
| At Month 4 — Very acceptable | 40 | 24 | 28 |
| At Month 4 — Acceptable | 6 | 14 | 5 |
| At Month 4 — Somewhat Acceptable | 4 | 3 | 2 |
| At Month 4 — A little Acceptable | 0 | 1 | 1 |
| At Month 4 — Not at all Acceptable | 0 | 0 | 0 |
| At Month 4 — Missing | 0 | 1 | 0 |
| At Month 12 — Very acceptable | 25 | 20 | 17 |
| At Month 12 — Acceptable | 8 | 8 | 5 |
| At Month 12 — Somewhat Acceptable | 4 | 4 | 1 |
| At Month 12 — A little Acceptable | 2 | 1 | 0 |
| At Month 12 — Not at all Acceptable | 0 | 0 | 0 |
| At Month 12 — Missing | 1 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of HIV and STI testing frequency.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - Would you say the frequency of HIV testing you have done is — Very acceptable | 31 | 24 | 29 |
| M4 - Would you say the frequency of HIV testing you have done is — Acceptable | 16 | 15 | 6 |
| M4 - Would you say the frequency of HIV testing you have done is — Somewhat acceptable | 2 | 3 | 1 |
| M4 - Would you say the frequency of HIV testing you have done is — A little acceptable | 0 | 0 | 0 |
| M4 - Would you say the frequency of HIV testing you have done is — Not at all acceptable | 0 | 0 | 0 |
| M4 - Would you say the frequency of HIV testing you have done is — Missing | 1 | 1 | 1 |
| M4 - Would you say the frequency of STI testing you have done is — Very acceptable | 31 | 23 | 28 |
| M4 - Would you say the frequency of STI testing you have done is — Acceptable | 15 | 16 | 7 |
| M4 - Would you say the frequency of STI testing you have done is — Somewhat acceptable | 3 | 2 | 1 |
| M4 - Would you say the frequency of STI testing you have done is — A little acceptable | 0 | 1 | 0 |
| M4 - Would you say the frequency of STI testing you have done is — Not at all acceptable | 0 | 0 | 0 |
| M4 - Would you say the frequency of STI testing you have done is — Missing | 1 | 1 | 1 |
| M12 - Would you say the frequency of HIV testing you have done is — Very acceptable | 24 | 23 | 15 |
| M12 - Would you say the frequency of HIV testing you have done is — Acceptable | 14 | 11 | 6 |
| M12 - Would you say the frequency of HIV testing you have done is — Somewhat acceptable | 0 | 0 | 2 |
| M12 - Would you say the frequency of HIV testing you have done is — A little acceptable | 1 | 0 | 0 |
| M12 - Would you say the frequency of HIV testing you have done is — Not at all acceptable | 0 | 0 | 0 |
| M12 - Would you say the frequency of HIV testing you have done is — Missing | 1 | 1 | 1 |
| M12 - Would you say the frequency of STI testing you have done is — Very acceptable | 23 | 21 | 16 |
| M12 - Would you say the frequency of STI testing you have done is — Acceptable | 14 | 11 | 6 |
| M12 - Would you say the frequency of STI testing you have done is — Somewhat acceptable | 1 | 2 | 1 |
| M12 - Would you say the frequency of STI testing you have done is — A little acceptable | 1 | 0 | 0 |
| M12 - Would you say the frequency of STI testing you have done is — Not at all acceptable | 0 | 0 | 0 |
| M12 - Would you say the frequency of STI testing you have done is — Missing | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to local reactions following an APRETUDE injection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - Did you experience any local reaction(s) following an injection appointment? — Yes | 21 | 12 | 14 |
| M4 - Did you experience any local reaction(s) following an injection appointment? — No | 27 | 28 | 22 |
| M4 - Did you experience any local reaction(s) following an injection appointment? — I don't know | 1 | 2 | 0 |
| M4 - Did you experience any local reaction(s) following an injection appointment? — Missing | 1 | 1 | 1 |
| M12 - Did you experience any local reaction(s) following an injection appointment? — Yes | 17 | 10 | 11 |
| M12 - Did you experience any local reaction(s) following an injection appointment? — No | 22 | 23 | 11 |
| M12 - Did you experience any local reaction(s) following an injection appointment? — I don't know | 0 | 1 | 1 |
| M12 - Did you experience any local reaction(s) following an injection appointment? — Missing | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of local reactions following an APRETUDE injection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - Acceptability of local reaction(s) — Totally acceptable | 1 | 3 | 3 |
| M4 - Acceptability of local reaction(s) — Very acceptable | 5 | 1 | 4 |
| M4 - Acceptability of local reaction(s) — Moderately acceptable | 7 | 7 | 6 |
| M4 - Acceptability of local reaction(s) — A little acceptable | 6 | 1 | 1 |
| M4 - Acceptability of local reaction(s) — Not at all acceptable | 2 | 0 | 0 |
| M12 - Acceptability of local reaction(s) — Totally acceptable | 4 | 2 | 4 |
| M12 - Acceptability of local reaction(s) — Very acceptable | 2 | 5 | 2 |
| M12 - Acceptability of local reaction(s) — Moderately acceptable | 9 | 3 | 1 |
| M12 - Acceptability of local reaction(s) — A little acceptable | 2 | 0 | 4 |
| M12 - Acceptability of local reaction(s) — Not at all acceptable | 0 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses on return to daily activities post-injection (e.g., going back to work, social events, exercise, driving).
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - How often can you return to usual daily activities after an injection appointment? — Never | 0 | 1 | 2 |
| M4 - How often can you return to usual daily activities after an injection appointment? — Rarely | 2 | 1 | 0 |
| M4 - How often can you return to usual daily activities after an injection appointment? — Sometimes | 4 | 3 | 0 |
| M4 - How often can you return to usual daily activities after an injection appointment? — Often | 13 | 7 | 5 |
| M4 - How often can you return to usual daily activities after an injection appointment? — Always | 30 | 30 | 29 |
| M4 - How often can you return to usual daily activities after an injection appointment? — Missing | 1 | 1 | 1 |
| M12 - How often can you return to usual daily activities after an injection appointment? — Never | 0 | 1 | 1 |
| M12 - How often can you return to usual daily activities after an injection appointment? — Rarely | 0 | 1 | 1 |
| M12 - How often can you return to usual daily activities after an injection appointment? — Sometimes | 1 | 3 | 1 |
| M12 - How often can you return to usual daily activities after an injection appointment? — Often | 11 | 7 | 6 |
| M12 - How often can you return to usual daily activities after an injection appointment? — Always | 27 | 22 | 14 |
| M12 - How often can you return to usual daily activities after an injection appointment? — Missing | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents data indicating how bothered by pain PSPs were during injection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - How bothered were you by pain during the injection? — Not at all | 17 | 8 | 14 |
| M4 - How bothered were you by pain during the injection? — A little | 17 | 21 | 14 |
| M4 - How bothered were you by pain during the injection? — Moderately | 13 | 10 | 5 |
| M4 - How bothered were you by pain during the injection? — Very | 2 | 2 | 3 |
| M4 - How bothered were you by pain during the injection? — Extremely | 0 | 1 | 0 |
| M4 - How bothered were you by pain during the injection? — Missing | 1 | 1 | 1 |
| M12 - How bothered were you by pain during the injection? — Not at all | 12 | 10 | 6 |
| M12 - How bothered were you by pain during the injection? — A little | 11 | 16 | 11 |
| M12 - How bothered were you by pain during the injection? — Moderately | 14 | 7 | 3 |
| M12 - How bothered were you by pain during the injection? — Very | 2 | 1 | 3 |
| M12 - How bothered were you by pain during the injection? — Extremely | 0 | 0 | 0 |
| M12 - How bothered were you by pain during the injection? — Missing | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of injection-related pain.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - Acceptability of your pain — Totally acceptable | 13 | 16 | 17 |
| M4 - Acceptability of your pain — Very acceptable | 16 | 9 | 10 |
| M4 - Acceptability of your pain — Moderately acceptable | 18 | 12 | 7 |
| M4 - Acceptability of your pain — A little acceptable | 1 | 3 | 2 |
| M4 - Acceptability of your pain — Not at all acceptable | 1 | 2 | 0 |
| M4 - Acceptability of your pain — Missing | 1 | 1 | 1 |
| M12 - Acceptability of your pain — Totally acceptable | 16 | 11 | 9 |
| M12 - Acceptability of your pain — Very acceptable | 9 | 13 | 9 |
| M12 - Acceptability of your pain — Moderately acceptable | 9 | 7 | 4 |
| M12 - Acceptability of your pain — A little acceptable | 5 | 3 | 1 |
| M12 - Acceptability of your pain — Not at all acceptable | 0 | 0 | 0 |
| M12 - Acceptability of your pain — Missing | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to pain reduction strategies post-injection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| M4 - Took over-the-counter pain relievers | 20 | 14 | 14 |
| M4 - Used a hot compress | 11 | 11 | 8 |
| M4 - Used a cold compress | 7 | 7 | 8 |
| M4 - Avoided sitting for long periods of time | 7 | 12 | 4 |
| M4 - Light stretching and exercise | 6 | 9 | 11 |
| M4 - Other | 3 | 2 | 2 |
| M4 - None | 13 | 11 | 6 |
| M4 - Missing | 1 | 1 | 1 |
| M12 - Took over-the-counter pain relievers | 16 | 10 | 10 |
| M12 - Used a hot compress | 11 | 8 | 11 |
| M12 - Used a cold compress | 9 | 2 | 4 |
| M12 - Avoided sitting for long periods of time | 3 | 5 | 6 |
| M12 - Light stretching and exercise | 6 | 12 | 5 |
| M12 - Other | 0 | 0 | 1 |
| M12 - None | 14 | 7 | 2 |
| M12 - Missing | 1 | 1 | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following first APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).
| Scores on a scale | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| At Month 4 | 4.0 ± 2.99 | 4.9 ± 2.93 | 3.7 ± 2.80 |
| At Month 12 | 4.3 ± 2.55 | 4.9 ± 2.93 | 5.6 ± 3.20 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following the most recent APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).
| Scores on a scale | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| At Month 4 | 3.3 ± 2.69 | 3.8 ± 2.69 | 2.3 ± 2.36 |
| At Month 12 | 2.2 ± 2.02 | 2.6 ± 2.41 | 2.8 ± 2.41 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions of the acceptability of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of acceptability of APRETUDE.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| M4 - Implementation self-efficacy | 3 | 3 | 0 |
| M4 - Patient support self-efficacy | 5 | 6 | 3 |
| M4 - Enthusiasm about APRETUDE for HIV prevention | 21 | 18 | 22 |
| M4 - Heightened knowledge and awareness | 8 | 8 | 7 |
| M12 - Alternative to daily pills | 10 | 9 | 10 |
| M12 - Met expectations | 15 | 7 | 16 |
| M12 - Positive patient reaction | 12 | 10 | 6 |
| M12 - Improved adherence/HIV protection | 7 | 6 | 10 |
| M12 - Bimonthly visits going well | 4 | 2 | 1 |
| M12 - More privacy/less stigma | 5 | 1 | 0 |
| M12 - Insurance barriers | 8 | 2 | 4 |
| M12 - Visit burden/ inconvenience | 4 | 3 | 3 |
| M12 - Prevention/ adherence challenges | 2 | 2 | 5 |
| M12 - Clinic challenges | 2 | 2 | 5 |
| M12 - Injection-site pain | 3 | 2 | 2 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSP perceptions of the feasibility of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of feasibility of APRETUDE.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| M12 - Facilitator: Organization of tasks | 9 | 7 | 5 |
| M12 - Facilitator: Staffing facilitators | 2 | 4 | 1 |
| M12- Facilitator: CABENUVA experience | 3 | 2 | 1 |
| M12 - Barrier: Staffing barriers | 1 | 1 | 4 |
| M12 - Internal tracking tools | 3 | 2 | 3 |
| M12 - Offers injection-only visits | 5 | 4 | 8 |
| M12 - Sees prescribing provider on set schedule | 4 | 3 | 7 |
| M12 - Sees prescribing provider every visit | 6 | 2 | 3 |
| M12 - Prescribing provider is on standby | 2 | 3 | 2 |
| M12 - Sees medical assistant most visits | 5 | 3 | 4 |
| M12 - Sees nurse most visits | 4 | 1 | 4 |
| M12 - Nurses inject | 7 | 4 | 8 |
| M12 - Prescribing providers inject | 4 | 5 | 4 |
| M12 - Medical assistants inject | 1 | 3 | 8 |
| M12 - Visits 30 mins or less | 10 | 6 | 7 |
| M12 - Visits 30 mins to 1 hr | 3 | 5 | 4 |
| M12 - Staffing structural limitations | 17 | 10 | 11 |
| M12 - Clinic space limitation | 6 | 4 | 6 |
| M12 - Options for appointments limitation | 5 | 6 | 2 |
| M12 - Workflow processes limitation | 4 | 1 | 2 |
| M12 - Funding and acquisition limitations | 6 | 3 | 5 |
| M12 - Increased outreach limitation | 4 | 5 | 2 |
| M12 - Cohesive, well-trained staff | 8 | 7 | 7 |
| M12 - Organized clinic processes | 7 | 5 | 6 |
| M12 - Dedicated staff for key tasks | 6 | 3 | 5 |
| M12 - Educating patients | 5 | 4 | 5 |
| M12 - Understanding of insurance | 5 | 0 | 3 |
| M12 -Materials for patient outreach | 3 | 3 | 1 |
| M12 -Improving operations | 5 | 2 | 1 |
| M12 - Increasing visit convenience | 3 | 4 | 2 |
| M12 - Decreasing cost barriers | 2 | 3 | 3 |
| M12 - Nothing they wish they had known | 3 | 5 | 2 |
| M12 - Infrastructure needs | 1 | 3 | 3 |
| M12 - How to handle insurance and acquisition | 4 | 1 | 1 |
| M12 - Fits well with clinic processes | 15 | 10 | 9 |
| M12 - Adjusting and innovating | 8 | 5 | 11 |
| M12 - Fit of bimonthly visits | 9 | 7 | 6 |
| M12 - Supportive, well- trained staff | 7 | 6 | 7 |
| M12 - Support from ViiV | 4 | 2 | 4 |
| M12 - Insurance challenges | 7 | 4 | 7 |
| M12 - Challenges initial start-up | 3 | 2 | 3 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of acceptability of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Concerns about pain | 12 | 7 | 11 |
| Not concerned about pain | 14 | 11 | 18 |
| Received first injection and experienced pain | 14 | 8 | 7 |
| Has pain management plan | 18 | 12 | 13 |
| Did not receive pain management tips from provider | 6 | 3 | 8 |
| PSP concerned about side effect concerns | 11 | 6 | 7 |
| Not concerned about side effects | 4 | 2 | 3 |
| Experienced side effects after first APRETUDE injection | 6 | 1 | 3 |
| Did not experience side effects after first APRETUDE injection | 1 | 4 | 6 |
| Provider discussed side effects | 3 | 1 | 3 |
| Provider didn't discuss side effects | 0 | 0 | 3 |
| Positive comments about decision to take APRETUDE | 20 | 13 | 17 |
| Negative comments about decision to take APRETUDE | 4 | 3 | 3 |
| Positive expectations of APRETUDE | 3 | 3 | 1 |
| Negative expectations of APRETUDE | 1 | 1 | 0 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of acceptability of APRETUDE at M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| APRETUDE as an effective method to help prevent HIV transmission | 11 | 6 | 8 |
| No injection site pain | 3 | 2 | 1 |
| Minor injection site pain/discomfort | 13 | 5 | 8 |
| Avoiding contact with injection site or massaging/rubbing the area | 4 | 2 | 2 |
| Intense injection site pain | 1 | 3 | 1 |
| Managing pain with medication | 4 | 0 | 1 |
| Pain management strategies from provider | 8 | 1 | 3 |
| Cold or warm compress | 4 | 1 | 1 |
| Walking/stretching | 0 | 4 | 0 |
| No experienced side effects | 11 | 2 | 6 |
| Endorsed Acceptability of APRETUDE | 14 | 7 | 12 |
| APRETUDE is easier than oral PrEP | 5 | 1 | 5 |
| More convenient than daily oral/more convenient way to be protected | 12 | 5 | 11 |
| APRETUDE is confidential/discreet | 4 | 0 | 3 |
| APRETUDE is a long-term fit | 8 | 5 | 11 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of feasibility of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Can easily incorporate injections into schedule | 17 | 11 | 8 |
| PSP sees healthcare provider monthly | 0 | 4 | 4 |
| PSP sees healthcare provider every 2-4 months | 5 | 2 | 0 |
| PSP sees healthcare provider every 6 months | 8 | 1 | 2 |
| PSP sees healthcare provider annually | 2 | 0 | 0 |
| PSP rarely sees a healthcare provider | 2 | 1 | 3 |
| PSP sees healthcare provider only as needed | 3 | 2 | 2 |
| Bimonthly appointments have good frequency | 4 | 1 | 1 |
| No challenges with accommodating injection schedule | 7 | 6 | 4 |
| Identified scheduling challenges, but these will not impact injection schedule | 8 | 4 | 6 |
| Identified scheduling challenges will impact injection schedule | 2 | 3 | 4 |
| Identified solution to injection scheduling challenges | 8 | 5 | 6 |
| Entering appointments into personal calendar | 4 | 3 | 1 |
| Using advanced planning to adhere to injection schedule | 10 | 6 | 4 |
| PSP discussed preparedness with clinic staff | 4 | 4 | 6 |
| Shared scheduling challenges and preferences with provider | 2 | 3 | 2 |
| Working with clinic staff to reschedule appointments when needed | 3 | 2 | 1 |
| Expectations for APRETUDE to be more convenient than oral PrEP | 11 | 8 | 9 |
| Expects APRETUDE to be convenient | 14 | 9 | 11 |
| Being able to take time off from work to address work-conflicts | 3 | 3 | 2 |
| APRETUDE will be/is a priority | 5 | 2 | 2 |
| Work responsibilities are a concern | 3 | 0 | 2 |
| Work responsibilities not a concern | 11 | 6 | 11 |
| No transportation challenges | 20 | 10 | 17 |
| Transportation challenges | 2 | 5 | 4 |
| Childcare challenges | 0 | 2 | 1 |
| No childcare challenges | 14 | 9 | 14 |
| Busy schedule/conflicting responsibilities | 1 | 4 | 4 |
| APRETUDE fits well with PSPs' schedule | 5 | 5 | 1 |
| Desire for expanded injection availability | 4 | 2 | 4 |
| Mentioned injection/appointment reminders | 3 | 1 | 2 |
| Mentioned their next APRETUDE related appointment | 4 | 3 | 4 |
| Mentioned knowing not to miss doses or appointments | 1 | 1 | 1 |
| Received a schedule of all APRETUDE injection appointments | 1 | 1 | 1 |
| Received a physical/written appointment schedule | 2 | 0 | 0 |
| APRETUDE fits well into other healthcare appointments | 15 | 12 | 10 |
| Discussed factors that increase feasibility | 3 | 2 | 10 |
| Discussed barriers to feasibility | 0 | 3 | 2 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of feasibility of APRETUDE at M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| APRETUDE is convenient | 16 | 7 | 11 |
| More convenient than daily oral/more convenient way to be protected | 12 | 5 | 11 |
| More people should be aware of APRETUDE convenience | 3 | 1 | 2 |
| Positive experience working with clinic staff and provider | 15 | 7 | 6 |
| APRETUDE perceived as providing an additional layer of protection | 6 | 4 | 5 |
| Insurance coverage | 3 | 1 | 4 |
| Positive injection experience with minimal of side effects | 4 | 3 | 2 |
| Receives assistance with transportation | 0 | 2 | 3 |
| No challenges or barriers | 4 | 3 | 6 |
| Clinic operations: Limited clinic hours and working with staff | 3 | 2 | 3 |
| Pain | 3 | 3 | 4 |
| Did not have transportation issues | 5 | 0 | 5 |
| Had issues with transportation to the clinic | 7 | 4 | 3 |
| Substantial traffic and commute to get to clinic | 5 | 2 | 1 |
| APRETUDE appointments did not interfere with work schedules | 11 | 4 | 8 |
| Childcare accommodations | 1 | 0 | 0 |
| Injection appointments take an hour or less | 11 | 8 | 10 |
| Having to go to specific clinic is inconvenient | 3 | 2 | 2 |
| Initially overwhelming injection appointments | 1 | 2 | 2 |
| Endorsed feasibility of APRETUDE | 12 | 6 | 7 |
| Appointment reminders and calendar tracking is helpful | 15 | 10 | 11 |
| Clinic staff work to help keep/maintain treatment schedule | 12 | 4 | 5 |
| Clinic flexibility when (re)scheduling appointments is helpful | 3 | 4 | 1 |
| APRETUDE appointments do not conflict with other medical appointments | 14 | 3 | 11 |
| Unfavorable Injection schedule | 6 | 3 | 3 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of use of oral cabotegravir pills as oral lead-in to APRETUDE injections was gathered using the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs who had OLI before APRETUDE injection.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Yes | 10 | 8 | 10 |
| No | 40 | 44 | 23 |
| I don't know | 3 | 4 | 9 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs who chose OLI before APRETUDE injection at baseline (M1).
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| No | 5 | 5 | 4 |
| Yes, for all patients | 1 | 4 | 3 |
| Yes, for some patients | 8 | 6 | 3 |
| Not sure | 1 | 5 | 2 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs who chose OLI before APRETUDE injection at M4 and M12.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| M4 - Directly with injection | 8 | 11 | 9 |
| M4 - With optional oral lead-in using oral cabotegravir | 6 | 4 | 6 |
| M4 - With oral PrEP (TDF/FTC or TAF/FTC) | 5 | 2 | 4 |
| M12 - Directly with injection | 9 | 11 | 10 |
| M12 - With optional oral lead-in using oral cabotegravir | 4 | 3 | 6 |
| M12 - With oral PrEP (TDF/FTC or TAF/FTC) | 2 | 2 | 5 |
SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions on reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). SSIs were not conducted with SSPs at BL. This outcome measure presents the SSPs with responses on reasons for decision to use OLI assessed by SSI at M4 and M12.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| M4 - Use of oral lead-in | 14 | 13 | 18 |
| M12 - Primarily DTI | 7 | 5 | 3 |
| M12 - Mix of OLI-DTI | 3 | 3 | 0 |
| M12 - DTI is simpler and quicker | 2 | 4 | 0 |
| M12 - Lack of clinical justification for OLI | 2 | 3 | 1 |
| M12 -Barriers obtaining OLI | 0 | 3 | 3 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at baseline (M1).
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| The ability to assess the safety/tolerability of APRETUDE in all patients | 8 | 8 | 8 |
| Ability to assess APRETUDE safety/tolerability in patients with allergy or drug intolerance history | 10 | 11 | 7 |
| The availability of more data from clinical trials using an oral lead-in phase | 5 | 5 | 1 |
| The ability to increase drug concentration before starting the injections | 4 | 3 | 1 |
| Being cautious with a new medication | 4 | 8 | 5 |
| Providing patient with protection against HIV until the injection arrives | 8 | 11 | 3 |
| Patient request | 10 | 8 | 7 |
| Other | 0 | 0 | 2 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M4.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| The ability to assess the safety/tolerability of APRETUDE in all patients | 7 | 7 | 6 |
| Ability to assess APRETUDE safety/tolerability in patients with allergy or drug intolerance history | 3 | 4 | 4 |
| The availability of more data from clinical trials using an oral lead-in phase | 1 | 1 | 1 |
| The ability to increase drug concentration before starting the injections | 3 | 2 | 0 |
| Being cautious with a new medication | 4 | 2 | 1 |
| Providing patient with protection against HIV until the injection arrives | 4 | 3 | 2 |
| Patient request | 8 | 8 | 4 |
| Enough data exists from clinical trials to start patients with injection without oral lead-in | 4 | 5 | 5 |
| Provide immediate protection with long-acting PrEP by not using oral lead-in | 1 | 2 | 1 |
| Other | 0 | 2 | 1 |
The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M12.
| Participants | SI - SSP | EI - SSP | ECI - SSP |
|---|---|---|---|
| The ability to assess the safety/tolerability of APRETUDE in all patients | 6 | 3 | 6 |
| Ability to assess APRETUDE safety/tolerability in patients with allergy or drug intolerance history | 5 | 2 | 3 |
| The availability of more data from clinical trials using an oral lead-in phase | 2 | 3 | 1 |
| The ability to increase drug concentration before starting the injections | 2 | 1 | 0 |
| Being cautious with a new medication | 3 | 2 | 2 |
| Providing patient with protection against HIV until the injection arrives | 3 | 5 | 3 |
| Patient request | 6 | 6 | 4 |
| Enough data exists from clinical trials to start patients with injection without oral lead-in | 3 | 4 | 3 |
| Provide immediate protection with long-acting PrEP by not using oral lead-in | 1 | 2 | 1 |
| Other | 0 | 1 | 3 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons for using oral cabotegravir pills as OLI to APRETUDE injections were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs' experiences with and reasons for using OLI or direct-to-injection (DTI) approach, assessed by SSIs.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Discussed experience of OLI | 2 | 1 | 3 |
| Used OLI because PSP was not on oral PrEP to assess side effects or adverse events | 1 | 3 | 0 |
| PSP used OLI in case APRETUDE approval was delayed | 1 | 1 | 0 |
| PSP used OLI because it was part of the clinic's process | 0 | 1 | 2 |
| PSP was unaware of reason for OLI | 0 | 0 | 1 |
| OLI experience - positive comments about entire process | 2 | 2 | 2 |
| OLI experience - negative comments about entire process | 0 | 2 | 0 |
| Confirmed use of DTI | 11 | 7 | 11 |
| Description of DTI process | 18 | 12 | 13 |
| Chose DTI because PSP was already on oral PrEP before | 7 | 3 | 7 |
| Chose DTI due to PSPs current sexual behaviors | 2 | 1 | 0 |
| PSP decided to use DTI | 2 | 2 | 3 |
| PSP was not offered OLI | 0 | 0 | 2 |
| PSP unsure why they were DTI | 1 | 0 | 1 |
| Chose DTI due to belief that its easier and more convenient than OLI | 5 | 1 | 5 |
| Chose DTI to avoid side effects of OLI/oral PrEP | 1 | 1 | 2 |
| DTI experience - positive comments about entire process | 15 | 12 | 16 |
| DTI experience - negative comments about entire process | 8 | 1 | 2 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs on reasons for decision to use OLI, assessed by surveys.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| It was primarily my decision | 7 | 6 | 5 |
| It was a joint decision between me and my provider | 3 | 1 | 3 |
| It was primarily my provider's decision | 0 | 1 | 2 |
| Other | 0 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses on reasons for decision for use of OLI, assessed by surveys.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| The doctor just started me on them | 4 | 4 | 7 |
| The doctor wanted to see how I would react to APRETUDE | 1 | 3 | 0 |
| I have a history of medication allergies, and the doctor wanted to assess reaction to APRETUDE | 0 | 0 | 0 |
| The doctor wanted to be cautious with a new medication | 0 | 1 | 0 |
| I wanted to make sure the medication was safe | 3 | 2 | 3 |
| I wanted to have protection until the injection arrived after it was ordered | 2 | 1 | 2 |
| The doctor wanted me to have protection until the injection arrived after ordering | 0 | 1 | 1 |
| Other | 1 | 0 | 0 |
| Missing | 1 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. Timeframe for evaluation of this outcome measure is BL.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Taken oral PrEP in the last 6 months — Yes | 34 | 20 | 27 |
| Taken oral PrEP in the last 6 months — No | 17 | 36 | 14 |
| Taken oral PrEP in the last 6 months — I prefer not to answer | 2 | 0 | 1 |
| Taken oral PrEP in the last 6 months — Missing | 0 | 0 | 0 |
| Has ever taken PrEP — Yes | 4 | 5 | 2 |
| Has ever taken PrEP — No | 14 | 28 | 13 |
| Has ever taken PrEP — I prefer not to answer | 0 | 0 | 0 |
| Has ever taken PrEP — Missing | 1 | 3 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to consistency in Oral PrEP use in past 6 months.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| I take oral PrEP consistently at least 5 or more days a week each week | 25 | 10 | 17 |
| I take PrEP consistently (at least 5 days a week) off and on which I need to but not every week | 4 | 6 | 5 |
| I take oral PrEP for less than 5 days a week each week | 3 | 1 | 5 |
| I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1 | 2 | 3 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to Oral PrEP duration.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Less than 2 months | 9 | 3 | 5 |
| 2 to 6 months | 8 | 9 | 10 |
| 7 to 12 months | 5 | 1 | 2 |
| 12 months or more | 11 | 6 | 10 |
| I prefer not to answer | 0 | 0 | 0 |
| I don't know | 1 | 1 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP use of the sexual health assessment (available only to the ECI arm) was gathered via the ISQ. Timeframe for evaluation of this outcome measure is at Baseline (BL) and M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs who completed a SHA and initiate APRETUDE. All PSPs enrolled in the study initiated APRETUDE.
| Participants | ECI - PSP |
|---|---|
| BL - Completed a Sexual Health Assessment before being told about this study — Yes | 27 |
| BL - Completed a Sexual Health Assessment before being told about this study — No | 6 |
| BL - Completed a Sexual Health Assessment before being told about this study — I don't know | 8 |
| BL - Completed a Sexual Health Assessment before being told about this study — Missing | 1 |
| M12 - Completed a Sexual Health Assessment in the last 12 months? (ECI only) — Yes | 14 |
| M12 - Completed a Sexual Health Assessment in the last 12 months? (ECI only) — No | 1 |
| M12 - Completed a Sexual Health Assessment in the last 12 months? (ECI only) — I don't know | 8 |
| M12 - Completed a Sexual Health Assessment in the last 12 months? (ECI only) — Missing | 1 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to experiences with Oral PrEP, assessed by surveys.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Side effects — Yes | 15 | 8 | 10 |
| Side effects — No | 23 | 17 | 19 |
| Insurance issues (e.g., delayed or denial of payment) — Yes | 6 | 5 | 1 |
| Insurance issues (e.g., delayed or denial of payment) — No | 32 | 20 | 28 |
| Problems remembering to take oral PrEP — Yes | 21 | 14 | 14 |
| Problems remembering to take oral PrEP — No | 17 | 11 | 15 |
| Concerns about running out of oral PrEP — Yes | 10 | 13 | 7 |
| Concerns about running out of oral PrEP — No | 28 | 12 | 22 |
| Feeling you had to hide oral PrEP from others — Yes | 9 | 8 | 7 |
| Feeling you had to hide oral PrEP from others — No | 29 | 17 | 22 |
| Thinking oral PrEP is not convenient for you — Yes | 18 | 10 | 16 |
| Thinking oral PrEP is not convenient for you — No | 20 | 15 | 13 |
| Difficulty paying for oral PrEP — Yes | 6 | 4 | 1 |
| Difficulty paying for oral PrEP — No | 32 | 21 | 28 |
| Difficulty swallowing oral PrEP — Yes | 8 | 2 | 9 |
| Difficulty swallowing oral PrEP — No | 30 | 23 | 20 |
| Worried about potential interaction with other medicines — Yes | 10 | 9 | 7 |
| Worried about potential interaction with other medicines — No | 28 | 16 | 22 |
| Not liking to take oral PrEP so frequently — Yes | 25 | 14 | 13 |
| Not liking to take oral PrEP so frequently — No | 13 | 11 | 16 |
| Worrying that people may find out you are taking oral PrEP — Yes | 7 | 2 | 7 |
| Worrying that people may find out you are taking oral PrEP — No | 31 | 23 | 22 |
| Worrying that people will think you have HIV if they see you taking oral PrEP — Yes | 13 | 7 | 11 |
| Worrying that people will think you have HIV if they see you taking oral PrEP — No | 25 | 18 | 18 |
| Worry that people think you have many sexual partners because you take oral PrEP — Yes | 15 | 9 | 12 |
| Worry that people think you have many sexual partners because you take oral PrEP — No | 23 | 16 | 17 |
| Worrying about your privacy because you live with someone — Yes | 3 | 5 | 3 |
| Worrying about your privacy because you live with someone — No | 35 | 20 | 26 |
| Worrying about your privacy because you're on your parent's health insurance plan — Yes | 2 | 1 | 2 |
| Worrying about your privacy because you're on your parent's health insurance plan — No | 36 | 24 | 27 |
| Other concerns — Yes | 6 | 3 | 4 |
| Other concerns — No | 32 | 22 | 25 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to Oral PrEP side effects, assessed by surveys.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Headache | 7 | 6 | 2 |
| Diarrhea | 5 | 4 | 5 |
| Nausea | 7 | 8 | 5 |
| Vomiting | 3 | 2 | 2 |
| Rash | 0 | 1 | 0 |
| Loss of appetite | 4 | 2 | 1 |
| Weight loss | 0 | 1 | 0 |
| Stomach pain | 3 | 4 | 4 |
| Gas or bloating | 3 | 4 | 4 |
| New or worse kidney problems | 0 | 1 | 1 |
| Bone problems | 0 | 1 | 1 |
| Other | 1 | 1 | 1 |
| None | 2 | 0 | 2 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to frequency of worry about Oral PrEP disclosure, assessed by surveys.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Rarely | 6 | 5 | 5 |
| Sometimes | 7 | 2 | 5 |
| Often | 0 | 0 | 1 |
| All the time | 0 | 0 | 0 |
The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to reasons for choosing APRETUDE, assessed by surveys.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| I never tried PrEP before, but I want to protect myself from HIV | 12 | 32 | 12 |
| I think APRETUDE is the most effective HIV prevention method available | 24 | 10 | 17 |
| I do not have to worry about HIV every day | 20 | 12 | 11 |
| I will be able to have sex at any moment and I know I am protected | 16 | 12 | 8 |
| I want to keep taking PrEP a secret | 1 | 0 | 2 |
| I want a prevention option that is more convenient for my life | 25 | 22 | 18 |
| My sexual partner will not know I am taking PrEP | 0 | 3 | 2 |
| My doctor suggested I take APRETUDE | 10 | 11 | 8 |
| My friend, family, acquaintance or co-worker suggested it | 2 | 0 | 0 |
| I won't have to remember to take PrEP everyday | 27 | 13 | 17 |
| I often forget to take pills | 26 | 15 | 17 |
| I want to try a new approach and see if it fits into my life | 14 | 12 | 10 |
| I prefer an injection for PrEP because I have difficulty swallowing pills | 6 | 3 | 8 |
| I was concerned about the long-term side effects of my oral PrEP | 4 | 7 | 3 |
| I do not have to worry or stress about missing a dose like oral PrEP | 29 | 12 | 17 |
| I would feel more comfortable not taking pills when going out with friends | 7 | 7 | 5 |
| I would feel more comfortable not taking pills with me when travelling | 13 | 8 | 10 |
| I hope that injections will be easier on my stomach/digestive system | 15 | 11 | 8 |
| Other reasons | 1 | 1 | 2 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection. This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at baseline (M1).
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Confirmation of previous PrEP history | 7 | 6 | 10 |
| Switched from PrEP - Expects APRETUDE to be convenient | 14 | 9 | 11 |
| Switched from PrEP - Experienced problems with oral PrEP | 5 | 5 | 3 |
| Switched from PrEP - Did not experience problems with oral PrEP | 4 | 1 | 1 |
| Switched from oral PrEP for convenience | 9 | 4 | 6 |
| Switched from oral PrEP specifically due to GI side effects or considerations | 5 | 3 | 2 |
| Switched from oral PrEP for fewer side effects | 4 | 4 | 2 |
| Switched from oral PrEP for other reasons | 2 | 1 | 4 |
| Switched from oral PrEP based on provider recommendation | 1 | 1 | 3 |
| Switched from oral PrEP because of the peace of mind APRETUDE provides | 4 | 3 | 4 |
| Switched from oral PrEP because of increased privacy that APRETUDE provides | 2 | 0 | 2 |
| Switched to APRETUDE due to increased personal perceived HIV risk | 9 | 5 | 5 |
| Chose APRETUDE based on experiences from others | 4 | 0 | 1 |
| Chose APRETUDE because of busy lifestyle | 5 | 2 | 1 |
| Chose APRETUDE because of convenience | 5 | 5 | 4 |
| Chose APRETUDE because of adherence concerns (vs. oral) | 3 | 6 | 5 |
| Chose APRETUDE due to increased perceived personal HIV risk | 5 | 6 | 5 |
| Chose APRETUDE because of side effect considerations | 2 | 1 | 0 |
| Chose APRETUDE because of associated peace of mind | 2 | 0 | 4 |
| Chose APRETUDE based on provider recommendation. | 2 | 2 | 1 |
| Found out about APRETUDE through friends | 2 | 3 | 2 |
| Discussed APRETUDE with friends or peers before initiating | 6 | 6 | 5 |
| Did not discuss APRETUDE with friends or peers before initiating | 6 | 5 | 11 |
| Did not discuss APRETUDE with friends or peers before starting but would have found it helpful | 2 | 2 | 3 |
| Did not discuss APRETUDE with friends or peers before starting and would not find it helpful | 1 | 1 | 4 |
| Had a partner who was involved in their decision to take APRETUDE | 7 | 9 | 1 |
| Did not involve partner in decision to take APRETUDE | 16 | 9 | 18 |
| Had a partner involved in decision-making who reacted positively to APRETUDE initiation | 7 | 6 | 4 |
| Discussed decision to take APRETUDE with family | 4 | 0 | 2 |
| Decision to take APRETUDE was supported by their family | 1 | 0 | 0 |
| Decision to take APRETUDE received unsupportively by their family | 1 | 0 | 2 |
| Used information from provider, clinic, or community to make their choice | 6 | 7 | 8 |
| Used information from personal research and past experience to make choice | 10 | 7 | 13 |
| Used information about sexual partners/behavior to make choice | 2 | 3 | 3 |
| Used information from provider/clinic to make a choice | 7 | 7 | 6 |
| Used information from community members/work to make decision | 2 | 1 | 2 |
| Used personal research to make decision | 7 | 4 | 10 |
| Made decision to contribute to research due to positive impact of the study | 2 | 0 | 1 |
| Used information from peers/experiences of others to make decision | 0 | 0 | 2 |
| Additional information about APRETUDE's efficacy and potential side effects | 2 | 4 | 2 |
| Testimonials from people would have been helpful | 0 | 1 | 0 |
| Additional information about PrEP in general and APRETUDE | 1 | 1 | 2 |
| Insurance details would have been helpful | 1 | 0 | 0 |
| Information about administration timeline would have been helpful | 1 | 1 | 0 |
| No additional info would have been helpful | 3 | 2 | 5 |
SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at M12.
| Participants | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Challenges remembering daily pill | 6 | 1 | 5 |
| APRETUDE is easier than oral PrEP | 5 | 1 | 5 |
| Safety and protection | 8 | 7 | 10 |
| Better than the pill | 3 | 3 | 2 |
| Confidential/discreet | 4 | 0 | 3 |
| APRETUDE addressed adherence challenges | 1 | 2 | 4 |
| More education needed for women to choose APRETUDE | 2 | 2 | 3 |
| Spoke to friends/ peers about APRETUDE and/or APRETUDE use | 10 | 6 | 5 |
| Talked about APRETUDE and/or APRETUDE use with partner | 4 | 1 | 0 |
| Participant talked about APRETUDE and/or APRETUDE use with family | 6 | 2 | 3 |
| Believes talking about APRETUDE and sexual health with family is important | 4 | 1 | 1 |
| Disclosed APRETUDE use to others | 9 | 6 | 7 |
| Feelings about APRETUDE have not changed over time | 12 | 4 | 9 |
| Experience with APRETUDE affirms that it's more convenient than Oral PrEP | 5 | 1 | 2 |
| Experience with APRETUDE aligns with initial expectations | 3 | 2 | 0 |
| Experience taking APRETUDE was better than initial expectations | 2 | 1 | 2 |
| Was initially hesitant about APRETUDE but now feels confident in the decision | 2 | 1 | 3 |
| PSP feels more protected from HIV and confident about their sexual health | 5 | 3 | 3 |
| Feels encouraged to advocate for APRETUDE/PrEP and has less stigma discussing it | 2 | 1 | 0 |
Collected over Serious adverse events (SAEs) were reported from signing of informed consent (a period starting up to 90 days before the first dose in Month 1) to Month 12 (study completion). Non serious Drug related AEs were reported from Month 1 (first dose) to Month 12 (study completion).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SI - PSP | 0/56 (0%) | 1/56 (1.8%) | 3/56 (5.4%) |
| EI - PSP | 0/63 (0%) | 0/63 (0%) | 1/63 (1.6%) |
| ECI - PSP | 0/44 (0%) | 1/44 (2.3%) | 1/44 (2.3%) |
| Event | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/56 | 0/63 | 1/44 |
| DysarthriaNervous system disorders | 0/56 | 0/63 | 1/44 |
| HypoaesthesiaNervous system disorders | 0/56 | 0/63 | 1/44 |
| PresyncopeNervous system disorders | 0/56 | 0/63 | 1/44 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/56 | 0/63 | 0/44 |
| Event | SI - PSP | EI - PSP | ECI - PSP |
|---|---|---|---|
| Injection site reactionGeneral disorders | 0/56 | 0/63 | 1/44 |
| Influenza like illnessGeneral disorders | 1/56 | 0/63 | 0/44 |
| Vulvovaginal candidiasisInfections and infestations | 1/56 | 0/63 | 0/44 |
| CyanosisVascular disorders | 1/56 | 0/63 | 0/44 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/56 | 1/63 | 0/44 |
| SyncopeNervous system disorders | 0/56 | 1/63 | 0/44 |
Baseline characteristics for SSPs were not collected as it was not required as per study design.
| Age, Continuous(Years) | SI - PSP | EI - PSP | ECI - PSP | Total |
|---|---|---|---|---|
| Mean | 38.1 ± 10.85 | 35.9 ± 11.10 | 36.1 ± 8.73 | 36.7 ± 10.41 |
| Sex/Gender, Customized(Participants) | SI - PSP | EI - PSP | ECI - PSP | Total |
|---|---|---|---|---|
| Cisgender Woman | 49 | 39 | 34 | 122 |
| Transgender Woman | 7 | 24 | 10 | 41 |
| Race/Ethnicity, Customized(Participants) | SI - PSP | EI - PSP | ECI - PSP | Total |
|---|---|---|---|---|
| Black or African American | 56 | 63 | 44 | 163 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Oct 2022 to primary completion in Sep 2025, 34 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 91 phase 4 interventional studies under HIV Infections, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 34 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir